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ABSTRACT 
DESIGN OF ROMP-BASED PROTEIN MIMICS FOR SIRNA DELIVERY 
 
February 2016 
 
BRITTANY MORGAN DERONDE, B.A., DOUGLASS COLLEGE, RUTGERS 
UNIVERSITY 
 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Gregory N. Tew 
 
Designing delivery agents for therapeutics is an ongoing challenge.  As 
treatments and desired cargoes become more complex, the need for improved delivery 
vehicles becomes critical.  Excellent delivery vehicles must ensure the stability of the 
cargo, maintain the cargo’s solubility, and promote efficient delivery and release.  In 
order to address these issues, many research groups have looked to nature for design 
inspiration.  Proteins, such as HIV-1 TAT and Antennapedia homeodomain protein, are 
capable of crossing cellular membranes. However, due to the complexities of their 
structures, they are synthetically challenging to reproduce in the laboratory setting.  
Being able to incorporate the key features of these proteins that enable cell entry into 
simpler scaffolds opens up a wide range of opportunities for the development of new 
delivery reagents with improved performance.   
Herein we report the development of guanidinium-rich polymeric protein mimics 
using a ring-opening metathesis polymerization (ROMP)-based scaffold capable of 
interacting with cell membranes and facilitating the internalization of small interfering 
ribonucleic acids (siRNAs).  These materials are referred to interchangeably as cell-
penetrating peptide mimics (CPPMs) or protein transduction domain mimics (PTDMs), 
and derive inspiration from proteins and peptides with cellular internalization capabilities, 
x	  
capturing key features of these materials necessary for intracellular delivery, including 
cationic charge content in the form of guanidinium moieties and a segregated, 
hydrophobic component.  This thesis documents the development of design principles 
for PTDMs with optimal membrane interactions and siRNA internalization and delivery. 
Chapter 2 documents the development of homopolymer CPPMs that contain 
aromatic rings with varying π-electronics.  This study demonstrated that a wide range of 
functional groups could be incorporated into CPPMs without negatively impacting their 
ability to interact with cellular membranes.  It is also suggested that other design 
parameters, such as cationic charge content and overall hydrophobic content, play more 
dominant roles in membrane interactions.  This finding ultimately influenced the PTDM 
optimization performed in later chapters. 
Chapter 3 documents the development of homopolymer and block copolymer 
PTDMs with varying numbers of guanidinium moieties that were tested to assess the 
affect cationic charge content and the addition of a segregated, hydrophobic block had 
on siRNA delivery.  This study demonstrated that there was a critical charge content 
necessary for internalization and established the importance of incorporating a 
hydrophobic block into PTDM structures.  Furthermore, this platform demonstrated that 
bioactive siRNA could successfully be delivered into cells and affect the target gene.   
Chapter 4 documents the exploration of hydrophobic block incorporated into 
copolymer PTDMs in order to determine how the length of the hydrophobic block of the 
PTDMs as well as the hydrophobic block composition of the PTDMs impacted siRNA 
internalization.  This study demonstrated that there was a critical hydrophobic content 
necessary for efficient siRNA internalization and that incorporation of additional 
hydrophobicity did not guarantee improved efficiencies.   
xi	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1 CHAPTER 1 
      INTRODUCTION 
1.1 Introduction 
Proteins are large, complex biomolecules that perform numerous biological 
functions.1  They contain both secondary and tertiary structure, which helps them 
arrange and fold into specific and functional conformations.  While nature has developed 
efficient ways to generate correctly folded and functional proteins, it is substantially more 
difficult to recreate these structures synthetically.  Many research groups have 
successfully developed peptidomimetics that mimic conformations of short peptide 
sequences, but to date, mimicking larger protein surfaces or entire protein functions 
represent more significant challenges.2  The field of proteomimetics looks to specifically 
address these challenges by moving away from naturally occurring amino acids and 
developing non-peptidic materials that can capture key secondary structures found in 
proteins.2  
An elegant example of synthetic protein mimic development is from Andrew 
Hamilton and coworkers in which they were able to mimic part of the protein helix from 
the myosin light chain kinase using a terphenyl scaffold.3  These synthetic mimics 
operate on the premise that the critical residues needed for efficient protein-protein 
interactions lie along one face of the α-helix.3,4  Using this scaffold, they were also able 
to assess binding affinities for calmodulin, which is a calcium-binding messenger that 
aids in cell signaling.3  Specifically, they were able to prove that the synthetic α-helix had 
similar binding properties to the myosin light chain kinase, thus demonstrating the 
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protein mimicking capacity of these materials.3  Other excellent work has also been 
published in this field.5-8 
In addition, many researchers have explored foldamers, which are chains of 
molecules that can fold into organized structures, such as α-helices and β-sheets, in 
solution.9-22  Foldamers differ from other proteomimetics in that they require non-covalent 
interactions for folding, such as hydrogen bonding, π-interactions, electrostatic 
interactions, van der Waal’s interactions, and solvophobic effects with non-adjacent 
surfaces.9,10,12,15,16,18,20,21 These molecules have been used to mimic the folding of 
proteins, polysaccharides, and nucleic acids.9,10,12,15,16,18,20,21  One specific subset of 
foldamers, referred to as abiotic foldamers, aim to capture key features of proteins, such 
as secondary structure, with non-natural materials.9-17,19-22  
While mimicking protein secondary structure is an impressive feat and can aid 
the future development of entirely synthetic protein mimics, it remains difficult to 
generate these scaffolds and to predict the proper folding or assembly processes.  
Protein mimics that capture key features using simpler scaffolds without secondary 
structures can more easily be attained with tunable, synthetic platforms.23,24  One 
prominent example involves mimicking antimicrobial peptides (AMPs).  AMPs are potent 
antibacterial agents that are part of the innate immune systems for many organisms.25-28  
Magainin 2, which is one of the many AMPs currently found in nature, and other similar 
antimicrobial agents have been shown to be effective against both Gram positive and 
Gram negative bacteria.25-27,29,30  These peptides have facially amphiphilic topologies, 
enabling segregation of hydrophilic (cationic) and hydrophobic residues for improved 
membrane activity and antimicrobial properties.25,31  Much effort has been devoted to 
understanding these peptides and the mechanisms by which they kill bacteria, both 
experimentally and computationally.25,32-49  Despite the level of controversy surrounding 
their mode of action, hydrophobic and electrostatic interactions between these peptides 
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and the bacterial cell wall play prominent roles in pore formation, which ultimately leads 
to bacterial cell death.44,45   
Given the rise in antibacterial resistance, researchers have turned to AMPs as a 
source of inspiration.  Incorporating key features of these peptides into synthetic 
scaffolds offer more structural options for tuning chemical compositions for improved 
performance.15,25,45,50-54  These molecules are often referred to as synthetic mimics of 
antimicrobial peptides (SMAMPs).  One example from DeGrado and coworkers 
demonstrated the use of β-peptides, which mimic the α-helical structures and 
amphiphilicity of many AMPs.55  Although many of these molecules contained α-helical 
structures, linear β-peptides made by Gellman and coworkers and β- and ϒ-peptides 
made by Seebach and coworkers demonstrated that α-helical structures were not 
necessary for potent antimicrobial properties.56,57  These studies paved the way for the 
development of synthetic mimics with completely abiotic scaffolds.  Such molecules, 
designed by Tew and coworkers, used facially amphiphilic triaryl scaffolds in which the 
hydrophobic content and cationic charge content (ammonium or guanidinium groups) 
could be tuned for improved antimicrobial properties and selectivities.58-61  By converting 
AMP designs to simple, synthetic scaffolds, production time and costs are considerably 
reduced.51  In addition, peptide in vivo limitations, such as proteolysis, tissue distribution, 
and toxicity, are overcome and robust in vivo antibacterial activity against drug-resistant 
infections has been demonstrated, specifically with a compound in phase II clinical 
trials.51  An important new development was the demonstration that polymers could be 
designed with AMP-like biological activity.15,17,23,50,53,54,62-72  Unlike proteins and peptides, 
which typically have a single, exact molar mass, synthetic polymers, even when termed 
monodisperse, are characterized by a distribution of molecular weights.  Although it is 
unclear how antimicrobial activity trends with dispersity, this opens a wider range of 
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molecules and chemistries that can be used for the development of synthetic 
antimicrobial mimics. 
By using the same process that gave rise to SMAMPs, researchers have used 
proteins and peptide sequences as inspiration for the design of the next generation of 
delivery reagents (Figure 1.1.1).23   
	  
Figure 1.1.  The progression from proteins and peptides to guanidinium-rich CPPMs.  
 
This is an area of particular interest since delivery of therapeutic agents is an ongoing 
challenge.  Although there is an increasing demand for new treatments and treatment 
options, the field lacks a clear understanding of how to efficiently and reliably deliver 
bioactive molecules across cellular membranes, especially as therapies move 
increasingly toward more complex biologics.73-79  Nature, however, is already capable of 
designing proteins that can perform these functions.  One example is HIV-1 TAT (trans-
activator of transcription) protein, which is responsible for the spread of the virus80,81  
This protein, along with others, contains a region referred to as a protein transduction 
domain (PTD) that is responsible for their abilities to enter cells.82-84  The study of TAT 
and other PTDs have subsequently led to the development of cell-penetrating peptides 
(CPPs), which are peptides that are capable of delivering cargo, such as small 
molecules, siRNA, pDNA, antibodies, and proteins, into cells via covalent or non-
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covalent interactions.85-90  Two examples of such molecules include TAT49-57, which is a 
guanidinium-rich sequence, and Pep-1, which has a segregated architecture similar to a 
block copolymer.83,84,90-92  While both peptides are cation-rich, Pep-1 also incorporates a 
hydrophobic segment that is thought to further aid in cellular uptake. 
Despite the development of CPPs such as Pep-1, which is now commercially 
available through Active Motif as Chariot™, moving away from the peptide scaffold 
offers distinct advantages.  Most peptides are prepared by solid phase synthesis, which 
is both costly and time-consuming because amino acids need to be sequentially added 
using a series of deprotection, addition, wash, and protection steps.  Switching to a 
completely abiotic backbone allows delivery agents to be made cheaper and potentially 
in larger quantities.  In addition, a non-peptide-based system offers many more structural 
options in terms of chemical compositions and molecular arrangements because it is not 
restricted to the incorporation of natural amino acids.23 This expanded chemistry toolset 
is expected to generate more efficient structures than their natural peptide analogs.23  
This chapter documents the early development of cell-penetrating peptide mimics 
(CPPMs), in particular ones based on polymeric scaffolds.  A number of recent reports 
suggest this area will develop similarly to SMAMPs and will provide new tools for biology 
and perhaps new delivery opportunities for society.23,24  A summary of the early CPP 
work is highlighted followed by an overview of polymeric CPPMs developed to date.  
 
1.2 Cell-penetrating Peptides (CPPs) 
CPPs are a class of peptides that can facilitate the delivery of various cargoes 
into cells.85-90  These peptides are generally 7-30 amino acid residues in length and 
cation-rich, usually containing multiple arginine and/or lysine residues.85  In general, 
CPPs can be broken down into three broad categories: protein-derived, chimera-derived, 
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and synthetic.  These classes of peptides are summarized in the following subsections 
and in Table	  1.1.85  
Table 1.1. Summary of Cell Penetrating Peptides (CPPs) color-coded based on 
classification into three categories: protein-derived (top, pink), chimera (middle, blue), 
and synthetic (bottom, yellow). 
Peptide Sequence Derivation 
Total # 
of 
charged 
residue
s 
Cargo Alternative Classification 
HIV-1 
TAT49-57 
74,93 
RKKRRQRR
R 
Human 
Immunodeficiency 
Virus 
8 protein, 
peptides, 
siRNA 
Non-amphipathic 
Penetratin9
4 
RQIKIWFQN
RRMKWKK 
Drosophila 
homeoprotein 
antennapedia 
7 protein, 
PNA, 
siRNA 
Secondary 
amphipathic 
pVEC95 LLIILRRRIRK
QAHAHSK 
Murine VE-cadherin 6 protein, 
peptides 
Secondary 
amphipathic 
VP2296 NAKTRRHER
RRKLAIER 
Herpes simplex virus 8 protein Secondary 
amphipathic 
Pep-190-
92,97 
KETWWETW
WTEWSQPK
KKRKV 
NLS from SV40 T-
antigen and a 
Tryptophan-rich 
domain 
5 protein, 
peptides 
Primary 
amphipathic 
MPG91,98,99 GALFLGFLG
AAGSTMGA
WSQPKKKR
KV 
Hydrophbic domain 
from fusion 
sequence of HIV 
gp41 and NLS of 
SV40 T-antigen 
5 siRNA, 
plasmids 
Primary 
amphipathic 
Transporta
n (TP10) 
100,101 
AGYLLGKINL
KALAALAKKI
L 
Galanin and 
mastoparan 
4 protein, 
PNA, 
siRNA 
Primary 
amphipathic 
M918102 MVTVLFRRL
RIRRACGPP
RVRV 
Tumor suppressor 
protein p14ARF 
7 Proteins, 
PNA 
Secondary 
amphipathic 
YTA2103 YTAIAWVKA
FIRKLRK 
MMP cleavage site 5 small 
molecules 
Secondary 
amphipathic 
YTA4103 IAWVKAFIRK
LRKGPLG 
MMP cleavage site 5 small 
molecules 
Secondary 
amphipathic 
MAP104,105 KLALKLALKA
LKAALKLA 
Synthetic 5 small 
molecules
, plasmids 
Secondary 
amphipathic 
Polyarginin
e83,84,89,106 
R5-15 HIV-1 TAT 5-15 protein, 
peptides, 
siRNA 
Non-amphipathic 
CADY107,10
8 
GLWRALWR
LLRSLWRLL
WRA 
Derived from PPTG1 
peptide 
5 protein, 
peptides, 
siRNA 
Secondary 
amphipathic 
	  
	   7 
 
1.2.1 Protein-derived CPPs 
Protein-derived CPPs are based on known sequences from naturally occurring 
proteins.85  The specific sequences used for these CPPs are generally derived from the 
protein transduction domains (PTDs) of these molecules.  Disruptions in these 
sequences often lead to partial or complete uptake inhibition.82,84,109  Two examples of 
protein-derived CPPs are TAT49-57 and the Antennapedia homeodomain protein 
derivative Penetratin.  These proteins are modeled in Figure	   1.2 with their PTDs 
highlighted in blue.   
 
Figure 1.2.  Models of HIV-1 TAT and antennapedia homeodomain protein with their 
protein transduction domains modeled in blue.   
 
In 1988, Green and Loewenstein, as well as Frankel and Pabo, independently 
reported that HIV-1 TAT had the unique ability to translocate into and out of cells.80,81  
Then, in 1994, Fawell et al. tested the delivery efficiencies of two truncated HIV-1 TAT 
sequences: TAT1-72 and TAT38-72.110  The former was examined because it was thought 
to be involved in protein binding and cellular uptake and the latter was examined 
because it lacked the cysteine-rich region (residues 22-37).110  Both sequences were 
able to deliver proteins, demonstrating that the entire protein sequence was not required 
for efficient delivery.110  This study also compared these sequences to shorter peptides, 
Tat37-58 and Tat47-58, which were also able to deliver proteins to cells.110  Following this 
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study, in 1997, Vives et al. studied four HIV-1 TAT-derived sequences to test the effects 
of altering the α-helical and basic regions on cellular uptake.82  Uptake data illustrated 
that the α-helix was not required for cellular uptake but that there could be no 
interruptions in the basic domain.82  
 In 2000, Wender et al. also studied the TAT peptide, as well as polyarginine.  
They confirmed that the basic region, amino acids 49-57, must be completely preserved 
in order for it to maintain its function.82,84  Truncating the sequence or substituting 
individual amino acids with alanine residues all resulted in a reduction in uptake 
efficiency.  By studying Tat49-57 sequences that were synthesized with D-amino acids 
and/or in reverse, they also illustrated that backbone chirality, hydrogen bonding, and 
overall peptide backbone were not critical for efficacy.84   
 Similar studies were also performed for the antennapedia homeodomain protein.  
This protein contains approximately 60 amino acids, which fold to give three α-helices, 
and is a transcription factor that aids in DNA binding in Drosophila.111  In 1991, it was 
discovered that this antennapedia homeodomain protein could translocate into cells and 
that the third α-helix was important for the its cellular uptake ability.111  Similar studies to 
those performed on HIV-1 TAT, demonstrated that the entire protein sequence was not 
required for cellular uptake, just the 3rd α-helix and that backbone chirality, hydrogen 
bonding, and peptide secondary structure were also not required for uptake.109,112 This 
sequence of amino acids required for uptake has since been referred to as Penetratin.109  
Other CPPs inspired by proteins include pVEC and VP22.95,96 
Through studying HIV-1 TAT, antennapedia homeodomain protein, and their 
structural derivatives, it became apparent that full protein sequences, protein secondary 
structures, and peptide-based backbones are not necessarily required for efficient 
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cellular uptake but that the cationic charge content was absolutely critical.82-84,94,109,110,112  
These results opened up the possibility of designing synthetic mimics. 
1.2.2 Chimera-derived CPPs 
As an alternative to shortened TAT sequences and overcoming some of the 
limitations of the full TAT-protein, amphiphilic peptides with improved stability were 
developed based on a chimeric scaffold.90  Chimera-derived CPPs are fusions of two or 
more naturally occurring protein or peptide sequences.85  Most often, they are the 
combination of sequences that enable specific protein functions, such as nuclear 
localization sequences (NLSs) and signaling sequences.85  One of the first chimera-
derived CPPs reported in the literature was Transportan (AGYLLGKINLKALAALAKKIL-
NH2), which was a fusion of the neuropeptide galanin1-13 and the wasp venom peptide 
mastoparan.100,101,113,114 
One of the most popular examples of a chimera-derived CPP is Pep-1. 90-92 This 
peptide has a block copolymer-like structure with a tryptophan-rich hydrophobic domain 
that is segregated from a lysine-rich hydrophilic domain by a linker and is based on the 
NLS of the simian virus 40 (SV-40) large T antigen, as well as on the reverse 
transcriptase of HIV.90-92  Pep-1 is considered to be a primary amphipathic peptide 
because the hydrophilic/hydrophobic segregation is not dependent on the secondary 
structure of the peptide.90-92  Although stability is often an issue with peptide-based 
carriers, Pep-1 has an acetylated N-terminus and a cystamide C-terminus to improve 
shelf life.  Since the development of Pep-1, structural variations have been made to 
enhance delivery of proteins, peptides, and peptide nucleic acids.91  In addition, Divita 
and coworkers have developed MPG for nucleic acid delivery, which is structurally 
similar CPP with a primary amphipathic and alpha-helical structure.91,98,99  This CPP is 
commercially available as DeliverX™ through Panomics.91,98,99 
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In addition to their amphiphilicity, what set Transportan, Pep-1, and MPG apart 
from others CPPs is their ability to deliver cargo using non-covalent attachment.90-92,99-
101,113,114  Many CPPs, such TAT49-57 and Penetratin, require covalent attachment for 
efficient cargo delivery.81,82,110-112  By developing a non-covalent system, the carrier can 
simply be mixed with its cargo to form a transient complex that can dissociate upon entry 
into cells.  Although this presents in vivo limitations because of the high risk of non-
specific binding, it could mean less complex synthetic procedures and fewer 
experiments to ensure activity is not lost upon chemical conjugation.  
1.2.3 Synthetic CPPs 
Synthetic CPPs are based on a peptide backbone but are not derived from 
naturally occurring protein or peptide sequences.85  CPPs that fall into this category 
include polyarginine; Amphiphatic Model Peptide (MAP), which is a lysine-rich 
secondary amphiphatic peptide; and CADY, which is arginine-rich and self-assembles to 
yield a facially amphiphilic structure.104,115 While polyarginine does not require secondary 
structure or self assembly for delivery, the delivery activities of MAP and CADY are 
highly dependent on their secondary structures.104,115  Disruptions in the helices or self 
assembly lead to diminished delivery efficiencies.104,115  The primary focus in this 
discussion will be polyarginine due to its importance in the development of synthetic 
guanidinium-rich molecular transporters.  
“Polyarginine” and “oligoarginine” broadly define a series of peptide sequences 
that only contain arginine residues and, depending on length, may be synthetically 
easier to prepare than TAT49-57.80-82,84,110  As part of Wender et al’s study in 2000, 
polyarginine (lengths = five to nine resides) was shown to outperform TAT49-57, with 
longer sequences performing better than shorter ones.84 Polyarginine sequences were 
also compared to their D enantiomers and their corresponding peptoids.84  Both sets led 
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to better cellular uptake.  This indicated that cellular uptake was not dependent on 
hydrogen bonding present in the peptide backbone and that the peptide backbone may 
not be necessary.84  Another study from Mitchell et al. in 2000 showed that guanidinium 
groups led to superior uptake efficiencies compared to other possible cationic residues.83  
They also demonstrated that cellular uptake increased as the number of arginine 
residues increased up to 15 and that further increases in arginine content led to 
decreased cellular uptake.83  This suggested that there is a critical number of arginine 
residues required for efficient uptake/delivery.  
Unlike other hydrophobic-containing CPPs such as Pep-1, MPG, MAP, and 
CADY, which contain hydrophobic components to aid in cellular uptake, polyarginine is 
purely hydrophilic.  To further explore polyarginine’s internalization efficiencies, Matile 
and coworkers studied the effect counter ions have on cellular uptake.106   In 2005, they 
reported that pairing polyarginine with bulky, aromatic activators, such as 
pyrenebutyrate, led to better peptide activity.  This study suggested that there was some 
intrinsic benefit to having a hydrophobic component in addition to cationic charge as 
opposed to just having cationic charge.106 
Through systematic studies with polyarginine and other synthetic peptides, it 
became clear that efficient delivery could be achieved without restricting structures to 
naturally occurring sequences.83,84,106  Not only did structure-activity relationships (SARs) 
reveal that these molecules could be optimized for more efficient delivery through 
altering molecular weights and/or structural compositions, but also that the peptide 
backbone was not necessarily essential for successful delivery.  This set the stage for 
the development of tunable delivery vehicles based on novel, abiotic scaffolds. 
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1.2.4 Alternative Classification of CPPs 
 As an alternative to the aforementioned CPP classification system, CPPs can be 
classified based on their distribution of hydrophilic/cationic amino acids and hydrophobic 
amino acids.116  These categories include primary amphipathic, secondary amphipathic, 
and non-amphipathic CPPs.116,117  A summary of CPPs that fall into these categories can 
be found in the last column of Table 1.  For primary amphipathic peptides, segregation 
of cationic and hydrophobic amino acids is based on the sequential order of amino 
acids.  Examples of these peptides include Pep-1, MPG, and Transportan.90-92,98-100  
Secondary amphipathic peptides, such as penetratin, MAP, pVEC, and M918, achieve 
the segregation of cationic and hydrophobic amino acids through their secondary 
structures, which enable them to either form α-helices or β-sheets.95,102,104,105,109,118  
Lastly, non-amphipathic peptides contain mostly cationic residues, with no 
cationic/hydrophobic amino acid segregation including polyarginine and TAT49-57.82-
84,89,110 
 
1.3 Survey of Cell-penetrating Peptide Mimics 
 Although a large body of work focused on the development of peptide and 
peptidomimetic scaffolds for intracellular delivery,79,83,84,119-127 moving away from naturally 
occurring amino acid residues and peptide backbones offers many advantages.  Solid 
phase peptide synthesis can be avoided, which saves both time and money in producing 
the desired delivery vehicles.  Additionally, a non-peptidic system, such as a polymeric 
scaffold, permits the use of different chemistries and allows the chemical compositions 
and polymer architectures to be tailored for efficient cargo delivery.23  As a direct result 
of the easily tunable scaffolds, these materials are expected to be more potent and 
provide new models for fundamental studies.  One prominent example of this is Tew and 
	  
	   13 
workers oxanorbornene-based mimics of R9 referred to as GMe9 and dG9.128  These 
polymeric-based mimics both contain nine repeat units, but dG9 has double the 
guanidine density (18 charges) than GMe9 (9 charges).128  Both of these mimics perform 
better than R9, with dG9 outperforming GMe9, suggesting that higher guanidinium 
density yields better cellular uptake.128  Branched peptide scaffolds have been 
developed127, which increase the guanidinium density.  These molecules have similar 
uptake efficiencies to their linear analogs; however, they are synthetically more difficult 
to access and develop, making it harder to tune uptake and delivery efficiencies.127  
Figure	   1.3 charts the development and progress of guanidinium-rich molecular 
transporters. While this review highlights the use of guanidinium-rich, polymeric 
materials, other scaffolds have been developed and extensively studied, including 
guanidinioglycosides, dendrimers/branched materials, and carbohydrates.129-137  
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Figure 1.3.  Development timeline for key guanidinium-rich CPPM scaffolds.  
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1.3.1 Ring-opening Metathesis Polymerization-based Scaffold 
 In 2008, Tew and coworkers, as well as Kiessling and coworkers independently 
demonstrated that they could use ring-opening metathesis polymerization-based 
scaffolds to design materials with CPP-like activity.  Tew and coworkers employ 
oxanorbornene-based systems for the design of their materials and Kiessling and 
coworkers primarily employ a norbornene-based system.  Both groups selected ROMP 
because it offers fast, efficient, and functional group tolerant polymerizations.138-146  
These polymerizations are often living, allowing for good control over molecular weights 
and polydispersities and allowing for the formation of more advanced architectures, such 
as block copolymers.23,129,147,148  Both groups’ work is summarized below.  
1.3.1.1 Oxanorbornene-based CPPMs 
The first ROMP-based CPPM developed by Tew and coworkers was 
polyguanidinium oxanorbornene (PGON).149,150  This molecule (Figure 4) was originally 
designed as an alternative to their amine-based antimicrobial agents.149  Although it had 
good antimicrobial activity against E. coli and S. aureus and was non-hemolytic, PGON 
was also not membrane-disruptive, suggesting it could also be used as a molecular 
transporter.149  Preliminary dye release experiments using model vesicle systems 
confirmed that PGON (degree of polymerization (DP) = 5-41) was able to induce dye 
release in a non-linear, molecular weight-dependent fashion, further indicating it was 
membrane active and potentially a molecular transporter.150  
In an effort to improve PGON’s activity, hydrophobic monomers, which contained 
alkyl chains ranging from methyl to dodecyl, were copolymerized with guanidinium-rich 
monomers to obtain a new series of CPPMs (Figure 1.3.2).  Inspiration for this came 
from a Matile and coworkers study, which showed that hydrophobic counterion activators 
improve cellular uptake of polyarginine.106  The goal was to develop CPPMs that were 
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“self-activating”, meaning they did not need external activators for improved efficiency.151  
CPPM activity improved with increasing alkyl chain length up until the incorporation of 
the butyl chain (Figure	   1.4)151  Beyond this, CPPM insolubility led to a reduction in 
polymer activity.151  All CPPMs, however, performed better than PGON, indicating the 
importance of incorporating hydrophobic moieties.149-151   
 
Figure 1.4.  Oxanorbornene-based “self-activating” CPPMs.  A) Molecular structures 
and B) Plot of EC50 vs. alkyl chain length.  
 
As a follow up to this study, CPPMs were designed to assess the role of aromaticity.152  
Aromatic groups were selected because they are common structural features in CPPs, 
such as Pep-1 and Penetratin, and because some of the best CPP activators contain 
aromatic groups.90-92,106,109,112  Also, many cellular components contain aromatic groups, 
such as transmembrane proteins, which use aromatic amino acids to stabilize the 
interface between the hydrophilic and hydrophobic portions of the protein.153,154  In 
addition, it has been shown that the flat, rigid shape of aromatic rings along with their 
quadrupole moments can aid in membrane interactions.155 The CPPMs containing 
phenyl rings were the most active in the series, thus indicating the importance of 
aromaticity for CPPM activity.152  Further studies looked to probe the role of π-
electronics in these phenyl ring systems through the incorporation of electron-donating 
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“more active”, because the concentration needed to reach
50% activity is lower. In Figure 1, EC50 values are plotted
against the alkyl chain length of the copolymers G1–G12 with
low and high molecular weights. Two trends are evident from
this data. First, within both molecular-weight series, a
comparison of the EC50 values shows that the activity of the
copolymers increases as the length of the hydrophobic side
chain is increased up to butyl (G4). For longer side chains, the
activity decreases.
Although it is not entirely clear why the more hydro-
phobic side chains are less active, it is likely that aggregation
of these relatively nonpolar polymers plays some role, as G9
and G12 are significantly less soluble than G1–G5. This
hypothesis is also supported by the Ymax values for G9 and
G12, which are significantly smaller than those for copoly-
mers G1–G5 (Supporting Information, Tables S1 and S2).
The second trend is that higher-molecular-weight samples
are more active across the entire series, in agreement with the
previously observed “polymer effect”.[6b] For example, G1 has
an EC50= (20.0! 0.9) mm and (6.4! 0.2) mm for the low- and
high-molecular-weight samples, respectively. Similarly, G4
has EC50 values of (0.20! 0.06) mm and (0.0030! 0.0005) mm.
In all cases, the Hill coefficient generally ranged between n=
1 and n= 3, implying poor cooperativity, which supports
transduction[6b] and no requirement for multichain structures
being involved in the transport activity. These results strongly
support the proposed hypothesis that the presence of hydro-
phobic side chains can be used for “self-activation”. At the
same time, this strong support assumes the mechanism of
action is transduction and not some type of general pore
formation. To investigate this aspect further, G1 and G4 were
evaluated against EYPC/EYPG (EYPG= egg yolk phospha-
tidylglycerol) vesicles containing either CF or calcein. Cal-
cein-loaded vesicles are routinely used to demonstrate pore
formation induced by antimicrobial peptides and their
synthetic mimics.[10]
Figure 2 shows that both G1 and G4 induced nonlinear
increases in the fractional fluorescence from EYPC/
EYPG"CF vesicles as a function of concentration in a
manner similar to that discussed previously. However, and in
sharp contrast, when EYPC/EYPG"calcein vesicles were
used, no fluorescence increase was observed (see triangles in
Figure 2). These experiments strongly support the hypothesis
that these new polymers exhibit transduction activity and that
they are “self-activated” by the presence of the alkyl
substituent.
Even further support for transduction comes from reports
of similar studies conducted on CPPs. These studies similarly
investigated calcein release for classical CPPs, including
R8,[11] R9,[12] and TAT[11,12] in various lipid systems. At very
low peptide-to-lipid (P/L) ratios of 0.05, R9 exhibited 7%
leakage from EYPC"calcein vesicles and was inactive against
EYPC/EYPG"calcein vesicles.[12] TAT48–60 showed 15 and
2% leakage from EYPC"calcein and EYPC/EYPG"calcein
vesicles, respectively.[12] Various P/L ratios were not reported.
Similarly, the ability of R8 and TAT48–61 to induce leakage of
DMPC/DMPG"calcein (DMPC= dimyristoyl phosphatidyl-
choline; DMPG= dimyristoyl phosphatidylglycerol) vesicles
was examined as a function of the P/L ratio.[11] Consistent with
the previous findings,[12] at low P/L ratios, little to no leakage
was observed; however, at P/L= 1.2, greater than 10%
leakage was observed (R8 ca. 18% and TAT48–61 ca.
10%).[11] As shown in Figure 2, G1 and G4 induced no
change in calcein emission, despite very high P/L (here:
polymer-to-lipid) ratios above 20 (Supporting Information,
Figure S5). These experiments clearly demonstrate that the
novel polymers reported herein are able to induce increases in
CF emission but not in calcein emission (even at very high P/L
ratios), completely consistent with the numerous reports on
CPP"CF transduction.
To further explore the molecular design of these CPP-like
polymers, we designed and synthesized another series of
polymers (G1’ and G4’, Scheme 2). Unlike the statistically
random copolymers G1–G12, these new homopolymers
contain a precise sequence of guanidinium and alkyl side
chains on every repeat unit. The monomers for G1’ and G4’
were synthesized in three steps and polymerized by ROMP
(Supporting Information, Scheme S6). G4’, with an EC50
value of (0.0010! 0.0004) mm, exhibited three orders of
magnitude better activity than G1’ (EC50= (1.3! 0.2) mm),
which is similar to the trend observed for G4 (EC50=
Figure 1. Effective concentrations (EC50) of low-molecular-weight and
high-molecular-weight copolymers G1–G12 as a function of alkyl side-
chain length.
Figure 2. Hill plot for copolymers G1 and G4 in EYPC/EYPG"CF
vesicles with fits to the Hill equation (circles). G1 EC50=0.4 mm, G4
EC50=0.04 mm. G1 and G4 remained inactive against EYPC/EYPG"
calcein vesicles (triangles).
Communications
6148 www.angewandte.org ! 2011 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2011, 50, 6147 –6150
A. B. 
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and electron-withdrawing groups.  All CPPMs, regardless of the electron rich or electron 
poor ring, maintained similar membrane activities.156  This demonstrated both the limits 
of the structural tuning that could be performed in this system and the number of 
structural options available without loss of membrane activity.156 
Tew and coworkers also designed CPPMs based on di-armed oxanorbornene 
monomers.  This system added more synthetic versatility as each monomer contains 
two functionalities that can be independently tuned.23  Homopolymers containing one 
guanidine group and one hydrophobic group (aliphatic, aromatic, electron rich / electron 
poor aromatic systems) per monomer were designed as a direct comparison to their 
imide counterparts.  These polymers had similar activities compared to the imide 
system.151,156 In addition, further studies were aimed at understanding the role of 
functional group segregation.  The results indicated improved delivery efficiencies of a 
block copolymer scaffold without loss of activity in the presence of serum compared to 
its homopolymer counterparts (Figure	   1.5).157  This block copolymer was designed to 
capture the guanidinium-rich nature of TAT49-57 and the amphiphilicity of Pep-1.82-84,90-92  
Follow-up studies explored the functional group distribution using constitutional 
macromolecular isomers, which are polymers of the same degree of polymerization but 
different arrangements of their pendent groups, ranging from completely segregated to 
completely mixed.158  These arrangements were accessed through block (completely 
segregated), gradient (partially segregated), and homopolymerizations (mixed 
distribution).158  Although studies indicated that the homopolymers enabled the best 
cellular uptake of the polymers, it is likely that block copolymers will deliver cargo more 
efficiently, as suggested by the literature.148,157,159,160 
While early studies with PGON strictly applied model vesicle systems to assess 
membrane activity, di-armed homopolymers were chosen to assess the effect of 
guanidinium density on cellular uptake in three different cell lines: HEK293T, CHO, and 
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Jurkat T cells.128  Although these polymers could enter all cell types with low cell death, 
uptake efficiencies were highly cell line-dependent.128  In all cases, these CPPMs 
outperformed polyarginine (R9).128  These studies were extended to explore 
constitutional macromolecular isomers, wherein cellular uptake was the best for the 
homopolymer tested and uptake efficiencies were found to be cell-type dependent.  To 
further these studies by probing the effect of architecture when delivering biologically 
relevant cargo, a block copolymer was synthesized containing a 1:1 (n=m=5) ratio of 
hydrophobic to cationic monomers (Figure	  1.5).157,161  
 
Figure 1.5.  Delivery of siRNA to NOTCH1 into human peripheral blood mononuclear 
cells (PBMCs).  A. Block copolymer structure used for delivery. B. Percent relative 
protein expression as a function of time for PBMCs that received siRNA to NOTCH1 
(siN1) and PBMCs that received a scrambled, negative control (siCont).  
 
This block copolymer was shown to deliver FITC-tagged siRNA and bioactive siRNA to 
NOTCH1 in Jurkat T cells and human peripheral blood mononuclear cells (hPBMCs), 
respectively, with > 90% viability.157  Delivery efficiencies were not altered by the 
presence of serum proteins in the media.  The NOTCH1 knockdown results were 
noteworthy because 50% knockdown of an active gene was reported (Figure 1.3.3).157  
This siRNA study represents proof of concept work that explored the delivery capabilities 
of this type of CPPM.  Additional SARs studies contained in this thesis aimed to 
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determine design princples for efficient siRNA delivery using these molecular 
transporters.  These studies will also be expanded in order to develop design 
parameters for other biologically relevant cargo.23 
1.3.1.2 Norbornene-based CPPMs 
 Kiessling and coworkers developed a norbornene-based scaffold.147,148  Single-
armed norbornene monomers for these materials initially contained succinimidyl ester 
moieties, which provided handles for post-polymerization functionalization.  Polymeric 
materials could be reacted with N-(3-aminopropyl)guanidine in the presence of N-methyl 
morpholine to achieve near complete replacement of the succinimidyl ester pendent 
groups.  This scaffold is based on previously published work.162  The guanidinium-rich 
scaffold builds on this initial work by terminating the polymers with an enol-ether, which 
allows for dye-labeling the polymer chains for easy tracking of the materials during 
cellular experiments.147  Uptake of these labeled molecules in HeLa cells was monitored 
using fluorescence imaging and results indicated that the polymer was trapped in 
endosomes, as noticed by punctated fluorescence, with some polymer dispersed in the 
cytosol.147  Greater than 95% viability was observed for all polymer concentrations tested 
(up to 5µM).147   
Given that after post-polymerization functionalization only homopolymer and 
random copolymer architectures can be accessed, follow-up work looked at the 
formation of block copolymers.147,148  Two monomers were developed that could be 
modified post-polymerization by chemospecific methods, one succinimidyl ester-
containing monomer and one alpha chloroacetamide-containing monomer.148  These 
monomers were polymerized sequentially in order to yield a block copolymer template.  
Based on the different chemistries involved, this template could be modified post-
polymerization using separate reactions to yield segregation of attached functional 
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groups.148 High degrees of conversion were demonstrated for both starting functional 
groups.148  Internalization of dye labeled block copolymers was demonstrated using 
HeLa cells, with cellular uptake following similar patterns to their previously reported 
homopolymer counterparts.148 
More recently, Kiessling and coworkers developed a completely degradable 
ROMP scaffold using oxazinone-based monomers.163  The authors demonstrated that a 
wide range of functional groups could be incorporated into these scaffolds, making them 
potential candidates for drug delivery and biomaterials applications.163-166 
1.3.2 Polymethacrylamides 
 In 2012, McCormick and coworkers reported the synthesis of guanidinium-rich 
polymethacrylamides using aqueous reversible addition fragmentation chain transfer 
(aRAFT).160  This synthetic method was advantageous for the synthesis of materials 
because polymerizations by this method are well-controlled and the guanidinium-
containing monomers could be polymerized without protecting groups.160  
Homopolymers were synthesized using a N-[3-(dimethylaminopropyl) methacrylamide 
monomer and copolymers were synthesized using a N-[3-(dimethylaminopropyl) 
methacrylamide and N-[2-(hydroxypropyl) methacrylamide monomer.160  Similar to 
polymers generated by the Tew and Wender groups, both sets of polymers were readily 
able to enter KB cells, with block copolymers out performing their homopolymer 
counterparts.148,157,159,160 The authors note that the good control over the polymerization 
technique could enable this platform to be used for bioactive cargo delivery.160  More 
recently, Peneva and coworkers developed a series of guanidinium-rich, statistical 
copolymers using aRAFT as potential siRNA delivery reagents.167  Binding strength and 
competitive binding were studied but, to date, no cellular uptake or viability results have 
been reported.167   
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1.3.3 Oligocarbonates 
Wender, Hedrick, Waymouth and coworkers developed a series of CPPMs 
based on oligocarbonate polymers.159,168  Molecules were synthesized using metal-free, 
ring-opening polymerization of cyclic carbonates.159,168  Initiators for these materials were 
designed such that the drug molecule or molecular probe to be delivered could be 
attached at the beginning of the polymerization to allow for simpler conjugation to 
various cargoes.168  These molecules were shown to be biodegradable under 
physiological conditions, with half-lives around eight hours.  Cellular uptake in Jurkat T 
cells revealed that these polymers entered in a charge-dependent manner, with longer 
polymers outperforming their shorter counterparts.  To assess whether a biologically 
active cargo could be delivered, proof-of-concept experiments were performed in which 
luciferin was successfully delivered and shown to luminesce in HepG2 cells.  
In a follow-up study, Wender, Hedrick, Waymouth and coworkers showed that 
they could tune their oligocarbonate structures through the incorporation of hydrophobic 
moieties for more efficient siRNA complexation and release.159  Experiments with a dual-
functional reporter HaCaT cell line that expressed both enhanced green fluorescent 
protein (EGFP) and Tomato fluorescent protein (tdTOM) was utilized to show specificity 
of knockdown.159  Delivery of siRNA to tdTOM was shown to yield efficient reduction in 
tdTOM protein levels but to have a negligible effect on EGFP protein levels, thus 
demonstrating good knockdown specificity.159  Polymers were shown to perform better in 
serum free media (86% knockdown) than in serum-containing media (64%).159  
Oligomers that incorporate longer alkyl chains (up to dodecyl) were also shown to out 
perform their counterparts that contained shorter alkyl chains.159  Shorter oligomer 
lengths were also shown to out perform their longer counterparts.159  Cell viability studies 
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using the 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) assay 
demonstrated that the most active polymers showed significant toxicity at the higher 
concentrations tested (100 nM) but could be greatly improved by cutting the polymer 
concentrations in half (50 nM).159  Lastly, it was demonstrated that knockdown 
efficiencies and complex sizes could be tuned by mixing different oligomers.159  Overall 
Wender, Hedrick, Waymouth and coworkers developed a versatile, biodegradable 
platform for efficient delivery of biologically active siRNA.  This platform has since been 
expanded by Wender et al. to include glycerol-based monomers to allow for better 
control over oligocarbonate/siRNA complex stability.169   
 
1.3.4 Poly(disulfide)s 
Poly(disulfide)s are polymers that contain at least one disulfide bond in the 
polymer repeat unit structure.170  These materials are different from proteins and 
vulcanized rubber, which both utilize disulfide bonds for crosslinking.170  Poly(disulfide)s 
can serve as efficient delivery reagents for nucleic acids and proteins, releasing their 
cargo through reductive de-polymerization in the presence of glutathione.  Initially 
poly(amido amines) (PAAs) containing disulfide bonds were explored.  These materials 
were synthesized by reacting cationic and/or hydrophobic monomers with 
cystaminebisacrylamide using Michael addition.171,172  This platform is functional group 
tolerant, allowing for the incorporation of a wide range of functionalities, which enabled 
fine-tuning of PAA structures for efficient uptake and delivery.173-175 Kim and coworkers, 
utilized a similar platform to design poly(disulfide amines) and their guanidinium-rich 
counterparts, which are often referred to as arginine-grafted bioreducible polymers 
(ABPs) and guanidinylated bioreducible polymers (GBPs).176-182 The ABPs and GBPs 
molecules led to higher transfection efficiencies when compared to their amine 
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counterparts.177,179-182  ABPs have been explored for RNAi applications related to anti-
angiogenesis gene therapy of tumors as well as ex vivo pDNA delivery vehicles for 
treatment of ischemic heart diseases.177,179-182   
 While most poly(disulfide) delivery reagents utilize non-covalent delivery 
strategies, Matile and coworkers developed an efficient method of generating cell 
penetrating poly(disulfide)s that are covalently attached to their cargo utilizing surface-
initiated ring-opening disulfide-exchange polymerization.183,184  Many probes, drugs, and 
bioactive cargoes contain or can be easily made to contain thiol moieties, which makes 
them convenient initiating species for this polymerization method.  Molecule formation 
and subsequent depolymerization in the presence of dithiothreitol (DTT) were monitored 
using dye-loaded vesicles.183,184  Fast, efficient delivery (5 minutes), and subsequent fast 
depolymerization rates to release cargo into the cytosol (1 minute) were demonstrated in 
HeLa cells.184  Low toxicities were demonstrated for all molecules tested up to 10µM.184  
Molecular uptake mechanism was independent of the cargo but could be altered based 
on the hydrophobic/cationic content of the materials.183  The authors also suggested a 
thiol/counterion-mediated uptake mechanism to explain cell entry and how chemical 
compositions of the delivery vehicles change their ability to enter cells efficiently.184   
 
1.4 Biophysical Characterization of CPP(M)s/PTD(M)s  
Biophysical assays using model membranes can assess internalization and 
membrane interactions of CPPs/PTDs and their synthetic mimics.106,149-152,170,183,185-189  
These methods represent simpler systems than cells and remove complexities of active 
transport, such as endocytosis, and receptor-mediated uptake and focus primarily on 
mimicking direct translocation and membrane interactions.  Commonly, large unilamellar 
vesicles (LUVs) that are swelled with dyes, such are carboxyfluorescein, are used to 
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evaluate membrane leakage.106,149-152,156,170,183,185-189  Carboxyfluorescein is self-
quenched at high concentrations and its release from model membranes can be 
monitored using either a fluorimeter, or in the case of a more high-throughput screening 
method, a fluorescence plate reader.156  Dye leakage as a function of polymer 
concentration can be monitored, and data points can be fit to the Hill Equation to 
determine EC50 values, which are the effective concentration at which 50% of the dye is 
released.106,149-152,156,185-190  These values can be compared across many peptide 
systems to assess their membrane activities.  Lipid compositions of these membranes 
can be tuned to assess how the incorporation of different lipids and/or the overall charge 
of the vesicles impacts membrane activity.152,156  Tew and coworkers,150-152,156 Matile and 
coworkers,106,150,170,183,188,189 and Almeida and coworkers185,186 used similar assays as a 
way to study the way molecules interact with model membranes.  In addition to these 
authors, other researchers, including Pooga and coworkers, developed more advanced 
lipid systems.191  Using chemical formulations, cells can be induced to produce small 
vesicles by budding off parts of their membranes.  These systems more closely 
resemble actual lipid membrane compositions because they often include membrane 
proteins and cell surface receptors.191 
 
1.5 Modes of Internalization for CPP(M)s 
The mechanisms of CPP(M) uptake remains highly debated in the 
literature.79,116,119,123  Early studies suggested direct translocation as the primary mode of 
internalization, which refers to molecules crossing membranes and directly entering the 
cytosol.192-194  However, many of these observations were shown to be erroneous, 
primarily due to cell fixation, which permeabilizes cell membranes and allows 
extracellular cargo to be internalized.192-194  Additional modes of uptake have been 
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considered, including engulfment of particular molecules by the cell’s membrane through 
forms of endocytosis, such as Clathrin-mediated endocytosis, caveolae-mediated 
endocytosis, macropinocytosis, and receptor-mediated endocytosis.116,119,123,194  
Glycosaminoglycans and lipid compositions are also thought to play a role in uptake 
mechanism.119  Complicating matters even further, experimental conditions including, but 
not limited to, composition, cargo, concentration, and cell types as well as incubation 
temperatures and times may play distinct roles in modes of internalization.79,116,119,123  
Extensive effort has been made to understand the primary modes of 
internalization.  One common way to do so is to inhibit certain entry methods and to 
compare uptake and delivery efficiencies to those cells under normal conditions.195-197  A 
summary of common methods can be found in Table	  1.2.  It is important to keep in mind 
that inhibiting specific modes of uptake may actually cause the cell to up-regulate other 
modes of entry or lead to off-target effects.195-197  It is also important to note that CPPs 
likely enter cells through multiple methods at the same time, with the different possible 
modes of cellular uptake being highly cell-type dependent.116,198,199 
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Table 1.2. Summary of Inhibitors, the pathways they affect, and the blocking 
mechanisms.  
Inhibitor Affected Pathways Blocking Mechanism 
Lowered Temperature 
(4°C)200 
Energy dependent Reduces cell metabolism, 
inhibiting energy-dependent 
pathways 
Sodium azide and 2-
deoxy-D-glucose201 
Energy dependent Depletes ATP 
Cytochalasin D119 Macropinocytosis Promotes disassembly of the 
actin cytoskeleton and blocks 
actin polymerization  
Wortmannin202 Macropinocytosis and 
Clathrin-mediated 
endocytosis 
Inhibitor of phosphatidylinositol 
3-kinase inhibitor 
5-(N-ethyl-N-
isopropylamiloride)119 
Macropinocytosis Inhibitor of sodium-proton pump 
exchange 
Chloroquine203,204 Endosomal Escape Promoted endosomal escape 
Nocodazole205,206 Macropinocytosis Blocks actin polymerization and 
disrupts actin cytoskeleton 
Chlorpromazine and 
sucrose207 
Clathrin-mediated 
endocytosis 
Depletes clathrin and AP2 
adapter protein complex 
Dynasore208 Clathrin-mediated 
endocytosis 
Dynamin inhibitor 
Methyl-β-Cyclodextrin209 Clathrin-independent 
endocytosis 
Cholesterol extraction from 
membrane 
In addition, colocalization studies, which look at where polymer/cargo complexes 
end up in cells, and biophysical methods, which look at interactions between 
polymer/cargo complexes with lipid membranes, have also been utilized to elucidate 
uptake mechanism.106,151,152,185,186,188,189,210-214  To date, no one method has been shown 
to clearly document all possible and prominent methods of internalization.79,116  Often 
many methods need to be taken together in order to begin to understand what is 
happening in the cellular environment.  This challenging problem is an area of active 
research.  
 
1.6 Methods of Bioactive Cargo delivery, with a Focus on T Cells 
 Delivery of therapeutic agents is an ongoing challenge for the biomedical 
community.73-79,215  Many methods have been developed in efforts to help efficiently and 
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reliably deliver bioactive molecules across cellular membranes.  Although CPP(M)s fall 
under the category of transfection/transduction, this method as well as other methods of 
delivery are summarized in this section, along with their major advantages and 
disadvantages, to have a more complete view of the delivery options available to the 
field.  
1.6.1 Electroporation 
Electroporation is a method of delivery that applies a short, high voltage pulse to 
cell membranes as a way to transiently permeabilize them.216,217  This technique was 
initially developed for gene delivery.  Voltages for this process typically range from 0.2-
1V, depending on the resting transmembrane potential of the cell type.216,217  The longer 
the pulse applied to the cells, the more pores that form in the membrane.216,217  While it 
only takes a couple seconds for pores to form, the resealing of the membrane can take 
several minutes, which provides time for charged cargo to enter the permeabilized cell.  
The major drawback of this method is the high cell death (50-60% viability often 
reported) due to high voltages and membrane resealing time.216-219  Although long-term 
stability results show improved viability, initial viability after treatment often remains 
low.218,219   
1.6.2 Viral Vectors 
Viral vectors harness the ability of viruses to infect host cells.85  In their design, 
the genes that allow them to replicate or cause toxicity are removed but the ones that 
allow for capsid formation and the incorporation into the host genome remain to facilitate 
stable expression of a desired addition to the infected cell type.85  The protein coating of 
the virus capsid can also be varied in order to allow for a wider range of cells to be 
transduced.85  Three different types of viral vectors used for these applications include 
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adenoviral vectors, retroviral vectors, and lentiviral vectors.85  Adenoviral vectors have 
been used in vitro for vaccine development and gene delivery.85  These vectors suffer 
from major drawbacks, which include the inability for its DNA to incorporate into the host 
genome and immune responses that are mounted by the host in response to the 
presence of the adenoviral vectors.85,216  For this method to be improved, adenoviral 
vectors that humans are not immune to would need to be identified.  
Retroviral vectors contain reverse transcriptase, which enables incorporation of 
the desired gene into the host cell;85 however, the major drawback of this method is that 
it requires that the cells be dividing in order to for genome incorporation to occur.85,216  
Without the breakdown of the nuclear membrane, which occurs during cell division, 
incorporation cannot be achieved.85,216  There have also been reports of this method 
leading to instances of malignancies as a result of genetic incorporation near proto-
oncogenes and alterations to the genome that may change copy number or delete the 
tumor suppressor genes.216  Lentiviral vectors, which are a subclass of retroviral vectors, 
offer the advantage that they can infect and integrate their genetic material into non-
dividing cells.216  Most often, HIV-based vectors are selected.  Despite the advantage 
offered by this system, there is still the chance that malignant transformations can 
occur.85,216  The safety of these vectors needs to be evaluated on a case-by-case basis.   
1.6.3 Microinjection 
 The process of microinjection involves gripping individual cells with a capillary 
holder and using a micro-needle to deliver cargo into the cell.220  This method offers 
many advantages, including that the exact amount of cargo injected into the cells is 
known, that it is not cell-type dependent, and that it can allow for quantitative delivery 
directly to the nucleus.220  Despite these advantages, this method suffers from major 
drawbacks.  For this method, cells need to be injected individually, which is both time 
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consuming and limits the numbers of cells that can be treated.220  The low cell numbers, 
in turn, makes extensive exploration of treatments difficult.220  Lastly, this method often 
has a steep learning curve and takes a long time to master.220  
1.6.4 Lipofection 
 Lipofection is a method of delivering cargo into cells using liposomes.221  Most 
often, cationic lipids are used to complex with anionic cargo to form liposomes, which in 
turn can fuse with the phospholipid bilayer of cells to deliver its cargo into the cytosol.221  
This method is advantageous because it is compatible with many cell types and 
generally has good efficiencies and low toxicities.221  The major drawback of this method 
is that this method has poor efficiencies in the presence of serum proteins.221   
1.6.5 Delivery Using Transfection/Transduction Reagents 
 This method of delivery uses a carrier molecule to associate with a desired cargo 
to help facilitate the cargo’s cellular internalization.  Delivery reagents of this sort can 
either be peptides90,92,107,110,113,115, lipids222,223, or polymers157,159,168-170,176,179,183,224 and 
they often associate with cargo by covalent or non-covalent interactions.  Methods of 
association with the cargo with the carrier molecule will be discussed in the next section. 
The ratio of delivery reagent to cargo ratio must also be determined for each new 
delivery reagent, cargo, and cell type used for experiments.  These materials hold much 
promise in the realm of biological cargo delivery due to the fact that they are often less 
toxic and lead to fewer mutagenic effects than other methods previously discussed.75,225-
227  Despite these advantages, some reagents still suffer from poor efficiencies in certain 
cell types, particularly immune cells.75,225-227  This thesis will primarily focus on the 
development of polymeric-based transfection reagents and how the structures of these 
	  
	   30 
materials impact their internalization efficiencies.  Development of design principles for 
these materials will help guide the further development of efficient delivery reagents.  
1.6.6 Association of Carrier Molecule with Cargo 
 For transfection experiments, the cargo of interest can be associated to the 
carrier molecule using covalent linkages or non-covalent interactions.  When using 
covalent attachment, chemical reactions are generally used to form either degradable or 
non-degradable linkages between the carrier molecule and the cargo.110,228-232  Although 
this method is advantageous, particularly for in vivo applications, because the covalent 
attachment ensures the cargo is always associated with the carrier molecule, the 
formation and presence of these linkages can lead to other complications.110,228-232  
Chemically modifying cargo presents the risks of either denaturing the cargo or adding 
the linkage to an area of the cargo that may impact its biological function.230  
Additionally, complex conjugation steps need to be preformed for each unique cargo to 
be delivered, which can be costly.228  CPPs such as TAT110, penetratin109, and 
polyarginine89 have all been shown to deliver covalently attached cargo. 
An alternative to the covalent attachment method is the association of cargo 
using non-covalent interactions.  Most often, this involves the use of electrostatic or 
hydrophobic interactions to associate the carrier molecule with the cargo.  This method 
is advantageous because the conditions for complex formation are more mild and 
because it opens up the opportunity to use one carrier molecule for multiple different 
cargoes.  The major drawback of this method, however, is the susceptibility for these 
complexes to exchange out their cargo for something else in the surrounding 
medium.216,233  This presents a major limitation for in vivo application, but may be 
avoided for ex vivo and in vitro experiments.  CPPs such as Pep-1 and MPG have been 
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used for the non-covalent delivery of proteins and siRNA, respectively.90,99  Non-covalent 
attachment has also been a common method used with polymeric deliver reagents.233 
1.6.7 Cargo Selection 
 When selecting a delivery reagent, it is very important to take into consideration 
the cargo being selected.  Although proteins, siRNA, pDNA, and small molecules may 
fall under the general umbrella of “bioactive cargo”, often times they require delivery 
reagents to be tailored for specific delivery of one type of cargo.234  For example, even 
though siRNA and pDNA are both negatively charged and comprised of nucleic acids, 
separate delivery reagents are often required given the different issues associated with 
delivery of each cargo.234   siRNA is much smaller, only consisting of 18-21 base pairs, 
and reagents needs to address issues with siRNA easily being exchanged out of a 
complex for other, larger, negatively charged molecules in the delivery medium and with 
the fact that it ribonucleic acids are not as stable as deoxyribonucleic acids and are 
therefore more easily degraded.234  In comparison, pDNA consists of thousands of base 
pairs and the primary delivery concern condensing the DNA and masking the negative 
charge.234  It is not uncommon for companies to offer different variations of delivery 
reagents that are tailored to specific cargo.  For this thesis, siRNA was specifically 
selected as the cargo of choice for structure activity relationship studies.   
1.7 siRNA and RNAi 
In 1998, Andrew Fire and Craig Mello published their discovery of RNA 
interference (RNAi), a process that has been shown to temporarily reduce gene 
expression following the destruction of mRNA.235  This process continues to be an 
important tool to probe molecular pathways and treat diseases.153,236-239  Small interfering 
RNA (siRNA), which represents one RNAi approach, must be present in the cytosol so 
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that the siRNA guide strand can be incorporated into the RISC complex and degrade its 
complementary mRNA.  This leads to transient, sequence-specific, post-transcriptional 
gene knockdown,240-242 which is advantageous for discrete biological and clinical 
applications.153,236-239  Although in some cases siRNA is endogenously produced, for 
most desired applications, it must be exogenously produced and then introduced into 
cells.243  siRNA’s net negative charge and susceptibility to degradation by RNases pose 
challenges for cellular internalization.216  Additional challenges associated with siRNA 
are related to off-target effects related to sequence overlaps within the biological system 
or due to concentration-dependent effects.244-248  Developing delivery strategies that 
meet the requirements of siRNA internalization while minimizing off-target affects is 
growing area of research and holds great promise for advancing our understanding of 
cellular processes and for developing new disease treatments. 
 
1.8 T Cells and Their Delivery Challenges 
 Although there are many challenges associated with intracellular delivery, 
delivery to T cells poses added difficulties.216  T cells are key components of the immune 
system.  They orchestrate essential functions during the immune response to 
pathogens, chronic inflammation, and autoimmune disorders.249  In vivo delivery to this 
subset of cells poses both the problems of targets T cells and crossing cellular 
membranes.216  While monoclonal antibodies specific to T cell receptors have been 
tethered to biomolecules to provide targeting capabilities, it does not address the issues 
with cellular internalization or cargo stability.216  These are particularly problems for 
cargoes such as siRNA, which can be easily degraded while traveling through the 
bloodstream without proper protection. 216    Although these challenges can largely be 
avoided using ex vivo delivery, which involves extracting cells from a patient, treating 
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them in vitro, and then re-introducing them into the patient, T cells, particularly primary T 
cells, are considered “hard-to-transfect.” 216   Only select commercial delivery reagents 
are able to facilitate cargo internalization in T cells lines and even fewer are able to 
delivery to primary T cells.  Although electroporation and viral vectors have sometimes 
been used in place of a reliable transfection reagent, these methods often lead to high 
cell death, immunogenicity effects, or require T cell activation prior to, or concurrently, 
with delivery. 216    The need for reliable T cell delivery vehicles is high.  Successful 
delivery reagents for these subsets of cells would provide avenues for exploring 
molecular pathways and for developing new disease treatments.   
 
1.9 Thesis Overview 
Herein we document efforts to tune polymer-based protein mimic structures for improved 
internalization and delivery of siRNA.  Ring-opening metathesis polymerization (ROMP) 
was utilized for the synthesis of these molecules since it is a fast, efficient, and functional 
group-tolerant method that also allows for relatively precise control over molecular 
weights and polydispersities.138-146  Also, since ROMP is a living polymerization, it allows 
for the formation of more advanced architectures, such as block copolymers.138-146  
Structure activity relationships (SARs) using model membranes and cells were used to 
probe how polymer composition, molecular weight, and architecture impact polymer 
activity and siRNA internalization and delivery efficiencies. By understanding the 
essential design principles necessary for siRNA internalization and delivery, the next 
generation of efficient CPPMs/PTDMs can be optimized for specific applications.   
 Chapter 2 explores how π-elections of aromatic systems incorporated into our 
CPPM/PTDM systems impacts their resulting membrane interactions.  Following this, 
chapters 3 and 4 document the development of design principles for the development of 
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our ROMP-based PTDMs.  Chapter 3 specifically establishes that there is a critical 
cationic charge content necessary for efficient siRNA delivery and that the addition of a 
hydrophobic block lead to improved efficiencies compared to their corresponding 
homopolymer counterparts with the same cationic charge content.  Building on this, 
Chapter 4 explores the role hydrophobicity plays in siRNA delivery efficiencies, 
establishing a critical hydrophobic window for which there is optimal siRNA 
internalization.  The thesis then concludes with Chapters 5 and 6, which address 
potential future directions for this work and summarize materials and methods, 
respectively.   
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2 CHAPTER 2 
DESIGN OF AROMATIC-CONTAINING CELL-PENETRATING PEPTIDE 
MIMICS WITH STRUCTURALLY MODIFIED π-ELECTRONICS 
2.1 Introduction 
Cell-penetrating peptides (CPPs) and their synthetic mimics (CPPMs) represent a 
unique class of molecules that is capable of crossing biological membranes.1-10  The 
peptides are generally short, cationic sequences rich in arginine and/or lysine residues, 
with some containing hydrophobic residues such as leucine, phenylalanine, or 
tryptophan.2,7,9,10  They derive inspiration from proteins with translocation abilities, such 
as HIV-1 Tat and Antennapedia Homeodomain protein.11-13  It has been shown that the 
cation-rich domains of these proteins, referred to as protein transduction domains 
(PTDs), are primarily responsible for their uptake abilities.11,14-16  Many studies have 
highlighted the ability of CPP(M)s to facilitate the intracellular delivery of various cargo, 
including, but not limited to, small molecules, siRNA, pDNA, and proteins via covalent or 
non-covalent interactions.2,3,5,7-10,17-22  Although their mechanism of uptake is debated in 
the literature, various forms of endocytosis, macropinocytosis, protein-dependent 
translocation, and energy-independent translocation are involved in the internalization 
process.23-28 
 In efforts to elucidate the mechanisms of CPP(M) uptake and assess the 
structural components of CPP(M)s necessary for uptake, model vesicle membrane 
studies have frequently been used.29-33  Vesicle experiments represent a simpler system 
for evaluating energy-independent methods of transduction than using cells, where it is 
difficult to decouple various methods of cellular uptake.  Previously, Matile and 
coworkers have used model vesicle systems to show that polyarginine, a widely used 
CPP, requires hydrophobic counterions to efficiently cross lipid membranes.30,34-37  For 
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these studies, lipids were swollen in a solution of carboxyfluorescein, which is a 
hydrophilic, anionic dye that self-quenches at high concentrations, and dye release was 
monitored as a function of peptide concentration.  Changes in peptide activity were 
assessed by calculating the effective concentrations to release 50% of the dye (EC50).  
Similar assays were also been used by Almeida and coworkers to explore CPP 
internalization mechanisms.38,39  The hydrophobic counterions selected for Matile and 
coworkers’ studies were said to help mask the overall cationic charge of the peptides to 
aid in transduction, a process referred to as activation.30,34-37  Although these studies 
showed that bulky aromatic activators, such as pyrene butyrate, outperformed aliphatic 
activators, the roles of hydrophobicity and aromaticity were not fully understood.   
Motivated by these studies, our lab previously developed a series of 
oxanorbornene imide-based CPPMs to assess the effect of hydrophobicity on CPPM 
activity.32,33  Instead of using external activators, the hydrophobic components were 
chemically incorporated into the polymeric structures to yield self-activating 
polymers.32,33  These polymers were correctly predicted to outperform their counterparts 
that only contained cationic residues.29,32,33  Initially, various aliphatic chains were 
incorporated into the CPPMs to assess the effect of chain length on activity.33  These 
results were evaluated by assessing differences in reported EC50 values from vesicle 
dye release assays.35  Although polymer activity improved by increasing the alkyl chain 
lengths from one carbon to four carbons, longer alkyl chains were less water soluble and 
thus led to poorer performance.33 
Another series of polymers was designed to evaluate the impact of various 
aromatic, cyclic non-aromatic, and alkyl hydrophobic moieties of similar hydrophobicity 
on polymer activity.32  This was done to gain a better understanding of the interplay 
between hydrophobicity and aromaticity.  Aromaticity was the cornerstone of that report 
because of the significant role it plays in protein-membrane interactions.  The aromatic 
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amino acids tyrosine and tryptophan are present as part of aromatic belts that flank 
either end of transmembrane proteins.40,41  These residues sit at the interface between 
the hydrophobic core of the proteins and the more hydrophilic external environment to 
enhance stability at those regions.40,41  Although not typically present in aromatic belts, 
phenylalanine has also been shown to aid in anchoring proteins in the membrane.42,43  
All three of these aromatic amino acids have been shown to provide favorable energies 
of insertion into membranes.42,43  It was further reasoned that aromatic moieties are ideal 
for incorporation into CPPMs because such residues are found in many CPPs such as 
Penetratin, Pep-1, and MPG and have been shown in some cases to be critical for 
uptake.5,44-47  Experiments in which aromatic residues in Tat and Penetratin were 
replaced with non-aromatic hydrophobic residues led to a reduction in cellular 
interalization efficiencies.5,44-47  
Using HPLC retention times to assess relative hydrophobicity of the polymer side 
chains48,49, these values were compared to the polymer EC50 values to illustrate that the 
effects of hydrophobicity and aromaticity could be distinguished.  Through these studies, 
it was suggested that aromatic hydrophobic moieties were superior activators.32  Similar 
results were obtained by Matile and coworkers when they monitored dye release of 
polyarginine with various external activators.37 
Given these observations and the different electronic properties of tyrosine, 
phenylalanine, and tryptophan (Figure 2.1) the role of aromaticity in CPP(M) activity was 
studied by exploring the effect that changes in quadrupole moments have on these 
systems.    
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Figure 2.1.  Electrostatic potential maps and values for modeled aromatic rings in amino 
acids phenylalanine, tyrosine, and tryptophan.  A) Electrostatic potential.  The range for 
electrostatic potential was set between -30.00 and 30.00 kcal/mol.  The color scale bar 
reflects this range with red representing electron-rich surfaces and blue representing 
electron-poor surfaces.  All surfaces were calculated at the HF level using the 3-21G* 
basis set.  B)  Electrostatic potential values in kcal/mol taken from the center of the 
aromatic ring system.   
 
The flat, planar structures of these aromatic rings and their associated quadrupole 
moments are thought to enable various π-interactions, such as π-π, π-cation, π-anion, 
and π-polar interactions within the cellular environment that can aid in membrane 
interactions.42,50-55  Since the quadrupole moment collects the electron density on the 
face of these planar, aromatic rings, it was hypothesized that by strengthening or 
weakening this phenomenon, the corresponding π-membrane interactions would provide 
additional handles for tuning of CPPM activity.  Specifically, this was attempted by 
incorporating electron donating and electron withdrawing groups into the aromatic 
systems as a way to alter the electron density of the ring system.  Although nature offers 
an electrostatic potential range for its aromatic amino acids between -31.41 kcal/mol 
(Trp) and -23.48 (Tyr) kcal/mol, by using synthetic systems, it was possible to examine a 
much wider electrostatic potential window of -29.69 kcal/mol (Figure	  2.2, R= b = CH3) to 
+15.57 kcal/mol (Figure	  2.4, R’= c = NO2).  All values are summarized in Table	  2.1.  
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Table 2.1.  Summary of electrostatic potential values for modeled aromatic rings 
incorporated into CPPM starting materials and polymers 
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As part of this study, π-rich and π-poor CPPMs were designed and synthesized based 
on both the diester and imide ROMP scaffolds.  CPPMs based on the diester system 
were synthesized since the dual-functional monomers offer greater potential for 
polymeric structure variations.  Also, CPPMs based on the imide scaffold were 
synthesized as a direct comparison to polymers from previous hydrophobicity structure 
activity relationships (SARs) with model membranes.32,33 These CPPMs were designed 
to contain π-rich and π-poor aromatic functionalities in order to assess the role of π-
interactions in tuning membrane activity.  
 
2.2 Monomer Synthesis 
Diester monomers were synthesized using a two-step process, as depicted in Figure 
2.2.1.  These procedures were adapted from previously described methods with 
modifications.17,56  In brief, oxanorbornene anhydride (1) was ring-opened using various 
aromatic alcohols (a-h) and DMAP to yield the half-ester intermediates.   
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Figure 2.2 Synthesis of diester monomers containing π-rich and π-poor aromatic rings. 
i)R-OH, DMAP, CH2Cl2,, RT, overnight; ii) 1,3-di-boc-2-(2-hydroxyethyl)guanidine, EDC, 
DMAP, CH2Cl2, 0°C to RT, overnight. 
 
Half-esters 2a-f were then further reacted with 1,3-di-boc-2-(2-hydroxyethyl)guanidine 
using EDC coupling conditions to yield monomers 3a-f. Half-esters 2g-h were not used 
for monomer synthesis because they proved to be unstable in solution at room 
temperature.   As shown in Figure	   2.3A, half-esters 2g-h underwent a spontaneous 
retro-Diels-Alder reaction to yield 4g-h and furan (5).  This was demonstrated by 
isolating the retro-Diels-Alder product, 4g, using column chromatography and verifying 
its chemical composition using 1H NMR, 13C NMR, and mass spectrometry (MS).  Retro-
Diels-Alder product 4h proved more difficult to isolate because of additional nitro-based 
impurities.  
 
However, peaks for the retro-Diels-Alder product were observed in the 1H NMR of 2h.  
Since 2a-f did not appear to undergo the retro-Diels-Alder reaction, it was hypothesized 
	  
	   50 
that this reaction was affected by the electron withdrawing substituents attached to the 
aromatic rings. To investigate this, all π-poor aromatic rings were modeled using 
Spartan molecular modeling software as shown in Figure	  2.3A.  The most electron poor 
(most blue in color) aromatic rings were the rings associated with the unstable half 
esters.  From this and a study by Nanjappan and Czarnik, it was concluded that 
electron-withdrawing groups destabilized Diels-Alder adducts and accelerated the retro-
Diels-Alder reaction.57   
 
 
Figure 2.3.  Stability of π-poor monomers. A) Retro-Diels-Alder reaction that occurs for 
monomers 4g-h. B) Stable and unstable π-poor monomer aromatic groups with their 
corresponding electrostatic potential maps.  The range for electrostatic potential was set 
between -30.00 and 30.00 kcal/mol.  The color scale bar reflects this range with red 
representing electron rich surfaces and blue representing electron poor surfaces. 
Surfaces were calculated at the HF level using the 3-21G* basis set. 
 
2g-h were not pursued for monomer formation because the retro-Diels-Alder impurities 
4g-h have the same reactive functional groups (-COOH, C=C) as 2a-f.  All stable half-
esters and monomers were characterized by 1H NMR, 13C NMR, and MS.  In terms of 
electrostatic potential values, the six stable monomers covered an electrostatic potential 
range from -4.66 kcal/mol (Scheme 1, R= e= NO2) to +29.69 kcal/mol (Scheme 1, R= 
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b= CH3).  Electrostatic potential values are summarized in Table	   2.1.  All 
characterization data is provided in the supporting information. 
 
Figure 2.4  Synthesis of imide monomers containing π-rich and π-poor aromatic rings. i) 
R1-OH, PPh3, DIAD, THF, RT, 18 hr. 
 
Imide monomers were synthesized using a one-step process adapted from Som 
et al., as illustrated in Figure	  2.4.32,33  Unlike the diester system, there were no issues 
with stability for the imide system and no retro-Diels-Alder products were observed.  All 
monomers were characterized by 1H NMR, 13C NMR, and MS.  In terms of electrostatic 
potential values for the aromatic groups incorporated, all stable monomers covered an 
electrostatic potential range from -18.10 kcal/mol (Figure	  2.4, R1 = a = OCH3) to 15.57 
kcal/mol (Figure	  2.4, R1 = c = NO2).  These monomers expand the negative end of the 
electrostatic potential range so that in total the monomer design spans -29.69 to +15.57 
kcal/mol as summarized in Table	  2.1. 
2.3 Polymer Synthesis  
Polymers were synthesized using ROMP with Grubbs 3rd generation catalyst, as 
illustrated in Figure	  2.5, Figure	  2.6, and Figure	  2.7.   
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Figure 2.5  Synthesis of diester homopolymers containing π-rich and π-poor aromatic 
rings. i) Dichloro-di(3-bromopyridino)-N,N’-Dimesitylenoimidazolino-Ru=CHPh (G3) 
catalyst, CH2Cl2,, RT, 45 min; ii) Ethyl vinyl ether, RT, overnight; iii) TFA/CH2Cl2 (1:1), 
RT, overnight. Products 9a-f further purified by dialysis with molecular weight cut-off : 
2,000 g/mol.  All polymers were synthesized with n=20.  R was defined in Figure 2.2. 
 
 
Figure 2.6.  Synthesis of imide random copolymers containing π-rich and π-poor 
aromatic rings. i) Dichloro-di(3-bromopyridino)-N,N’-Dimesitylenoimidazolino- Ru=CHPh 
(G3) catalyst, CH2Cl2,, RT, 45 min; ii) Ethyl vinyl ether, RT, overnight; iii) TFA/CH2Cl2 
(1:1), RT, overnight. All polymers were synthesized with n=20 and m=20.  R1 was 
defined in Figure 2.4. 
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Figure 2.7.  Synthesis of diester random copolymers containing π-rich and π-poor 
aromatic rings. i) Dichloro-di(3-bromopyridino)-N,N’-Dimesitylenoimidazolino- Ru=CHPh 
(G3) catalyst, CH2Cl2,, RT, 45 min; ii) Ethyl vinyl ether, RT, overnight; iii) TFA/CH2Cl2 
(1:1), RT, overnight. Products 15a,c,e further purified by dialysis with molecular weigth 
cut-off: 1,000 g/mol.  All polymers were synthesized with n=8 and m=12.  R was defined 
in Figure 2.2.   
 
All boc-protected polymers (8a-f, 10a-c, 13a,c,e) were characterized by 1H NMR to 
assess chemical composition and gel permeation chromatography (GPC) to assess 
relative molecular weights.  Molecular weight data is summarized in Table	   2.2 and 
representative chromatograms are in Figure	  2.8, Figure	  2.9, and Figure	  2.10.  
Table 2.2.  Molecular weight characterization of π-rich and π-poor CPPMs. 
A.    B. 
Diester Homopolymers  Imide and Diester Random Copolymers 
CPPM Mn
[a] 
(Da) Đ 
 CPPM n:m Mn
[a] 
(Da) Đ 
8a 11,600 1.05  11a 56:44 16,200 1.06 
8b 11,200 1.05  11b 55:45 13,700 1.07 
8c 11,300 1.05  11c 58:42 17,000 1.06 
8d 12,600 1.05  14a 38:62 10,600 1.10 
8e 11,400 1.05  14b 40:60 12,100 1.08 
8f 11,500 1.05  14c 39:61 10,700 1.14 
 [a]Number average molecular weight (Mn) and polydispersity indices (Đ=Mw/Mn) 
determined by GPC using polymethyl methacrylate (PMMA) standards for diester 
polymers and polystyrene standards for the imide polymers using tetrahydrofuran (THF) 
as the eluent and toluene as the flow marker.  [b]Ratio of residues, where n represents 
the percentage of hydrophobic residues and m represents the percentage of guanidine-
containing residues.  
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Figure 2.8.  THF GPC chromatograms for boc-protected diester homopolymer CPPMs 
8a-f.   
 
Figure 2.9.  THF GPC chromatograms for boc-protected imide random copolymer 
CPPMs 11a-c.  
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Figure 2.10.  THF GPC chromatograms for boc-protected diester random copolymer 
CPPMs 14a, c, e.  
 
 
Polymers were subsequently deprotected using trifluoroacetic acid (TFA) and 
CH2Cl2 (1:1) overnight.17,32,33,56  TFA was removed by azeotropic distillation with 
methanol.  Diester polymers were dialyzed for three days in water using membranes 
with a molecular weight cut-off of 2,000 g/mol for homopolymers and 1,000 g/mol for 
random copolymers.  All polymers were then dissolved in water and lyophilized to yield 
dry 9a-f, 12a-c, and 15a,c,e. 
2.4 Dye Release Assays  
All polymers were tested using a vesicle dye release assay to assess relative 
polymer activity using a fluorescence plate reader.29,31-33  This assay is summarized in 
cartoon form in Figure 2.11.  This high throughput screening method enabled the testing 
of all samples in a 12-well plate at the same time.  Carboxyfluorescein (CF) filled 
phosphatidylcholine (PC) or PC/phosphatidylserine (PS) vesicles were prepared as 
described in the supporting information and then used for these experiments.   
	  
	   56 
For this dye release assay, the baseline fluorescence (F0) of Tris saline buffer 
with carboxyfluorescein filled vesicles was determined.  Then, polymer solutions (in 
DMSO) of varying concentrations were added to the vesicle-containing solutions. After  
 
Figure 2.11.  Cartoon depiction of the dye release assays performed.  
 
10 minutes, the fluorescence intensity (Ff,0) was measured again. Triton X-100 (5% in 
DMSO) was then added to each experimental solution to lyse the vesicles and release 
all of the dye. The final fluorescence measurement (Ft) was taken after five minutes.  
The results were normalized according to the baseline and Triton controls to yield 
fractional dye release (If) according to Equation 1.  
 
If = (Ff,0 – F0) / (Ft – F0)             
Equation 1 
            
Baseline  
Fluorescence  
A. B. 
Polymer-induced 
Dye Release 
Maximum 
Fluorescence  C. 
D. 
A.  Intact vesicles (0.020 mL) in Tris 
Buffer Solution (1.960 mL). 
 
B.  Polymer (0.020 mL) added to 
solution to induce dye release. 
C.  Triton-X 100 (0.020 mL) added to 
lyse all vesicles.  
 
D.  End of experiment.  
CF 
CF 
CF 
+
+ +
+ +
CF 
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For Hill analysis, If was plotted against polymer concentration, c, and fit to the Hill 
equation, Equation 2, to give the EC50, where If,0 and If,max are the minimum and 
maximum value of If obtained for each well, respectively. 
 
If = If,0 + (If,max – If,0) / [(1 + c / EC50)n]            
Equation 2 
       
The first set of polymers tested were 9a-f and 12a-c, since both sets of polymers 
had comparable hydrophobic and hydrophilic contents (roughly 1:1) but different 
backbone compositions.  Overlays of all diester homopolymer CPPMs are shown in 
Figure	  2.12 and overlays of all imide random copolymer CPPMs are shown in Figure	  
2.13.  A summary of the EC50, If,max, and n values obtained from testing 9a-f and 12a-c 
with PC vesicles are displayed in Table	  2.3. 
 
 
Figure 2.12.  Overlay of hill plots for diester homopolymer CPPMs 9a-f (red, green, 
black, orange, blue, and purple, respectively) using 100 nm PC large unilamellar 
vesicles swelled with carboxyfluorescein.  Data was fit to the Hill Equation and If 
represents the fraction of dye released.   
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Figure 2.13.  Overlay of hill plots for imide random copolymer CPPMs 12a-c (red, black, 
and blue, respectively) using 100 nm PC large unilamellar vesicles swelled with 
carboxyfluorescein.  Data was fit to the Hill Equation and If represents the fraction of dye 
released.   
 
For comparison, representative overlays of π-rich and π-poor polymers from both 
sets of polymers are shown in Figure	  2.14.  All EC50 values were similar (7-12 nM) and, 
with the exception of the lower If,max for 12c, the Hill plots were also almost identical.  
Only EC50 values that differ over several orders of magnitiude represent significant 
changes, as observed in previous studies where the aliphatic hydrophobic group 
incorporated was changed from a methyl group (EC50 = 6.4 µM) to a butyl group (EC50 = 
0.003 µM).33 
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Table 2.3.  EC50, Ymax, and Hill coefficient n values for diester homopolymer and imide 
random copolymer-based CPPM activity using 100 nm PC large unilamellar vesicles 
swelled with carboxyfluorescein. 
CPPM EC50
[a] 
(nM) Ymax
[b] n [c] 
9a 8.27 ± 0.84 0.89 ± 0.00 2.01 ± 0.04 
9b 7.36 ± 1.87 0.92 ± 0.02 1.59 ± 0.04 
9c 9.07 ± 0.79 0.90 ± 0.01 1.93 ± 0.02 
9d 7.48 ± 0.50 0.91 ± 0.01 1.43 ± 0.01 
9e 9.93 ± 0.50 0.92 ± 0.02 1.50 ± 0.06 
9f 8.63 ± 0.52 0.85 ± 0.02 1.79 ± 0.01 
12a 10.09 ± 1.96 0.87 ± 0.01 1.59 ± 0.07 
12b 11.85 ± 0.19 0.84 ± 0.05 1.63 ± 0.14 
12c 10.64 ± 0.21 0.72 ± 0.02 1.93 ± 0.15 
[a]Effective concentrations (EC50) needed to reach Ymax/2, [b]Maximum fraction of 
carboxyfluorescein released compared to total dye released upon addition of Triton-X 
100. [c]n is the Hill coefficient.  Standard deviation from three independent experiments is 
reported.  
 
Within each series, it was determined that the nature of the π-rich or π-poor aromatic 
rings incorporated did not have a significant impact on CPPM activity.  By comparing 
CPPMs from both series, it was determined that the nature of the CPPM backbone also 
had a negligible effect on CPPM activity.  Although many of our previous SAR studies 
were based on the imide system, in this paper all further testing was conducted with the 
diester system since backbone architecture had little impact on results and this system 
offers more options for structural tuning.  
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Figure 2.14.  Diester vs. imide Hill plots for π-rich CPPMs 9a and 12a (red) and π-poor 
CPPMs 9e and 12c (blue) using 100 nm PC large unilamellar vesicles swelled with 
carboxyfluorescein.  Data was fit to the Hill Equation and If represents the fraction of dye 
released. Solid lines represent diester-based CPPMs and dashed lines represent imide 
random copolymer-based CPPMs.  
 
 
To further probe the effect of π-electronics on CPPM activity, dye-swelled 
vesicles were prepared by adding negatively charged PS lipids (20 mol%) to PC lipids.  
This lipid composition was selected in order to exploit potentially favorable π-anion 
interactions that can occur between anionic lipids and electron deficient aromatic 
systems while also capitalizing on electron repulsions between anionic lipids and 
electron-rich aromatic systems.58  Based on the nature of π-interactions, it was 
anticipated that CPPM activity would trend based on π-electron density, with π-poor 
CPPMs exhibiting better activity due to favorable π-anion interactions.  In contrast, π-
rich polymers were expected to have weaker activity due to electron repulsion between 
the anionic lipids and the electron-rich aromatic rings.  For these studies, polymers 9a, c, 
and e were tested and the results were compared to those obtained for PC vesicles.  A 
summary of the EC50, If,max, and n values can be found in Table 2.4. 
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Table 2.4 EC50, If,max, and Hill coefficient n values for diester homopolymer-based CPPM 
activity using 100 nm EYPC/Brain PS (80/20) large unilamellar vesicles swelled with 
carboxyfluorescein. 
CPPM EC50a (nM) If,maxb nc 
9a 9.10 0.89 1.34 
9c 11.69 0.90 1.14 
9e 11.90 0.89 1.47 
a Effective concentrations (EC50) needed to reach If,max/2, b Maximum fraction of 
carboxyfluorescein released compared to total dye released upon addition of Triton-X 
100. c n is the Hill coefficient Standard deviation from three independent experiments is 
reported.  
 
In addition, representative overlays of π-rich and π-poor polymers tested with PC and 
PC/PS vesicles can be found in Figure	  2.15.  EC50 values for polymers 9a, c, and e 
tested with PC/PS vesicles were similar to those obtained from studies with PC vesicles.  
There was also little difference in the Hill Plots for these polymers, regardless of the 
nature of the π-rich or π-poor aromatic ring incorporated or type of vesicles used for the 
study. 
 
 
Figure 2.15.  Anionic vs. zwitterionic vesicle Hill plots for π-rich polymer 9a (red) and π-
poor polymer 9e (blue) using two types of 100 nm large unilamellar vesicles swelled with 
carboxyfluorescein: PC (solid lines) and PC/PS (80/20, dashed lines). Data was fit to the 
Hill Equation. If represents the fraction of dye released.  
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Based on these results, a set of diester random copolymers was designed that 
had a more dilute hydrophobic content to be sure that the results observed were not due 
to the CPPM hydrophobic content being too high.  The CPPMs designed are shown in 
Figure	  2.7.  A summary of the EC50, If,max, and n values can be found in Table	  2.5 for PC 
and Table	  2.6 for PC/PS vesicles.  In addition, representative overlays for the diester 
random copolymers as they compare to their corresponding diester homopolymers for 
PC and PC/PS vesicles can be observed in Figure	  2.16 and Figure	  2.17, respectively.  
Table 2.5.  EC50, Ymax, and Hill coefficient n values for diester random copolymer-based 
CPPM activity using 100 nm EYPC large unilamellar vesicles swelled with 
carboxyfluorescein. 
CPPM EC50a (nM) If,maxb nc 
15a 6.50 0.80 1.76 
15c 5.60 0.79 1.99 
15e 6.74 0.72 1.87 
a Effective concentrations (EC50) needed to reach If,max/2, b Maximum fraction of 
carboxyfluorescein released compared to total dye released upon addition of Triton-X 
100. c n is the Hill coefficient Standard deviation from three independent experiments is 
reported.  
 
Table 2.6.  EC50, Ymax, and Hill coefficient n values for diester random copolymer-based 
CPPM activity using 100 nm EYPC/Brain PS (80/20) large unilamellar vesicles swelled 
with carboxyfluorescein. 
CPPM EC50a (nM) If,maxb nc 
15a 27.94 0.87 1.91 
15c 28.96 0.87 1.91 
15e 44.59 0.88 1.46 
a Effective concentrations (EC50) needed to reach If,max/2, b Maximum fraction of 
carboxyfluorescein released compared to total dye released upon addition of Triton-X 
100. c n is the Hill coefficient Standard deviation from three independent experiments is 
reported.  
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Figure 2.16.  Homopolymer vs. random copolymer Hill plots for π-rich polymers 9a and 
15a (red) and π-poor polymers 9e and 15e (blue) using 100 nm PC large unilamellar 
vesicles swelled with carboxyfluorescein.  Data was fit to the Hill Equation and If 
represents the fraction of dye released. Solid lines represent diester homopolymers and 
dashed lines represent diester random copolymers.  
 
EC50 values for 14a, c, and e were similar to those obtained for 9a, c, and e 
when tested with PC vesicles and the overlays of the Hill plots in Figure	  2.16 further 
suggest that there was little difference between the activity of the diester homopolymers 
and the less hydrophobic random copolymers.  When tested with PC/PS vesicles, there 
was a slight increase in EC50 values for the random copolymers as compared to the 
homopolymers and there was a noticeable shift in the Hill plots in Figure	   2.17.  
However, the shift was about the same for all diester random copolymers and thus 
attributed to the lower hydrophobic content and not due to the π-electronics of the 
system.  Since no trend was observed, it was concluded that π-electronics do not play a 
major role in CPPM activity.  Alternatively, it is possible that the assay used here does 
not have the fidelity to distinguish the subtleties of π –interactions despite the fact that 
these same assays previously illustrated that adding hydrophobicity improves activity, 
with aromatic groups outperforming aliphatic groups. 32,33  Even though we were able to 
synthesize a series of polymers that contained aromatic groups with an electrostatic 
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potential range of -29.69 to 15.57 kcal/mol, it is also possible that the structural 
modifications made to the polymers may not have been significant enough to impact 
CPPM activity.  While it is likely that overall CPPM hydrophobicity and cationic charge 
are more influential design parameters than π-electronics, these results indicate that a 
wide range of aromatic groups can be incorporated into the polymer structures with 
limited impact on CPPM activity.  From a design standpoint, this opens up additional 
ways in which CPPMs can be modified without inhibiting their performance.  
 
 
Figure 2.17.  Homopolymer vs. random copolymer Hill plots for π-rich polymers 9a and 
15a (red) and π-poor polymers 9e and 15e (blue) using 100 nm PC/PS (80/20) large 
unilamellar vesicles swelled with carboxyfluorescein.  Data was fit to the Hill Equation 
and If represents the fraction of dye released. Solid lines represent diester 
homopolymers and dashed lines represent random copolymers.   
 
2.5 Conclusion 
For this study, aromatic groups containing electron donating and electron 
withdrawing groups were chemically incorporated into CPPM structures as a way to tune 
π-interactions.  It was hypothesized that tuning the quadrupole moments of the aromatic 
rings would provide additional control over CPPM activity.  When synthesizing the 
monomers for these studies, it was established through small molecule synthesis that 
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highly electron-withdrawing groups could not be chemically incorporated into the diester 
versions of our oxanorbornene monomers because it spontaneously induced a retro-
Diels-Alder reaction.   
Within the synthetically accessible series, vesicle dye release experiments were 
performed as a way to determine the CPPMs’ EC50 values and assess their relative 
activities.  It was shown using PC vesicles that polymer backbone did not impact activity 
for the π-rich/ π-poor CPPMs and that the electron donating or electron withdrawing 
groups as well as the relative hydrophobic content did not impact activity either.  Diester 
CPPMs were also tested with PC vesicles containing 20% PS anionic lipids in efforts to 
more thoroughly understand π-membrane interactions.   
However, it would seem that only overall hydrophobicity dictated polymer activity 
and not the incorporated electron donating or electron withdrawing groups.  Although it is 
possible that the assay used could not distinguish the subtleties of π-interactions, it is 
also likely that the structural modifications made to the polymers were not significant 
enough to impact CPPM activity, despite the fact that molecules containing aromatic 
rings with an electrostatic potential range of -29.69 kcal/mol to 15.57 +kcal/mol were 
explored.  This suggests that other design parameters, such as overall hydrophobicity 
and cationic charge, have a greater impact on CPPM activity.  The results also indicate 
that a wide range of aromatic groups can be incorporated into the polymer structures 
with limited impact on CPPM activity.  This is encouraging from a design standpoint as it 
expands potential functionality without impacting activity.  Understanding these design 
principles will help guide the development of future CPPMs. 
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3 CHAPTER 3 
DEVELOPMENT OF ROMP-BASED PROTEIN MIMICS FOR EFFICIENT SIRNA 
DELIVERY INTO HUMAN T CELLS 
3.1 Introduction:  
RNA interference (RNAi), discovered almost two decades ago, continues to be 
an important tool to probe molecular pathways and to potentially treat diseases.1-5  Small 
interfering RNA (siRNA), which represents one RNAi approach, must be present in the 
cytosol so that the siRNA guide strand can be incorporated into the RISC complex and 
degrade its complementary mRNA.  This leads to transient, sequence-specific, post-
transcriptional gene knockdown,6-8 which is advantageous for discrete biological and 
clinical applications,1-5 a strategy of critical importance in the context of the immune 
system and T cells.9-12  
T cells are key components of the immune system.  They orchestrate essential 
functions during the immune response to pathogens, chronic inflammation, and 
autoimmune disorders.10  Harnessing the capabilities of RNAi would allow immunologists 
to explore molecular pathways leading to a better understanding of T cell activation, 
signaling, and other biological processes, eventually providing new treatment options for 
autoimmune diseases.9-12  Unfortunately, progress in this area has been severely limited 
due to the lack of robust delivery technologies for T cell lines and primary cells.10,12-17  
Three major strategies are routinely used for siRNA delivery into T cells and primary 
cells: electroporation, viral vectors, and transfection.12-17  The use of electroporation and 
viral vectors both have severe drawbacks, which include high cell death and potential 
mutagenic/immunogenic effects, respectively.14,16  Transfection is generally a safer 
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alternative, with higher cell survival rates; however, many current delivery vehicles 
exhibit low efficiencies in T cell lines and primary cells.13,15,17  Although designing 
successful carriers for T cells has been a challenge, highly modular protein transduction 
domain mimics (PTDMs), sometimes referred to as cell-penetrating peptide mimics 
(CPPMs), have been used successfully in other more easily transfected cell types and 
can provide insight for the design of more efficient delivery vehicles.18-20  
Inspiration for PTDMs is derived from proteins with translocation abilities, such as 
the HIV-1 TAT and Antennapedia homeodomain proteins, as well as other protein 
transduction domains (PTDs) and cell-penetrating peptides (CPPs) that exhibit delivery 
capabilities.21-23  PTDMs incorporate important features of PTDs and CPPs critical for 
intracellular delivery24-29, including cationic charge content provided by guanidinium 
groups, and partial hydrophobicity contributed by the backbone architecture and/or the 
incorporation of hydrophobic monomers.18,19  Although some PTDs and CPPs, such as 
CADY and MPG, possess these key features and have already been designed and 
commercialized for siRNA delivery, PTDMs offer many distinct advantages over their 
peptide counterparts.30,31  Moving away from a peptide-based architecture provides 
protection from proteolysis and avoids solid phase peptide synthesis.  Additionally, a 
non-peptidic system offers many more structural options, since it is not restricted to the 
incorporation of known amino acids.18,19,32  Consequently, different chemistries can be 
used to design molecules, and chemical compositions can be tuned more widely to 
improve delivery of specific cargo.18,19,32  This design rationale has proven successful in 
creating more potent antimicrobial peptide mimics, where the key features, including 
their facially amphiphilic architecture,33-35 were incorporated into synthetic scaffolds to 
yield new antimicrobial agents.19,35-37  
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In the realm of delivery reagents, several groups have demonstrated the utility of 
synthetic, guanidinium-rich, polymeric scaffolds to deliver siRNA.18,19,38-44  Ring-opening 
metathesis polymerization (ROMP)20,45-47, polymethacrylamide42,48, arginine-grafted 
bioreducible polydisulfide40,41, and oligocarbonate38,39,44 scaffolds have all been 
developed and screened for siRNA delivery.  The successful design of PTDMs will 
further the understanding of the key features necessary for efficient delivery, as well as 
enable the development of more effective delivery reagents.18,19,32  
Related to this long term goal, in 2008, the Tew research group first reported the 
development of polymeric guanidinium-rich PTDMs based on a ROMP scaffold that 
mimics PTDs/CPPs, such as TAT49-57 and oligoarginine (R9).19,49,50  Initial studies aimed 
to understand the effects of PTDM length51, hydrophobicity52, aromaticity53, aromatic π-
electronics54, and sequence segregation of cationic/hydrophobic components55 on 
membrane interactions and cellular uptake.43  In early 2013, we extended this platform to 
include siRNA delivery.  It was demonstrated that our PTDMs delivered FITC-siRNA into 
Jurkat T cells with efficiencies greater than 90% and achieved 50% knockdown of 
NOTCH1 protein in human T cells from human peripheral blood mononuclear cells 
(hPBMCs).20 Due to the initial success of siRNA delivery using these PTDMs, further 
understanding of the relationship between PTDM structure and siRNA delivery efficiency 
in T cells was desired. 
Herein we document our efforts to tune ROMP-based PTDM structures for 
improved siRNA delivery.  Structure activity relationships using Jurkat T cells and 
hPBMCs were used to probe how polymer charge content and the addition of a 
segregated, hydrophobic block impacted siRNA internalization and delivery efficiencies.  
Specifically, two polymer series were developed, homopolymers and block copolymers, 
with matching cationic charge contents (Figure 3.1).  All block copolymers contained a 
	  
	   71 
constant hydrophobic block of approximately five repeat units.  It should be noted that 
guanidinium moieties were incorporated to mimic arginine residues and phenyl moieties 
were incorporated in the block copolymer PTDMs to mimic phenylalanine residues, both 
of which have been shown to play critical roles in membrane interactions.27,29,43,51-54,57,58  
In this study, we elucidate the essential design parameters for siRNA delivery using our 
PTDMs, which can be used to develop the next generation of highly efficient transfection 
reagents.  
3.2 PTDM Design and Characterization 
Proteins and peptides have been utilized extensively for intracellular delivery 
applications.18,32,60-62  These materials, however, have presented many limitations, 
including long and costly synthetic procedures, as well as poor stability, all of which can 
be avoided by leveraging more versatile synthetic platforms.  In this report, ROMP with 
Grubbs’ third generation catalyst was used to synthesize all PTDMs since it is a fast, 
efficient, and functional group tolerant method that also allows for good control over 
molecular weights and dispersities.  The living nature of many ROMP polymerizations 
also enables the synthesis both of homopolymers and block copolymers, and allows the 
influence of an added hydrophobic block on internalization and delivery efficiencies to be 
evaluated within the same monomer chemistry.63-71  Additionally, the oxanorbornene-
based dual-functional monomer platform is quite versatile, allowing for the incorporation 
of the same or different functionalities to tune the polymer structures at the monomer 
level.18  For this particular endeavor, a monomer containing two Boc-protected 
guanidinium groups (dG; Figure 3.1) and a second monomer containing a methyl group 
and a phenyl group (MePh; Figure 3.1) were synthesized.  
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Figure 3.1.  Monomer and polymer structures used for this study.  A) Monomer 
structures. B) Polymer structures. C) Table summarizing the polymer nomenclature and 
the corresponding number of positive charges each polymer contains.  Blue represents 
cationic moieties and green represents hydrophobic moieties.  
 
All molecular weight characterization for these libraries of polymers are summarized in 
Table 3.1, Table 3.2, Figure 3.2, Figure 3.3, Figure 3.4, and Figure 3.5. Guanidinium 
moieties were selected as the cations because they have been previously shown to yield 
superior uptake and delivery efficiencies as compared to their ammonium counterparts 
found in lysine and ornithine.27  
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Table 3.1.  Molecular weight characterization of boc-protected homopolymers 5a-f and 
block copolymers 6a-f. 
 
 
 
 
 
 
 
 
aNumber average molecular weight (Mn), weight average molecular weight (Mw), 
molecular weight at the peak maximum (Mp), and dispersity indices (Đ=Mw/Mn) 
determined by GPC using poly(methyl methacrylate) (PMMA) standards, tetrahydrofuran 
(THF) as the eluent, and toluene as the flow marker.  
 
Figure 3.2.  THF GPC chromatograms for boc-protected homopolymers PTDMs 5a-f. A 
summary of molecular weight data can be found in Table 3.1. 
 
Polymer Mna (Da) Mwa (Da) Mpa (Da) 
Đa 
(Mw/Mn) 
5a 4,300 4,600 4,500 1.06 
5b 6,400 6,800 6,700 1.07 
5c 12,700 13,400 13,500 1.06 
5d 23,600 27,200 30,500 1.15 
5e 40,500 45,400 48,700 1.12 
5f 50,200 59,200 71,000 1.18 
6a 5,400 5,900 5,900 1.08 
6b 8,300 9,000 9,300 1.08 
6c 16,000 17,100 17,500 1.07 
6d 27,600 31,500 36,800 1.14 
6e 36,800 41,300 46,700 1.12 
6f 45,000 57,100 71,100 1.27 
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Figure 3.3.  THF GPC chromatograms for boc-protected block copolymer PTDMs 6a-f.  
B1 (grey) is a representative chromatogram for the first block of the BCP PTDMs.  A 
summary of molecular weight data can be found in Table 3.1. 
 
Table 3.2.  Molecular weight characterization of deprotected homopolymers dGn and 
block copolymers MePh5-b-dGn. 
Polymer Mna (Da) Mwa (Da) Mpa (Da) 
Đa 
(Mw/Mn) 
dG5 8,800 9,300 9,000 1.05 
dG10 11,400 12,000 11,700 1.05 
dG20 18,300 19,400 19,400 1.06 
dG40 31,500 33,900 36,000 1.08 
dG60 45,600 49,100 50,800 1.08 
dG80 57,100 80,400 67,500 1.41 
MePh5-b-dG5 10,200 10,900 10,100 1.07 
MePh5-b-dG10 14,900 15,800 15,200 1.06 
MePh5-b-dG20 21,800 23,500 23,500 1.08 
MePh5-b-dG40 33,300 36,600 39,500 1.10 
MePh5-b-dG60 39,700 43,700 45,600 1.10 
MePh5-b-dG80 n.d.b n.d.b n.d.b n.d.b 
[aNumber average molecular weight (Mn), weight average molecular weight (Mw), 
molecular weight at the peak maximum (Mp), and dispersity indices (Đ=Mw/Mn) 
determined by GPC using poly(methyl methacrylate) (PMMA) standards, 2,2,2-
trifluoroethanol (TFE) with 20 mM NaTFA salt as the eluent, and methanol as the flow 
marker. bnot determined (n.d.) due to insolubility in TFE eluent. 
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Figure 3.4.  TFE GPC chromatograms for deprotected homopolymer PTDMs.  A 
summary of molecular weight data can be found in Table 3.2. 
 
Figure 3.5.  TFE GPC chromatograms for deprotected block copolymer PTDMs.  A 
summary of molecular weight data can be found in Table 3.2. 
 
The number average molecular weight (Mn) for the homopolymerization of the dG 
monomer increased linearly with monomer to initiator ratio ([M]/[I]), while maintaining low 
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dispersities.  This indicated that it polymerized in a controlled fashion and can be used to 
synthesize both homopolymers and block copolymers (Figure 3.6). 
 
Figure 3.6.  Plot of number average molecular weight (Mn) and dispersity index (Đ) with 
respect to monomer / initiator [M]/[I] ratio for the dGm series. The linear relationship (R2 = 
0.993) reflects the controlled nature of the polymerization.  
 
Homopolymer and block copolymer PTDMs were synthesized to determine how 
the cationic charge content, as well as the incorporation of a segregated hydrophobic 
region, impacted siRNA delivery.  To that end, PTDMs with increasing amounts of 
cationic charge were synthesized, as documented in Figure 3.1.  Since the cationic 
monomer contains two guanidinium groups, the number of charges is reported as twice 
the degree of polymerization (Figure 3.1C).  In addition, block copolymer PTDMs were 
designed with segregated hydrophobic and cationic domains, as shown in Figure 3.1 
These were specifically designed because the incorporation of a hydrophobic domain 
has been shown to improve internalization and delivery efficiencies through interactions 
with hydrophobic lipids.31  The performance of the block copolymers was compared to 
their corresponding homopolymer derivatives, which contained the same charge content, 
in order to assess the effect of incorporating a hydrophobic block.  In both cases, the 
R2 = 0.993 
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charge content was varied up to 160 charges (80 repeat units); however, PTDMs with 
160 charges had limited solubility and were therefore not used for any biological studies.  
Overall, this series of PTDMs provided insight into key design parameters for efficient 
siRNA internalization and delivery.   
3.3 FITC-siRNA Delivery  
Preliminary studies were conducted using fluorescein isothiocyanate (FITC) 
labeled siRNA (FITC-siRNA), to assess trends in internalization efficiencies in Jurkat T 
cells resulting from differences in PTDM charge content and the presence or absence of 
a hydrophobic block.  The fluorescent label on the siRNA allowed cell populations to be 
analyzed using flow cytometry.  Jurkat T cells were selected because they are typically 
difficult to transfect and manipulate.10,12-17  The N:P ratio, which is the ratio of the number 
of positively charged nitrogen atoms in the PTDMs to the number of negatively charged 
phosphate atoms in siRNA, used for complex formation between PTDMs and siRNA was 
8:1 and was established by screening FITC-siRNA internalization efficiencies (Figure 3.7 
and Figure 3.8) as a function of N:P ratio in addition to using gel retardation assays to 
assess siRNA complexation.  This N:P ratio used was consistent with our previous 
publication.20  Gel retardation assays for PTDM/siRNA complexes at N:P ratios of 0.5:1, 
1:1, 2:1, 4:1, 8:1, and 12:1 are shown below (Figure 3.9-Figure 3.17).   
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Figure 3.7.  N/P ratio screening for FITC-siRNA delivery into Jurkat T cells using ROMP-
based PTDMs. Jurkat T cells (cell density = 4x105 cells/mL) were treated with 
polymer/FITC-siRNA complexes with an N:P ratio = 8:1 in complete media for four hours 
at 37°C and compared with untreated cells and cells only receiving FITC-siRNA.  A) 
Percent positive cells.  B) MFI of the cell population. Each data point represents the 
mean ± SEM of three independent experiments. 
 
 
Figure 3.8.  Percent viable cells using a 7-Amino-actinomycin (7-AAD) Jurkat T Cell 
viability assay. Jurkat T cells (cell density = 4x105 cells/mL) were treated with 
PTDM/FITC-siRNA complexes with an N:P ratio = 8:1 in complete media for four hours 
at 37°C and compared with untreated cells and cells only receiving FITC-siRNA. Cells 
were stained at four hours.  Each data point represents the mean ± SEM of three 
independent experiments. 
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Figure 3.9.  Gel retardation assay to assess PTDM / siRNA complex formation using 
dG10.  All samples were run on a 0.8% agarose gel and the N:P ratios tested ranged 
from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
 
Figure 3.10.  Gel retardation assay to assess PTDM / siRNA complex formation using 
dG20.  All samples were run on a 0.8% agarose gel and the N:P ratios tested ranged 
from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
 
Figure 3.11.  Gel retardation assay to assess PTDM / siRNA complex formation using 
dG40.  All samples were run on a 0.8% agarose gel and the N:P ratios tested ranged 
from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
siRNA 0.5:1 1:1 2:1 4:1 8:1 12:1 
siRNA 0.5:1 1:1 2:1 4:1 8:1 12:1 
siRNA 0.5:1 1:1 2:1 4:1 8:1 12:1 
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Figure 3.12.  Gel retardation assay to assess PTDM / siRNA complex formation using 
dG60.  All samples were run on a 0.8% agarose gel and the N:P ratios tested ranged 
from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
 
Figure 3.13.  Gel retardation assay to assess PTDM / siRNA complex formation using 
MePh5-b-dG5.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
 
Figure 3.14.  Gel retardation assay to assess PTDM / siRNA complex formation using 
MePh5-b-dG10.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
siRNA 0.5:1 1:1 2:1 4:1 8:1 12:1 
siRNA 0.5:1 1:1 2:1 4:1 8:1 12:1 
siRNA 0.5:1 1:1 2:1 4:1 8:1 12:1 
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Figure 3.15.  Gel retardation assay to assess PTDM / siRNA complex formation using 
MePh5-b-dG20.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
 
Figure 3.16.  Gel retardation assay to assess PTDM / siRNA complex formation using 
MePh5-b-dG40.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
 
Figure 3.17.  Gel retardation assay to assess PTDM / siRNA complex formation using 
MePh5-b-dG60.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
In brief, it was demonstrated that shorter polymers (40 charges or less) 
completely complexed siRNA at lower N:P ratios than longer polymers (80 charges or 
more).  In terms of media composition, it was previously reported that our ROMP-based 
PTDMs do not experience significant reduction in performance when tested in the 
presence of serum.20  Therefore, all cell data was collected in the presence of serum.20   
siRNA 0.5:1 1:1 2:1 4:1 8:1 12:1 
siRNA 0.5:1 1:1 2:1 4:1 8:1 12:1 
siRNA 0.5:1 1:1 2:1 4:1 8:1 12:1 
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A summary of FITC-siRNA internalization efficiencies for homopolymer and block 
copolymer PTDMs is shown in Figure 3.18, where Figure 3.18A presents the percentage 
of the cell population that received FITC-siRNA and Figure 3.18B presents the median 
fluorescence intensity (MFI) of the cell populations.  In both data sets, PTDM 
internalization efficiencies increased in a charge-dependent manner up to approximately 
40 charges (dG20 and MePh5-b-dG20) and then diminish at higher charge contents.   
MePh5-b-dG20, with an MFI of 2,300, delivered the most siRNA, three times more than 
the next best PTDM, MePh5-b-dG10, with an MFI of 800.  This demonstrates that there is 
an optimal guanidinium content necessary for efficient internalization and above that 
charge content, the carriers are no longer as effective and show reduced performance.  
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Figure 3.18.  FITC-siRNA internalization in Jurkat T cells using homopolymer and block 
copolymer PTDMs.  Jurkat T cells (cell density = 4x105 cells/mL) were treated with 
PTDM/FITC-siRNA complexes with an N:P ratio = 8:1 in complete medium for four hours 
at 37°C and compared to cells only receiving FITC-siRNA.  All data was normalized to 
an untreated control.  A) Percent FITC positive cells.  B) Median fluorescence intensity 
(MFI) of the cell population. Data represents the mean ± SEM of three independent 
experiments.  * = p < 0.05, ** = p < 0.01, *** = p < 0.001, ns = not significant, as 
calculated by the unpaired two-tailed student t-test.  * represents significance between 
homopolymer and block copolymer PTDMs with the same charge content.  
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Figure 3.19.  Representative histograms for FITC-siRNA delivery into Jurkat T cells 
using ROMP-based protein mimics.  Jurkat T cells (cell density = 4x105 cells/mL) were 
treated with polymer/FITC-siRNA complexes with an N/P ratio = 8/1 in complete media 
for four hours at 37°C and compared with untreated cells and cells only receiving FITC-
siRNA.  A) Overlay of representative histograms for cells treated with 
homopolymer/siRNA complexes.  B) Overlay of representative histograms for cells 
treated with block copolymer/siRNA complexes. 
 
From this data set, it can also be seen that the block copolymer PTDMs 
significantly outperformed their homopolymer counterparts, particularly at charge 
contents of 40 or less.  Both MePh5-b-dG20 and MePh5-b-dG10 had MFI values that were 
six times higher than their corresponding homopolymers (dG20 and dG10, respectively).  
At larger charge contents, MFI values were similarly diminished for both homopolymer 
and block copolymer PTDMs.  The block copolymer PTDM with 80 charges (MePh5-b-
dG40) delivered FITC-siRNA to 66% of the cell population, which is approximately double 
the cell population that its homopolymer PTDM counterpart, dG40, could reach.  The 
observation that block copolymers outperformed their homopolymer counterparts is 
consistent with other reported guanidinium-rich siRNA transport molecules.39,48  In 
addition to Figure 3.18, flow cytometry histograms can be found in Figure 3.19.  PTDMs 
were also tested for their ability to deliver FITC-siRNA into HeLa cells to demonstrate 
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that they enabled internalization in adherent cells and to establish trends in a second cell 
type.  Block copolymer PTDMs containing 20 and 40 charges (MePh5-b-dG10 and 
MePh5-b-dG20) were shown to deliver double the amount of siRNA than their 
homopolymer counterparts.  PTDMs with 80 charges (dG40 and MePh5-b-dG40) were 
able to deliver the most siRNA, with similar MFIs of 4,100 and 4,500, respectively.  A 
significant drop-off in internalization efficiency for the largest charged segment was still 
observed (Figure 3.26 -Figure 3.29).  All polymer-treated cells showed greater than 90% 
viability using 7-AAD/Annexin V staining (Figure 3.21-Figure 3.24, Figure 3.30-Figure 
3.31).  
	  
Figure 3.20. Percent viable cells using a 7-Amino-actinomycin (7-AAD) Jurkat T Cell 
viability assay. Jurkat T cells (cell density = 4x105 cells/mL) were treated with 
PTDM/FITC-siRNA complexes with an N:P ratio = 8:1 in complete media for four hours 
at 37°C and compared with untreated cells and cells only receiving FITC-siRNA. Cells 
were stained at four hours.  Each data point represents the mean ± SEM of three 
independent experiments.  
 
	  
	   86 
 
Figure 3.21.  Percent viable cells using a 7-Amino-actinomycin (7-AAD) and Annexin-V 
Jurkat T cell viability assay. Jurkat T cells (cell density = 4x105 cells/mL) were treated 
with polymer/FITC-siRNA complexes with an N:P ratio = 8:1 in complete media for four 
hours at 37°C and compared with untreated cells and cells only receiving FITC-siRNA. 
Cells were stained at four hours.  Each data point represents the mean ± SEM of three 
independent experiments.  
 
In a separate viability study, promising PTDM/siRNA complexes were compared 
to samples that were treated with PTDMs alone in the same working concentrations 
used for complex formation.  Cells were harvested four hours after treatment and 
washed.  Samples were split and viability was determined on one half of the cells.  The 
other half were re-plated in fresh serum-containing medium and viability was assessed 
after an additional 24 hours of incubation. This procedure not only assessed PTDM 
toxicity at the maximum free concentrations, but it also probed longer-term toxicity 
effects of the treatment.  All cells exhibited greater than 90% viability as assessed by 7-
AAD/Annexin V staining both at the four-hour and 24-hour time points (Figure 3.22-
Figure 3.24).  In addition, cells were also counted at the 24-hour time point to measure 
cell proliferation.  All cell populations were found to approximately double over the 24-
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hour period, suggesting that PTDM/siRNA treatment did not impair cell growth (Figure 
3.25).  
 
Figure 3.22.  Percent viable cells using a 7-Amino-actinomycin (7-AAD) Jurkat T Cell 
viability assay. Jurkat T cells (cell density = 4x105 cells/mL) were treated with 
PTDM/FITC-siRNA complexes with an N:P ratio = 8:1 or the same concentration of 
polymer with no siRNA in complete media for four hours at 37°C and compared with 
untreated cells and cells only receiving FITC-siRNA. Half of the cell populations (2x105 
cells) were stained at four hours.  The other half (2x105 cell) were re-plated in complete 
media and stained at 24 hours.  Each data point represents the mean ± SEM of three 
independent experiments. 
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Figure 3.23.  Percent viable cells using a 7-Amino-actinomycin (7-AAD) and Annexin-V 
Jurkat T cell viability assay at the four hour time point. Jurkat T cells (cell density = 4x105 
cells/mL) were treated with PTDM/FITC-siRNA complexes with an N:P ratio = 8:1 or the 
same concentration of PTDM with no siRNA in complete media for four hours at 37°C 
and compared with untreated cells and cells only receiving FITC-siRNA. Half the cell 
populations (2x105 cells) were stained at four hours and the other half (2x105 cells) were 
re-plated for a 24 hour time point.  Each data point represents the mean ± SEM of three 
independent experiments. 
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Figure 3.24. Percent viable cells using a 7-Amino-actinomycin (7-AAD) and Annexin-V 
Jurkat T cell viability assay at the 24 hour time point. Jurkat T cells (cell density = 4x105 
cells/mL) were treated with PTDM/FITC-siRNA complexes with an N:P ratio = 8:1 or the 
same concentration of PTDM with no siRNA in complete media for four hours at 37°C 
and compared with untreated cells and cells only receiving FITC-siRNA. Half the cell 
populations (2x105 cells) were stained at four hours and the other half (2x105 cells) were 
re-plated and stained at the 24 hour time point.  Each data point represents the mean ± 
SEM of three independent experiments. 
	  
Cell Counts 
In addition to viability staining at 4 and 24 hr, cells were counted at 24 hr to 
assess proliferation.  1/20 dilution of each experimental well in trypan blue was used for 
cell counts.  Since Jurkat T cells have a doubling time of 24 hr, it was anticipated that 
healthy cell populations would double by the 24 hr time point.  Cells were not counted at 
the 4 hr time point since they were initially counted at the start of the experiment.  
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Figure 3.25.  Cell counts 24 hours following PTDM/FITC-siRNA or polymer alone 
treatments. Jurkat T cells (cell density = 4x105 cells/mL) were treated with PTDM/FITC-
siRNA complexes with an N:P ratio = 8:1 in complete or the same concentration of 
PTDM with no siRNA media for four hours at 37°C and compared with untreated cells 
and cells only receiving FITC-siRNA. The entire cell population was counted 24 hours.  
Comparison wells receiving polymer and no siRNA were also used as controls.  Each 
data point represents the mean ± SEM of three independent experiments.  
 
Figure 3.26.  N:P ratio screening for FITC-siRNA delivery into HeLa cells using ROMP-
based PTDMs.  HeLa cells (cell density = 5x104 cells/mL 48 hours prior to experiment; 
70-90% confluent on the day of the experiment) treated with polymer/FITC-siRNA 
complexes with an N:P ratio of either 4:1, 8:1, or 12:1 in complete media for four hours 
at 37°C and compared cells only receiving FITC-siRNA.  All data was compared to an 
untreated control. A) Percent positive cells.  B) MFI of the cell population. Each data 
point represents the mean ± SEM of three independent experiments.  
Un
tre
at
ed
siR
NA dG
10
dG
20
Me
Ph
5
-b
-d
G 5
Me
Ph
5
-b
-d
G 1
0
Me
Ph
5
-b
-d
G 2
0
0.0×10+00
1.0×1005
2.0×1005
3.0×1005
4.0×1005
5.0×1005
Controls
Polymer/siRNA
Polymer Alone
C
el
l C
ou
nt
siR
NA
Me
Ph
5
-b
-d
G 5
Me
Ph
5
-b
-d
G 2
0
Me
Ph
5
-b
-d
G 6
0
0
20
40
60
80
100
Control
4:1
8:1
12:1
%
 P
os
iti
ve
 C
el
ls
siR
NA
Me
Ph
5
-b
-d
G 5
Me
Ph
5
-b
-d
G 2
0
Me
Ph
5
-b
-d
G 6
0
0
2000
4000
6000
8000
10000
Control
4:1
8:1
12:1
M
ed
ia
n 
Fl
uo
re
sc
en
ce
 
In
te
ns
ity
 (M
FI
)
A. B. 
	  
	   91 
 
Figure 3.27.  Representative histograms for FITC-siRNA delivery into HeLa cells using 
ROMP-based PTDMs.  HeLa cells (cell density = 5x104 cells/mL 48 hours prior to 
experiment; 70-90% confluent on the day of the experiment) treated with polymer/FITC-
siRNA complexes with an N:P ratio = 8:1 in complete media for four hours at 37°C and 
compared cells only receiving FITC-siRNA and to an untreated control.  A) Overlay of 
representative histograms for cells treated with PTDM/siRNA complexes with an N:P = 
4:1.  B) Overlay of representative histograms for cells treated with PTDM/siRNA 
complexes with an N:P = 8:1.  C) Overlay of representative histograms for cells treated 
with PTDM/siRNA complexes with an N:P = 12:1. 
 
 
	  
Figure 3.28.  FITC-siRNA delivery into HeLa cells using ROMP-based protein mimics.  
HeLa cells (cell density = 5x104 cells/mL 48 hours prior to experiment; 70-90% confluent 
on the day of the experiment) treated with polymer/FITC-siRNA complexes with an N:P 
ratio = 8:1 in complete media for four hours at 37°C and compared cells only receiving 
FITC-siRNA.  All data was normalized to an untreated control. A) Percent positive cells.  
B) MFI) of the cell population. Each data point represents the mean ± SEM of three 
independent experiments. 
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Figure 3.29.  Representative histograms for FITC-siRNA delivery into HeLa cells using 
ROMP-based protein mimics.  HeLa cells (cell density = 5x104 cells/mL 48 hours prior to 
experiment; 70-90% confluent on the day of the experiment) treated with polymer/FITC-
siRNA complexes with an N:P ratio = 8:1 in complete media for four hours at 37°C and 
compared cells only receiving FITC-siRNA and to an untreated control.  A) Overlay of 
representative histograms for cells treated with homopolymer/siRNA complexes.  B) 
Overlay of representative histograms for cells treated with block copolymer/siRNA 
complexes. 
 
Figure 3.30.  Percent viable cells using a 7-Amino-actinomycin (7-AAD) HeLa cell 
viability assay. HeLa cells (cell density = 5x104 cells/mL 48 hours prior to experiment; 
70-90% confluent on the day of the experiment) were treated with polymer/FITC-siRNA 
complexes with an N:P ratio of either 4:1, 8:1, or 12:1 in complete media for four hours 
at 37°C and compared with untreated cells and cells only receiving FITC-siRNA. Cells 
were stained at four hours.  Each data point represents the mean ± SEM of three 
independent experiments. 
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Figure 3.31.  Percent viable cells using a 7-Amino-actinomycin (7-AAD) HeLa cell 
viability assay. HeLa cells (cell density = 5x104 cells/mL 48 hours prior to experiment; 
70-90% confluent on the day of the experiment) were treated with polymer/FITC-siRNA 
complexes with an N:P ratio = 8:1 in complete media for four hours at 37°C and 
compared with untreated cells and cells only receiving FITC-siRNA. Cells were stained 
at four hours.  Each data point represents the mean ± SEM of three independent 
experiments. 
 
Based on these results, two block copolymer PTDMs, MePh5-b-dG5 and MePh5-
b-dG20, were compared to a range of commercial reagents commonly used for siRNA 
internalization and delivery, including R9 (peptide, Peptide2.0), DeliverX (peptide, 
Affymetrix), Xfect (polymer, ClonTech), N-Ter (peptide, Sigma Aldrich), and RNAiMAX 
(lipid, Life Technologies).  In addition, JetPEI, a common polyethyleneimine-based 
pDNA delivery reagent, was included.  All commercial reagents were used as directed 
by the vendor.  A summary of FITC-siRNA internalization efficiencies for block 
copolymer PTDMs and commercial reagents is shown in Figure 3.32, where Figure 
3.32A presents the percentage of the cell population that received FITC-siRNA and 
Figure 3.32B presents the MFI of the cell populations.  MePh5-b-dG5 and MePh5-b-dG20 
were both shown to enable internalization in a greater percentage of cells than the 
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commercial reagents (Figure 3.32A).  In addition, MePh5-b-dG20 resulted in a nearly 10-
fold greater MFI than the commercial reagents, indicating it was able to deliver 
quantitatively more cargo inside the cells (Figure 3.32B-Figure 3.33).  Viability was 
assessed using 7-AAD / Annexin V staining (Figure 3.33).  All samples had greater than 
90% viability, with the exception of samples treated with RNAiMAX, which had viabilities 
closer to 80% (Figure 3.34).  This data demonstrates the superiority of our PTDMs for 
siRNA delivery compared to common commercial reagents and establishes these 
materials as viable delivery vehicles for hard-to-transfect T cell lines, for which options 
for efficient delivery are limited.   
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Figure 3.32.  Comparison of PTDM and commercial reagent FITC-siRNA internalization 
efficiencies in Jurkat T cells (cell density = 4x105 cells/mL). Cells treated with 
PTDM/FITC-siRNA complexes with an N:P ratio = 8:1 or with commercial reagent/FITC-
siRNA complexes (used as directed) in complete medium for four hours at 37°C and 
compared to cells only receiving FITC-siRNA.  All data was normalized to untreated 
controls. A) Percent FITC positive cells.  B) Median fluorescence intensity (MFI) of the 
cell population.  Data represents the mean ± SEM of three independent experiments.  All 
PTDM data is statistically different from the commercial reagents (p <0.001) as 
calculated by the unpaired two-tailed student t-test.   
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Figure 3.33.  Representative histograms for FITC-siRNA delivery into Jurkat T cells 
using ROMP-based protein mimics and commercially available reagents.  Jurkat T cells 
(cell density = 4x105 cells/mL) were treated with polymer/FITC-siRNA complexes with an 
N:P ratio = 8:1 in complete media for four hours at 37°C and compared with untreated 
cells and cells only receiving FITC-siRNA.   
 
Figure 3.34.  Percent viable cells using a 7-Amino-actinomycin (7-AAD) Jurkat T Cell 
viability assay. Jurkat T cells (cell density = 4x105 cells/mL) were treated with 
PTDM/FITC-siRNA complexes with an N:P ratio = 8:1 or commercial reagents/FITC-
siRNA complexes used as directed in complete media for four hours at 37°C and 
compared with untreated cells and cells only receiving FITC-siRNA. Cells were stained 
at four hours.  Each data point represents the mean ± SEM of three independent 
experiments. 
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3.4 Delivery of Biologically Active siRNA to NOTCH1  
Based on the FITC-siRNA internalization results from Jurkat T cells, four 
promising PTDMs (MePh5-b-dG5, MePh5-b-dG10, MePh5-b-dG20, and dG20) were 
screened for delivery of a biologically active siRNA to NOTCH1.  NOTCH1 was selected 
as the primary target for siRNA knockdown studies because it represents an active gene 
in T cells.  Unlike looking at a reporter gene, which is not required for normal cellular 
activities, the gene of interest is required for cellular function and represents a more 
sophisticated and realistic system for knockdown assessment.  Although NOTCH1 
protein is constitutively expressed in Jurkat T cells, it is a mutation in the NOTCH1 gene 
together with increased NOTCH1 protein stability that gives the T cell line its immortality, 
thus making down regulation of NOTCH1 expression difficult to monitor.  To overcome 
this limitation, hPBMCs were used in NOTCH1 down regulation experiments.  At the 
same time, demonstrating robust delivery into primary T cells is of critical practical 
importance.  hPBMCs, which are a mixed population of primary lymphocytes and 
monocytes obtained from human donors, were cultured overnight to enrich for the viable 
cell population, most of which were CD4+ and CD8+ T cells.  Surface staining cells at 
the 48 hour time point to check for CD4 and CD8 expression revealed that 
approximately 30% of the population was CD8+ and approximately 50% of the 
population was CD4+.  The gating strategy for this determination is shown in Figure 
3.35.  
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Figure 3.35.  Representative flow cytometry cell gating to determine the fraction of the 
population that represent CD8+T cells and CD4+ T cells. A) Plot of forward vs. side 
scatter showing the gate on the cell population used for analysis.  B) Plot of FITC 
fluorescence vs. forward scatter showing the gate on the FITC-positive cells (CD8+ T 
cells).  C) Plot of APC fluorescence vs. forward scatter showing the gate on the APC-
positive cells (CD4+ T cells).  
 
In these experiments, hPBMCs were treated with PTDM/siRNA complexes for 
four hours in serum-containing medium.  A fixed amount of siRNA (100nM) was used for 
each experiment to assess the effect PTDM structure has on knockdown efficiencies.  
Specifically, within the block copolymer architecture, the length of the cationic sequence 
was examined.  After four hours, the cells were transferred to anti-CD3 and anti-CD28-
coated well plates for stimulation and allowed to incubate for 48 hours.  T cell stimulation 
will result in an induction in NOTCH1 expression and allow us to assess the effect 
treatment had on NOTCH1 protein levels in comparison to untreated samples.  This time 
point was selected because it is the point of maximum protein expression, and we 
expect the cells that successfully received siRNA to NOTCH1 would have decreased 
protein expression compared to the untreated controls.  Flow cytometry was used as the 
primary method to analyze protein expression, enabling us to stain for protein content 
and quantify the extent to which protein levels were reduced on a per cell basis.   
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The percent relative protein expression data for these experiments is shown in Figure 
3.36, all gated histograms are shown in Figure 3.37, and a summary of the MFI data can 
be found in Figure 3.38.  In this case, percent relative protein expression is the MFI of 
the total population multiplied by the percent NOTCH1 positive population all normalized 
to an untreated blank.   
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Figure 3.36.  Relative NOTCH1 expression levels in PBMCs and their corresponding 
viabilities (cell density = 1x106 cells/mL). Cells were treated with PTDM/NOTCH1 siRNA 
complexes or PTDM/scrambled siRNA with an N:P ratio = 8:1 in complete media for four 
hours at 37°C.  After treatment, cells were washed and then stimulated with plate-bound 
anti-CD3 and anti-CD28 for 48 hours.  All data was normalized to an untreated control 
(grey bar). A) Relative NOTCH1 levels in PBMCs after 48-hour treatment with 
PTDM/NOTCH1 siRNA (light blue bars) or PTDM/scrambled siRNA complexes (purple 
bars).  B) Percent viable cells following staining with 7-AAD. Data represents the mean ± 
SEM of four independent experiments using cells isolated from different donors. * = p < 
0.05, ** = p < 0.01, *** = p < 0.001, ns = not significant, as calculated by the unpaired 
two-tailed student t-test. 
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Figure 3.37.  Representative histograms for hNOTCH1 knockdown in PBMCs using 
ROMP-based PTDMs.  PBMCs (cell density = 1x106 cells/mL). Cells treated with 
PTDM/siN1 complexes or PTDM/siCont with an N:P ratio = 8:1 in complete media for 
four hours at 37°C.  After treatment, cells were washed and then stimulated with plate-
bound anti-CD3 and anti-CD28 for 48 hours.  Untreated samples, samples receiving 
hNOTCH1 siRNA (siN1), and samples receiving scrambled control siRNA (siCont) are 
represented in grey, red, and blue, respectively.  
 
For the PTDM with the shortest cationic sequence, MePh5-b-dG5, NOTCH1 expression 
was reduced to ~50%, which is significant given that NOTCH1 is not a reporter gene.  
Doubling the cationic length with MePh5-b-dG10 resulted in a lower NOTCH1 expression 
of ~37%.  The lowest NOTCH1 expression obtained, ~16%, was observed for MePh5-b-
dG20.  This data was consistent with the previous data shown in Figure 3.18 and Figure 
3.32, which support the suggestion that this PTDM is able to deliver the most siRNA into 
PBMCs.  In fact, it appears that for these experiments with 100 nM siRNA that MePh5-b-
dG20 delivers too much siRNA since resolution was lost between the target (light blue 
bars) and scrambled siRNA (purple bars), a common observation when excess siRNA is 
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present intracellularly.72-75  Although reducing the siRNA concentration may help limit 
these effects73-75, sequence overlaps with target and off-target mRNAs are also a 
contributing factor and may be present, even at reduced concentrations.72,76  Better 
screening for scrambled controls that avoid the target mRNA sequence would be 
expected to improve the specificity of NOTCH1 knockdown experiments.76  While the 
primary goal of this study was to explore how the polymer structures impact siRNA 
delivery efficiencies, future studies will be geared towards optimizing these materials for 
improved specificity.   
When evaluating protein expression, it was critical to assess cell viability to 
ensure that diminished protein expression was not due to cell death.  Since monitoring 
protein content by flow cytometry requires cells to be fixed, cell samples were split after 
harvest to determine cell viability on the unfixed population.  hPBMC viability was 
assessed by staining with 7-AAD, a DNA-intercalating dye that is excluded from live cells 
but taken up by dead and dying cells that have compromised membrane integrity.  As 
shown in Figure 3.36B, all samples were greater than 80% viable, which suggests that 
reduced protein expression in the cells is a consequence of PTDM/siRNA treatment and 
not due to cell death.   
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Figure 3.38.  MFI for hNOTCH1 protein in hPBMCs (cell density = 1x106 cells/mL). Cells 
treated with PTDM/hNOTCH1 siRNA complexes or PTDM/scrambled siRNA with an N/P 
ratio = 8/1 in complete media for four hours at 37°C.  After treatment, cells were washed 
and then stimulated with plate-bound anti-CD3 and anti-CD28 for 48 hours.  All data was 
normalized to an untreated control. Each data point represents the mean ± SEM of four 
independent experiments. 
 
 In addition to using flow cytometry, a western blot was used to monitor protein 
reduction in cells treated with siRNA to NOTCH1 or treated with scrambled siRNA as 
they compared to untreated cells for MePh5-b-dG20 (Figure	   3.39).  This data was 
consistent with the flow cytometry data.   
 
Figure 3.39.  Western blot analysis showing knockdown of NOTCH1 by MePh5-b-dG20.  
Unstimulated, untreated cells (lane 1), untreated, stimulated cells (lane 2), treated with 
MePh5-b-dG20/scrambled siRNA complexes (siCont, lane 3) or MePh5-b-dG20/NOTCH1 
siRNA complexes (siN1, lane 4). Total protein lysates were immunoblotted with 
antibodies that detect the active NOTCH1 intracellular domain and GAPDH. Untreated, 
unstimulated PBMCs (lane 1) were included as a negative control of the active NOTCH1 
intracellular domain. siCont stands for scrambled siRNA and siN1 stands for siRNA to 
NOTCH1. 
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3.5 Conclusions 
 RNAi is an attractive approach to study gene function and has potential for 
therapeutic applications involving T cells due to its transient knockdown of target 
proteins; however, difficulties in delivery to these cell types limit its use.  In efforts to 
address an unmet need in the area of T cell delivery and to better understand how 
polymer composition impacts delivery and knockdown efficiencies, we report the 
development of two guanidinium-rich PTDM series for siRNA delivery.  Homopolymer 
and block copolymer PTDMs with varying cationic charge contents were tested to 
assess the role of cationic charge content and the addition of a segregated, hydrophobic 
block in the internalization of FITC-siRNA in Jurkat T cells and knockdown of hNOTCH1 
in hPBMCs.  FITC-siRNA internalization in Jurkat T cells demonstrated that there was an 
optimal cationic charge content necessary for efficient delivery (40 charges), which, once 
surpassed, resulted in diminished delivery capabilities.  Cells incubated with PTDMs and 
their corresponding siRNA complexes exhibited greater than 90% viability using 7-
AAD/Annexin-V staining.  Block copolymers also significantly outperformed commercial 
reagents designed for siRNA delivery, making these PTDMs potential alternatives for T 
cell siRNA transfections.  Based on the FITC-siRNA internalization results, select PTDM 
candidates were screened for knockdown of NOTCH1 in hPBMCs.  For this set of 
PTDMs, protein expression was reduced as the cationic charge content increased, with 
the block copolymer PTDM MePh5-b-dG20 providing the most reduction in protein 
expression.  Viability data indicated that knockdown was due to PTDM/siRNA treatment 
and not cell death.  Overall, optimization of the cationic charge content led to improved 
delivery efficiencies, as well as improved knockdown efficiencies.  This demonstrates the 
importance of understanding the essential PTDM design parameters for delivery of 
siRNA and will help guide the design of the next generation of efficient PTDMs.  
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4 CHAPTER 4 
CRITICAL HYDROPHOBIC CONTENT IN ROMP-BASED PROTEIN MIMICS 
REQUIRED FOR EFFICENT SIRNA INTERNALIZATION 
4.1 Introduction 
Intracellular delivery of therapeutics, particularly siRNA, continues to be a 
challenge for the biomedical community.1,2  Transient gene knockdown plays an 
important role in the exploration of molecular pathways and in the development of more 
advanced treatment options; the field, however, needs a clearer understanding of how to 
efficiently and reliably deliver bioactive molecules across cellular membranes, 
particularly in primary human cells.2-8  Nature, however, is already capable of designing 
proteins that can perform these functions.9-11  One example is HIV-1 TAT, which is 
responsible for the spread of the viral genome of HIV.9,10  This protein contains a region 
referred to as a protein transduction domain (PTD), which is primarily responsible for its 
ability to enter cells.12-14  These regions in proteins are generally cation-rich, containing 
lysine and arginine residues which aid in cellular uptake.  Structure-activity relationships 
(SARs) related to this protein, as well as others such the Antennapedia homeodomain 
protein, led to the development of cell-penetrating peptides (CPPs).  These peptides are 
capable of delivering cargo such as small molecules, siRNA, pDNA, and proteins into 
cells using covalent or non-covalent interactions.15-20 Three examples of CPPs include 
TAT49-57, which is an arginine-rich peptide based on the PTD of the HIV-1 TAT protein, 
and Pep-1 and MPG, which are lysine-rich primary, amphipathic peptides.13,14,20-24   
Although extensive work has been devoted to exploring CPPs for siRNA delivery 
applications24-27, the extension of design principles learned from these systems to the 
development of synthetic mimics, referred to as cell-penetrating peptide mimics 
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(CPPMs) or protein transduction domain mimics (PTDMs), offers many distinct 
advantages.28,29  Breaking out of the synthetic confinement of amino acids, a wider 
range of chemistries can be used to manipulate key features of CPPs, including a 
segregated hydrophobic component and cationic charge content, primarily in the form of 
guanidinium moieties.28  The field of mimetic polymer chemistry has demonstrated the 
utility of a range of polymer scaffolds for the development of siRNA delivery 
reagents28,30,31, including an oxanorbornene-based scaffold28,30,32, a polymethacrylamide-
based scaffold33, an arginine-grafted bioreducible polydisulfide-based scaffold34,35, and 
an oligocarbonate-based scaffold.36-38  A similar design rationale was successfully used 
for the design of antimicrobial peptides, where the facially amphiphilic structures of 
antimicrobial peptides were successfully mimicked using highly modular synthetic 
scaffolds.39-43  In order to realize the full potential of these PTDM materials and continue 
to improve internalization and delivery efficiencies, extensive SARs studies are 
necessary to elucidate key design parameters.  
To this end, our research group has devoted an extensive amount of research 
into understanding how the structures of our ring-opening metathesis (ROMP) based 
protein mimics influence their membrane interactions29,40,44-48, cellular uptake 
efficiencies29,49, and siRNA delivery efficiencies.30,32  With respect to siRNA delivery, our 
group has demonstrated the utility of our platform for the successful internalization of 
siRNA and for the knockdown of active biological genes in T cells.30,32  Previous SARs 
established that there was a critical cationic block length required for efficient siRNA 
delivery, which, not surprisingly, showed some cell-type dependencies.32  Additionally, 
the incorporation of a fixed-length, segregated, hydrophobic segment into our block 
copolymer PTDM structures improved siRNA internalization efficiencies by six fold 
compared to their homopolymer counterparts with the same relative cationic block 
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lengths.32  From our preliminary studies, a great deal was learned about the cationic 
block length of our PTDMs;32 however, further studies were needed to understand how 
the amount and type of hydrophobic content influenced siRNA internalization 
efficiencies.   
Many literature reports demonstrate that adding hydrophobicity, either through 
direct incorporation or through the use of bulky counter ions, generally improves 
membrane interactions, cellular uptake, and delivery efficiencies of CPPs and their 
synthetic mimics.30,32,37,47,48,50-55  Pep-1 and MPG, two common CPPs used for protein 
and siRNA delivery, respectively, have primary amphipathic structures and their 
hydrophobic components improve membrane interactions and internalization 
efficiencies.23,24  In light of these trends and the wide variety of hydrophobic groups 
available, it is important to understand how the lengths within our PTDMs and the nature 
of the hydrophobic moiety impacts siRNA internalization efficiencies.  At the same time, 
the need to optimize the cationic block length should not be overlooked either as it also 
influences the PTDM design landscape.   
Structure activity relationships using Jurkat T cells and HeLa cells were used to 
probe how the length and the nature of the hydrophobic block impacted siRNA 
internalization efficiencies.  To explore the length of the hydrophobic block, two series of 
diblock copolymers (n + m) with symmetric (n = m) or asymmetric (n ≠ m) block lengths 
were synthesized (Figure 4.2.1).  In a separate series of PTDMs, the hydrophobic side 
chain composition was varied to probe how the relative hydrophobicity impacted siRNA 
internalization.  After initial testing, this set of PTDMs was further expanded to 
incorporate additional hydrophobic side chains to elucidate the hydrophobic window for 
which our PTDMs had optimal activity.  Relative hydrophobicities of the hydrophobic 
building blocks were estimated using HPLC retention times to guide the selection of 
	  
	   112 
structures used for analysis.  Probing the effects of hydrophobicity on siRNA 
internalization efficiencies enabled us to better elucidate the essential design principles 
for our PTDMs.  
4.2 Initial PTDM Design and Characterization 
 In this report, we document the use of ring-opening metathesis polymerization 
(ROMP) for the synthesis of block copolymer (BCP) PTDMs with varying hydrophobic 
block lengths.  ROMP is a facile polymerization method that is functional group tolerant 
and allows for good control over molecular weights and dispersities.59-66  In addition, we 
continue to exploit the versatile, dual-functional oxanorbornene-based monomer platform 
as a means to tailor the overall polymer properties; in this case with a focus on the 
hydrophobic block length and moieties incorporated as side chains.  The monomers and 
polymers designed and synthesized for this study are summarized in Figure 4.2.1.  The 
guanidinium-rich monomer (dG), shown in its boc-protected form and meant to mimic 
arginine residues, was used as the cationic component of the BCP PTDMs.  This 
selection was made based on previous literature that demonstrates the superior 
performance of guanidinium moieties over their ammonium counterparts, which are 
reminiscent of lysine and ornithine residues.67   
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Figure 4.1.  Monomer and polymer structures used for this study.  A) Monomer 
structures B) Polymer Structures. Blue represents cationic moieties and green 
represents hydrophobic moieties.  
 
The three initial hydrophobic monomers were designed to contain either two methyl 
substituents (dimethyl, dMe), one methyl and one phenyl substituent (methyl phenyl, 
MePh), or two phenyl substituents (diphenyl, dPh) (Figure 4.2.1A) and were selected 
because HPLC retention times indicated that they spanned a range of hydrophobicities.  
These retention times were 14.2 min (dMe), 27.8 min (MePh), and 36.1 min (dPh).  The 
phenyl-based hydrophobic groups have also demonstrated useful activities in prior 
studies30,32,44,47  MePh, which has traditionally been selected by our group as the 
hydrophobic component of PTDMs for siRNA delivery, was used to synthesize BCPs 
with symmetric (n = m) or asymmetric (n ≠ m, with n being fixed at five for all polymers in 
the series) block sizes.  This allowed us to explore how the length of the hydrophobic 
block impacts internalization efficiencies at a fixed cationic charge length.    A summary 
	  
	   114 
of molecular weight data for the block polymer PTDMs is shown in Figure 3.3, Figure 
3.5, Table 4.1, and Table 4.2, Figure 4.2, and Figure 4.3.   
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Table 4.1. Molecular weight characterization of Boc-protected block copolymer PTDMs 
from the MePhn-b-dGm, dMe5-b-dGm, and dPh5-b-dGm series. 
Polymer Mna (Da) Mwa (Da) Mpa (Da) 
Đa 
(Mw/Mn) 
25a 5,400 5,900 5,900 1.08 
25b 8,300 9,000 9,300 1.08 
25c 16,000 17,100 17,500 1.07 
25d 27,600 31,500 36,800 1.14 
25e 9,900 10,800 11,100 1.09 
25f 19,800 21,400 22,800 1.08 
25g 31,600 38,400 44,700 1.22 
26a 5,500 5,800 5,900 1.06 
26b 9,500 10,300 10,600 1.08 
26c 14,600 15,900 16,600 1.09 
27a 5,200 5,600 5,700 1.08 
27b 8,500 9,300 9,500 1.09 
27c 14,400 16,100 17,100 1.11 
[aNumber average molecular weight (Mn), weight average molecular weight (Mw), 
molecular weight at the peak maximum (Mp), and dispersity indices (Đ=Mw/Mn) 
determined by GPC using poly(methyl methacrylate) (PMMA) standards, tetrahydrofuran 
(THF) as the eluent, and toluene as the flow marker.  
 
 
Figure 4.2.  THF GPC chromatograms for boc-protected block copolymer PTDMs 25e-
g.  A summary of molecular weight data can be found in Table 4.1. 
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Table 4.2. Molecular weight characterization of deprotected block copolymer PTDMs. 
Polymer Mna (Da) Mwa (Da) Mpa (Da) Đa (Mw/Mn) 
MePh5-b-dG5 10,200 10,900 10,100 1.07 
MePh5-b-dG10 14,900 15,800 15,200 1.06 
MePh5-b-dG20 21,800 23,500 23,500 1.08 
MePh5-b-dG40 33,300 36,600 39,500 1.10 
MePh10-b-dG10 19,500 21,000 19,300 1.08 
MePh20-b-dG20 29,600 33,200 30,700 1.12 
MePh40-b-dG40 45,000 49,500 51,900 1.10 
dMe5-b-dG5 12,300 12,900 12,500 1.05 
dMe5-b-dG10 18,100 18,900 18,800 1.05 
dMe5-b-dG20 24,000 25,300 25,500 1.05 
dPh5-b-dG5 13,000 14,400 12,200 1.11 
dPh5-b-dG10 17,600 19,200 17,200 1.09 
dPh5-b-dG20 25,000 26,800 25,900 1.07 
[aNumber average molecular weight (Mn), weight average molecular weight (Mw), 
molecular weight at the peak maximum (Mp), and dispersity indices (Đ=Mw/Mn) 
determined by GPC using poly(methyl methacrylate) (PMMA) standards, 2,2,2-
trifluoroethanol (TFE) with 20 mM NaTFA salt as the eluent, and methanol as the flow 
marker.  
 
 
Figure 4.3.  TFE GPC chromatograms for deprotected block copolymer PTDMs MePh10-
b-dG10, MePh5-b-dG10, MePh5-b-dG20, and MePh5-b-dG40.  A summary of molecular 
weight data can be found in Table 4.2.  
 
In addition, BCPs containing a fixed hydrophobic block length of five consisting of dMe, 
MePh, or dPh hydrophobic blocks and a cationic charge block of five, ten, or twenty dG 
units were synthesized as a way to further probe the relationship between the 
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hydrophobic component and the length of the charged block for siRNA internalization 
efficiencies.  A summary of molecular weight data for is shown in Figure 4.4, Figure 4.5, 
Figure 4.6, Figure 4.7, Table 4.1, and Table 4.2.   
 
Figure 4.4.  THF GPC chromatograms for boc-protected block copolymer PTDMs 26a-c. 
A summary of molecular weight data can be found in Table 4.1. 
 
 
Figure 4.5.  THF GPC chromatograms for boc-protected block copolymer PTDMs 8a-c. 
A summary of molecular weight data can be found in Table 4.1.  
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Figure 4.6.  TFE GPC chromatograms for deprotected block copolymer PTDMs dMe5-b-
dG5, dMe5-b-dG10, and dMe5-b-dG20.  A summary of molecular weight data can be found 
in Table 4.2. 
 
 
Figure 4.7.  TFE GPC chromatograms for deprotected block copolymer PTDMs dPh5-b-
dG5, dPh5-b-dG10, and dPh5-b-dG20.  A summary of molecular weight data can be found 
in Table 4.2. 
 
Previous work in this area documented the effect of cationic charge block length and the 
addition of a hydrophobic block had on siRNA internalization and delivery.32  In that 
study, BCP PTDMs significantly outperformed their homopolymer counterparts, 
recapitulating the importance of an added hydrophobic component.32  This study further 
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builds from this initial finding to explore how the quantity of hydrophobic repeat units and 
the type of hydrophobic moiety used impacts siRNA internalization efficiencies. 
4.3 FITC-siRNA Delivery: Symmetric vs. Asymmetric  
 The first studies explored the MePhn-b-dGm PTDM series.  A total of seven 
PTDMs were designed to contain equal hydrophobic and cationic block lengths 
(symmetric, n = m = 5, 10, 20, and 40) and three contained a fixed hydrophobic block of 
five repeat units (asymmetric, n ≠ m) with cationic charge blocks of approximately 10, 
20, and 40 repeat units. The cationic block length was varied from 5 to 40 based on our 
previous findings.32  Fluorescein isothiocyanate (FITC) labeled siRNA (FITC-siRNA) was 
used to establish trends in siRNA internalization efficiency for both series in Jurkat T 
cells, a representative suspension cell type, and HeLa cells, a representative adherent 
cell type, using complete media.  In this report, only FITC-labeled siRNA was used since 
we recently demonstrated the internalization relationship for our PTDMS between FITC-
siRNA in Jurkats and siRNA for NOTCH1 in human peripheral blood mononuclear cells 
(PBMCs).  The N:P ratios for these experiments, which are the ratios of the number of 
positively charged nitrogen atoms in the PTDMs to the number of negatively charged 
phosphate atoms in the FITC-siRNA, were set at 8:1 and 4:1, respectively, and were 
previously optimized by our group.32  The selection of these N:P ratios were further 
supported by gel retardation assays, which demonstrated that all PTDMs fully bound 
siRNA at N:P ratios of 4:1 or less (Figure 4.8-Figure 4.20).  
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Figure 4.8.  Gel retardation assay to assess PTDM / siRNA complex formation using 
MePh5-b-dG5.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
 
Figure 4.9.  Gel retardation assay to assess PTDM / siRNA complex formation using 
MePh5-b-dG10.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
 
Figure 4.10.  Gel retardation assay to assess PTDM / siRNA complex formation using 
MePh5-b-dG20.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
siRNA 0.5:1 1:1 2:1 4:1 8:1 12:1 
siRNA 0.5:1 1:1 2:1 4:1 8:1 12:1 
siRNA 0.5:1 1:1 2:1 4:1 8:1 12:1 
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Figure 4.11.  Gel retardation assay to assess PTDM / siRNA complex formation using 
MePh5-b-dG40.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
 
Figure 4.12.  Gel retardation assay to assess PTDM / siRNA complex formation using 
MePh10-b-dG10.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
 
Figure 4.13.  Gel retardation assay to assess PTDM / siRNA complex formation using 
MePh20-b-dG20.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
siRNA 0.5:1 1:1 2:1 4:1 8:1 12:1 
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Figure 4.14.  Gel retardation assay to assess PTDM / siRNA complex formation using 
MePh40-b-dG40.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
 
Figure 4.15.  Gel retardation assay to assess PTDM / siRNA complex formation using 
dMe5-b-dG5.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
 
Figure 4.16.  Gel retardation assay to assess PTDM / siRNA complex formation using 
dMe5-b-dG10.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
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Figure 4.17.  Gel retardation assay to assess PTDM / siRNA complex formation using 
dMe5-b-dG20.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
 
Figure 4.18.  Gel retardation assay to assess PTDM / siRNA complex formation using 
dPh5-b-dG5.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
 
Figure 4.19.  Gel retardation assay to assess PTDM / siRNA complex formation using 
dPh5-b-dG10.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
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Figure 4.20.  Gel retardation assay to assess PTDM / siRNA complex formation using 
dPh5-b-dG20.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
 A summary of FITC-siRNA internalization efficiencies for these symmetric and 
asymmetric PTDMs is shown in Figure 4.3.14, where Figure 4.3.14A and Figure 4.3.14B 
present the percentage of the cell population that received FITC-siRNA and Figure 
4.3.14C and Figure 4.3.14D present the median fluorescence intensity (MFI) of the cell 
populations.  The corresponding flow cytometry histograms are shown in Figure 4.22 
and Figure 4.23 for Jurkat T cells and HeLa cells, respectively. 
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Figure 4.21.  FITC-siRNA delivery into Jurkat T cells and HeLa cells using symmetric 
and asymmetric ROMP-based protein mimics.  Jurkat T cells (cell density = 4x105 
cells/mL) treated with polymer/FITC-siRNA complexes with an N:P ratio = 8:1 in 
complete media for four hours at 37°C and compared cells only receiving FITC-siRNA. 
HeLa cells (cell density = 5x104 cells/mL 48 hours prior to experiment; 70-90% confluent 
on the day of the experiment) treated with polymer/FITC-siRNA complexes with an N/P 
ratio = 4/1 in complete media for four hours at 37°C and compared cells only receiving 
FITC-siRNA.   All data was compared to an untreated control. A) Percent positive Jurkat 
T cells.  B) Percent positive HeLa cells. C) Median fluorescence intensity (MFI) of the 
Jurkat T cell population. D) Median fluorescence intensity (MFI) of the HeLa cell 
population. Each data point represents the mean ± SEM of three independent 
experiments. * = p < 0.05 and ns = not significant, as calculated by the unpaired two-
tailed student t-test.  Statistics represents significance between symmetric and 
asymmetric block copolymer PTDMs with the same cationic charge content.   
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Figure 4.22.  Representative histograms for FITC-siRNA delivery into Jurkat T cells 
using ROMP-based protein mimics.  Jurkat T cells (cell density = 4x105 cells/mL) were 
treated with polymer/FITC-siRNA complexes with an N/P ratio = 8/1 in complete media 
for four hours at 37°C and compared with untreated cells and cells only receiving FITC-
siRNA.  A) Overlay of representative histograms for cells treated with asymmetric block 
copolymer/siRNA complexes.  B) Overlay of representative histograms for cells treated 
with symmetric block copolymer/siRNA complexes.  C) Overlay of representative 
histograms for cells treated with the dimethyl block copolymer/siRNA complexes.  D) 
Overlay of representative histograms for cells treated with the diphenyl block 
copolymer/siRNA complexes.  E) Overlay of representative histograms for cells treated 
with block copolymer/siRNA complexes, where the block copolymers have a constant 
cationic charge content of 20. 
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Figure 4.23.  Representative histograms for FITC-siRNA delivery into HeLa cells using 
ROMP-based protein mimics.  HeLa cells (cell density = 5x104 cells/mL 48 hours prior to 
experiment; 70-90% confluent on the day of the experiment) treated with polymer/FITC-
siRNA complexes with an N/P ratio = 8/1 in complete media for four hours at 37°C and 
compared cells only receiving FITC-siRNA and to an untreated control.  A) Overlay of 
representative histograms for cells treated with asymmetric block copolymer/siRNA 
complexes.  B) Overlay of representative histograms for cells treated with symmetric 
block copolymer/siRNA complexes.  C) Overlay of representative histograms for cells 
treated with the dimethyl block copolymer/siRNA complexes.  D) Overlay of 
representative histograms for cells treated with the diphenyl block copolymer/siRNA 
complexes. 
 
All PTDM-treated cells showed greater than 85% viability using 7-AAD staining (Figure 
4.24 and Figure 4.25).   
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Figure 4.24.  Percent viable Jurkat T cells using a 7-Amino-actinomycin (7-AAD) viability 
assay. Jurkat T cells (cell density = 4x105 cells/mL) were treated with polymer/FITC-
siRNA complexes with an N/P ratio = 8/1 in complete media for four hours at 37°C and 
compared with untreated cells and cells only receiving FITC-siRNA. Cells were stained 
at four hours.  Each data point represents the mean ± SEM of three independent 
experiments.  
 
Figure 4.25.  Percent viable cells using a 7-Amino-actinomycin (7-AAD) HeLa cell 
viability assay. HeLa cells (cell density = 5x104 cells/mL 48 hours prior to experiment; 
70-90% confluent on the day of the experiment) were treated with polymer/FITC-siRNA 
complexes with an N/P ratio = 8/1 in complete media for four hours at 37°C and 
compared with untreated cells and cells only receiving FITC-siRNA. Cells were stained 
at four hours.  Each data point represents the mean ± SEM of three independent 
experiments. 
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For both cell types, symmetric and asymmetric PTDMs containing the same cationic 
charge contents were able to deliver to the same percentages of the cell populations 
(Figure 4.3.14A and Figure 4.3.14B) regardless of the different hydrophobic block 
lengths.  When looking at the MFI data, PTDMs with five, ten, and forty cationic repeat 
units lead to similar internalization amounts regardless of the hydrophobic block length; 
however, for PTDMs with 20 cationic repeat units, the asymmetric PTDM MePh5-b-dG20, 
significantly outperformed its symmetric counterpart (Figure 4.3.14C and Figure 
4.3.14D).  For both cell types, MePh5-b-dG20 had double the fluorescence intensity of 
MePh20-b-dG20.  This result demonstrates that the relationship between hydrophobicity 
and cationic block length is not always trivial and that increasing the hydrophobic block 
length further does not guarantee superior performance.37  In addition, this result 
suggests that a certain ratio between hydrophobic and cationic block lengths is 
necessary for efficient internalization. 
4.4 FITC-siRNA Delivery: Varying the hydrophobic block 
To further probe the relationship between hydrophobic and cationic block 
lengths, PTDMs with a fixed hydrophobic block length of five repeat units of either low 
(dMe), moderate (MePh), or high hydrophobicity (dPh) were prepared and studied.  The 
relative hydrophobicities of these monomers was determined using HPLC and can be 
found in Table 4.3.  The given retention times were 14.2 min, 27.8 min, and 36.1 min, 
respectively, where larger HPLC retention times reflect increased hydrophobicity.  Based 
on previous results and those shown in Figure 2, the hydrophobic block length was held 
constant at five repeat units while the cationic block length was varied from five to 
twenty.  This generated a total of nine PTDMs.  FITC-siRNA was again used to establish 
trends in siRNA internalization efficiency in Jurkat T cells and HeLa cells using complete 
media.  The N:P ratios were set at 8:1 and 4:1, respectively, and were supported by gel 
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retardation assays, which demonstrated that all PTDMs bound siRNA at N:P ratios of 4:1 
or less  (Figure 4.8-Figure 4.20).  A summary of FITC-siRNA internalization efficiencies 
for the PTDMs with variable hydrophobic block compositions is shown in Figure 4.4.1, 
where Figure 4.4.1A and Figure 4.4.1B present the percentage of the cell populations 
that received FITC-siRNA and Figure 4.4.1C and Figure 4.4.1D present the MFIs of the 
cell populations.  All PTDM-treated cells showed greater than 85% viability using 7-AAD 
staining (Figure 4.27 and Figure 4.28).   
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Figure 4.26.  FITC-siRNA delivery into Jurkat T cells and HeLa cells using ROMP-based 
protein mimics with different hydrophobic blocks.  Jurkat T cells (cell density = 4x105 
cells/mL) treated with polymer/FITC-siRNA complexes with an N:P ratio = 8:1 in 
complete media for four hours at 37°C and compared cells only receiving FITC-siRNA. 
HeLa cells (cell density = 5x104 cells/mL 48 hours prior to experiment; 70-90% confluent 
on the day of the experiment) treated with polymer/FITC-siRNA complexes with an N/P 
ratio = 4/1 in complete media for four hours at 37°C and compared cells only receiving 
FITC-siRNA.   All data was compared to an untreated control. A) Percent positive Jurkat 
T cells.  B) Median fluorescence intensity (MFI) of the Jurkat T cell population.  C) 
Percent positive HeLa cells.  D) Median fluorescence intensity (MFI) of the HeLa cell 
population. Each data point represents the mean ± SEM of three independent 
experiments. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 as calculated by the unpaired 
two-tailed student t-test.  Statistics represents significance between dMe-containing and 
MePh-containing PTDMs.   
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Figure 4.27.  Percent viable Jurkat T cells using a 7-Amino-actinomycin (7-AAD) viability 
assay. Jurkat T cells (cell density = 4x105 cells/mL) were treated with polymer/FITC-
siRNA complexes with an N/P ratio = 8/1 in complete media for four hours at 37°C and 
compared with untreated cells and cells only receiving FITC-siRNA. Cells were stained 
at four hours.  Each data point represents the mean ± SEM of three independent 
experiments. 
 
Figure 4.28.  Percent viable cells using a 7-Amino-actinomycin (7-AAD) HeLa cell 
viability assay. HeLa cells (cell density = 5x104 cells/mL 48 hours prior to experiment; 
70-90% confluent on the day of the experiment) were treated with polymer/FITC-siRNA 
complexes with an N/P ratio = 8/1 in complete media for four hours at 37°C and 
compared with untreated cells and cells only receiving FITC-siRNA. Cells were stained 
at four hours.  Each data point represents the mean ± SEM of three independent 
experiments. 
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For both cell types, MePh- and dPh-containing PTDMs with the same cationic block 
length were able to deliver to the same percentages of the cell populations; however, in 
all cases, the dMe-containing PTDMs delivered to a significantly smaller percentage of 
the population, particularly at the lower cationic block lengths.  This percentage 
increased from 20% (dMe5-b-dG5) to 80% (dMe5-b-dG20), supporting the idea that 
cationic charge blocks larger than five (up to 20) improve FITC-siRNA internalization 
efficiencies.  In addition, for Jurkat T cells, the MFIs for the MePh- and dPh-containing 
PTDMs were not statistically different but were significantly higher when compared to the 
dMe-containing PTDMs.  Specifically, MePh5-b-dG10 and dPh5-b-dG10 had four times 
the fluorescence intensity of dMe5-b-dG10, and at higher cationic block lengths, MePh5-
b-dG20 and dPh5-b-dG20 had double the fluorescence intensity of dMe5-b-dG20.  This 
observed trend was similar for HeLa cells when comparing the MePh5-b-dGm series to 
the dMe5-b-dGm series, with the MePh-containing PTDMs having roughly double the 
fluorescence intensity regardless of the cationic block length.  Taken together, this data 
suggests that there may be a minimum hydrophobic block length necessary for efficient 
siRNA internalization, but there also seems to be a limit to which increasing the 
hydrophobicity improves siRNA internalization.  
4.5 Expanding the Hydrophobic Monomer Set 
To further understand the hydrophobic window necessary for optimal 
internalization and gain more insight regarding the tunability of the hydrophobic domain, 
several additional monomers were designed.  In order to select the appropriate PTDMs, 
a series of hydrophobic monomers were synthesized and analyzed using HPLC to 
assess their relative hydrophobicities in addition to calculating logP values using 
MarvinSketch (ChemAxon Ltd).68 Monomers with longer retention times required more 
organic component in the mobile phase in order to be eluted and are considered to be 
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more hydrophobic.	   	   The corresponding HPLC chromatograms can also be found in 
Figure	  4.29. 
Table 4.3.  Summary of Monomers and Their Corresponding HPLC Retention Times 
and LogP Values. 
 
aHPLC data collected using a linear gradient from 100% water to 100% CH3CN at a flow 
rate of 1 mL/min. HPLC Detection Wavelength = 215 nm.  bLogP is the octanol/water 
partition coefficient. All values were calculated using MarvinSketch (ChemAxon Ltd.)  
 
The values were obtained by eluting the monomers on a C8 column using a linear 
gradient from 100% water with 0.1% TFA to 100% acetonitrile with 0.1% TFA at a flow 
rate of 1 mL/minute.  Monomers with longer retention times required more organic 
component in the mobile phase in order to be eluted and are considered to be more 
hydrophobic. 
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Figure 4.29.  Overlay of HPLC chromatograms for hydrophobic monomers.  
 
A plot of HPLC retention time (RT) as it relates to logP value can be found in Figure	  
4.30.  The linear relationship between HPLC retention and logP value supports the use 
of HPLC RTs as a viable, experimental method for assessing relative monomer 
hydrophobicity.56-58 Alternatively, it also allows more confidence with calculated logP 
values for this monomer class going forward.  A summary of the monomers synthesized, 
along with their corresponding HPLC RTs and logP values are reported in Table 4.5.1. 
The monomer names reflect the substituents used for the monomer R groups, R1 and 
R2, which can either be the same or different. The wide variety of hydrophobic 
monomers synthesized in Table 4.5.11 also highlights the versatility of the diester 
monomer platform. 69   
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Figure 4.30.  Plot of HPLC RT as it relates to LogP value.  R2=0.975.  All value 
correspond to HPLC retention times found in Table 4.3 of the main text.  
 
The original hydrophobic monomers used for this study were dMe, MePh, and 
dPh, which had HPLC RTs of 14.2 min, 27.8 min, and 36.1 minutes, respectively.  From 
the eleven monomers in Table	  4.3, three new candidates were selected based on their 
overall hydrophobiciies; diEt falls in the hydrophobic window between dMe and MePh, 
diBu has similar hydrophobicity to MePh and dPh, and dCy is the most hydrophobic of 
the eleven monomers.  These new monomers and their corresponding polymers are 
summarized in Figure	  4.31.   
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Figure 4.31.  Additional monomer and polymer structures used for this study based on 
monomer hydrophobicity estimates.  A) Monomer structures B) Polymer Structures. Blue 
represents cationic moieties and green represents hydrophobic moieties.  
 
Given the similar trends observed with cationic block length compared to our previous 
study,32 only one cationic block length, 20 repeat units, was selected for study.  The 
molecular weight data for this series is summarized in Figure	  4.32, Figure	  4.33, Table	  
4.4, and Table	  4.5.  For all FITC-siRNA experiments performed with these polymers the 
N:P ratios used were 8:1 and 4:1 for Jurkat T cells and HeLa cells, respectively.  Gel 
retardation assays supported these selections (Figure	  4.34-Figure	  4.36). A summary of 
the FITC-siRNA internalization data can be found in Figure	   4.37 while the median 
fluorescence intensity values for these PTDMs, plotted as a function of the monomers’ 
HPLC RTs, is shown in Figure	  4.38.  All PTDM-treated cells showed greater than 85% 
viability using 7-AAD staining (Figure	   4.39).  This plot shows the initial three PTDMs 
(dMe5-b-dG20, MePh5-b-dG20, and dPh5-b-dG20, red circles) with the three new PTDMs 
(dEt5-b-dG20, diBu5-b-dG20, and dCy5-b-dG20, blue circles). 
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Table 4.4.  Molecular Weight Characterization of deprotected block copolymer PTDMs. 
Polymer Mna (Da) Mwa (Da) Mpa (Da) 
Đa 
(Mw/Mn) 
28 15,100 16,100 16,600 1.06 
29 16,000 17,100 17,500 1.07 
30 16,200 17,200 17,400 1.06 
[aNumber average molecular weight (Mn), weight average molecular weight (Mw), 
molecular weight at the peak maximum (Mp), and dispersity indices (Đ=Mw/Mn) 
determined by GPC using poly(methyl methacrylate) (PMMA) standards, tetrahydrofuran 
(THF) as the eluent, and toluene as the flow marker.  
 
 
Figure 4.32.  THF GPC chromatograms for boc-protected block copolymer PTDMs 28-
30. A summary of molecular weight data can be found in Table 4.5.2. 
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Table 4.5.  Molecular Weight Characterization of deprotected block copolymer PTDMs. 
Polymer Mna (Da) Mwa (Da) Mpa (Da) Đa (Mw/Mn) 
dEt5-b-dG20 24,800 26,300 25,900 1.06 
diBu5-b-dG20 25,700 27,600 26,100 1.06 
dCy5-b-dG20 27,200 29,500 27,500 1.06 
aNumber average molecular weight (Mn), weight average molecular weight (Mw), 
molecular weight at the peak maximum (Mp), and dispersity indices (Đ=Mw/Mn) 
determined by GPC using poly(methyl methacrylate) (PMMA) standards, 2,2,2-
trifluoroethanol (TFE) with 20 mM NaTFA salt as the eluent, and methanol as the flow 
marker. 
 
 
Figure 4.33.  TFE GPC chromatograms for deprotected block copolymer PTDMs dEt5-b-
dG20, diBu5-b-dG20, and dCy5-b-dG20.  A summary of molecular weight data can be found 
in Table 4.5. 
 
 
Figure 4.34.  Gel retardation assay to assess PTDM / siRNA complex formation using 
dEt5-b-dG20.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
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Figure 4.35.  Gel retardation assay to assess PTDM / siRNA complex formation using 
diBu5-b-dG20.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
 
Figure 4.36.  Gel retardation assay to assess PTDM / siRNA complex formation using 
dCy5-b-dG20.  All samples were run on a 0.8% agarose gel and the N:P ratios tested 
ranged from 0.5:1 to 12:1, with 1 µg of siRNA per well.   
 
 
Figure 4.37.  FITC-siRNA delivery into Jurkat T cells using ROMP-based protein mimics 
containing the same cationic charge content but different hydrophobic blocks.  Jurkat T 
cells (cell density = 4x105 cells/mL) treated with polymer/FITC-siRNA complexes with an 
N/P ratio = 8/1 in complete media for four hours at 37°C and compared cells only 
receiving FITC-siRNA. All data was compared to an untreated control. A) Percent 
positive Jurkat T cells.  B) Median fluorescence intensity (MFI) of the Jurkat T cell 
population. * p = < 0.05, ** = p < 0.01, *** = p < 0.001, ns = not significant, as calculated 
by the unpaired two-tailed student t-test.  * represents significance between block 
copolymer PTDMs with the same charge content.   
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Figure 4.38.  Plot of relative FITC fluorescence as it relates to monomer HPLC retention 
times. Green dashed lines indicate the hydrophobic window for optimal PTDM 
performance.  Red data points represent hydrophobic monomers initially used.  Blue 
data points represent hydrophobic monomers added after monomer hydrophobicity 
assessment by HPLC.  
 
Figure 4.39.  Percent viable Jurkat T cells using a 7-Amino-actinomycin (7-AAD) viability 
assay. Jurkat T cells (cell density = 4x105 cells/mL) were treated with polymer/FITC-
siRNA complexes with an N/P ratio = 8/1 in complete media for four hours at 37°C and 
compared with untreated cells and cells only receiving FITC-siRNA. Cells were stained 
at four hours.  Each data point represents the mean ± SEM of three independent 
experiments. 
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From the initial studies, there appeared to be a hydrophobic threshold (dMe < 
MePh ~ dPh) for efficient internalization shown by the green dashed line near 24 
minutes.  The new dEt-containing PTDM appears to support this hypothesis given that it 
delivers similar amounts of FITC-siRNA compared to the dMe-containing PTDM despite 
being more hydrophobic.  Increasing the monomer hydrophobicity with diBu-containing 
PTDMs beyond the “threshold value” yields internalization values similar to MePh- and 
dPh-containing PTDMs; however, a further increase in the monomer hydrophobicity to 
dCy yields a PTDM that generates lower FITC-siRNA internalization than the three 
PTDMs composed of monomer HPLC RTs of 27.8 minutes to 36.1 minutes.  This would 
suggest a window of optimal hydrophobicity when using these PTDMs for siRNA 
internalization.  Furthermore, polymers that fall within this critical hydrophobic window 
are comprised of both aromatic and non-aromatic-containing PTDMs, suggesting that 
overall hydrophobicity may be more important than monomer composition.   
4.6 Conclusions 
Understanding the structural components of carrier molecules necessary for 
efficient siRNA internalization is critical for the development of more efficient delivery 
reagents.  In efforts to better determine appropriate design principles for our ROMP-
based PTDMs, several new PTDMs were designed to understand how the length and 
relative hydrophobicity of the non-charged block had on FITC-siRNA internalization 
efficiencies in Jurkat T cells, a suspension cell type, and HeLa cells, an adherent cell 
type.  Initially a set of symmetric (n = m) and asymmetric (n ≠ m, with n being fixed at 
five for all polymers in the series) BCP PTDMs were tested with m = 5, 10, 20, or 40.  At 
fixed cationic block lengths, the percentage of the cell population receiving FITC-siRNA 
remained the same regardless of the hydrophobic block length; however, the 
asymmetric MePh5-b-dG20 had twice the fluorescence intensity of MePh20-b-dG20, 
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demonstrating the complex relationship between hydrophobic and cationic block lengths.  
In a separate series of polymers, the hydrophobic block length was held constant at five 
repeat units, but the hydrophobic component was varied from dMe-, to MePh-, to dPh-
based repeat units, which represent a range of hydrophobicities.  In this series, the dMe-
based PTDMs exhibited diminished internalization efficiencies in comparison to their 
more hydrophobic counterparts (MePh- and dPh-based PTDMs).  This suggested there 
was a minimum hydrophobicy required for efficient internalization.  HPLC retention times 
were used to assess the relative hydrophobicity of monomers and to select a few for the 
design of additional PTDMs prepared, (dEt-b-dG20, diBu-b-dG20, and dCy-b-dG20) to 
more fully explore this optimal hydrophobic window.  An approximately 10 minute 
retention time window between 27 and 37 (or logP values of 1.78 and 3.50) was shown 
to yield optimal PTDM siRNA internalization efficiencies.  Below this threshold, PTDMs 
lack sufficient hydrophobicity to promote efficient internalization and the PTDM above 
this hydrophobicity also showed diminished internalization capabilities.  The polymers 
that fall within the critical hydrophobic window are comprised of both aromatic and non-
aromatic-containing PTDMs, suggesting that overall hydrophobicity may be more 
important than monomer composition.  Overall, optimization of PTDM hydrophobicity led 
to a better understanding of the structural components necessary for efficient siRNA 
internalization, which will be used in the future to guide the development of superior 
delivery reagents. 
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5 CHAPTER 5 
PERSPECTIVE AND FUTURE DIRECTIONS 
5.1 Perspective 
Looking forward, intracellular delivery of siRNA, pDNA, proteins, and other 
biologics will be at the forefront of the development of more sophisticated therapeutic 
treatment options.  In turn, this will require equally sophisticated and well understand 
delivery systems to be designed to meet the challenges associated with the cellular 
internalization of these complex molecules.1 It is further anticipated that CPPMs and 
PTDMs will play critical roles in this area.  Early structure-activity relationship studies on 
proteins led to the elucidation of essential design features for CPPs and enabled protein 
mimics to be developed.  These essential features include cationic charge content, often 
in the form of guanidinium moieties, and hydrophobic content, often completely 
segregated from the cationic component.1-3 The extension of these design principles to 
polymers represents another critical step in our fundamental understanding and is 
expected to produce some of the most useful CPPMs and PTDMs.   
One of the major strengths of polymeric CPPMs and PTDMs is the tunability of 
their scaffolds.1 Researchers over the last decade have demonstrated that a wide range 
of polymer backbones such as poly(oxa)norbornene,3-14, polymethacrylamide15, 
poly(disulfide-amine)16-21, oligocarbonate22,23, and polydisulfide24,25can be used to display 
key features of CPPs while the development of new backbone chemistries is ongoing.  
Additionally, polymeric mimics offer the ability to tune molecular compositions and 
molecular weights more easily and with more structural options than offered by peptide-
base scaffolds.1 This allows elegant, well-controlled structure-property relationship 
studies to be performed in order to understand the influence polymer structures and 
compositions have on bioactive cargo internalization and delivery.  Unfortunately, the 
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role structure plays in efficient bioactive cargo internalization and delivery is often 
underappreciated.  Many researchers put their primary focus on establishing the 
therapeutic potential of a material as opposed to understanding how or why a material 
works and if a better design exists.  Moving forward, however, a more complete 
understanding of the structural components necessary for efficient internalization and 
delivery is critical for the development of the next generation of delivery reagents.   
5.2 Future Directions 
This thesis primarily documented structure-activity relationships with ROMP-
based protein mimics to elucidate the essential design principles that govern efficient 
membrane interactions as well as siRNA internalization and delivery.14,26 The findings 
presented here defined the critical cationic charge content and the ideal hydrophobic 
window for efficient siRNA delivery.14 These parameters are expected to serve as 
guidelines for the future development of PTDMs for siRNA delivery applications.  It is 
also anticipated that future structure-activity relationship studies will be extended to 
include the imide-based ROMP scaffold, which our group has extensively explored using 
biophysical assays as well as to use both ROMP scaffolds to explore how complex size 
trends with PTDM structures using dynamic light scattering (DLS) and cryogenic 
transmission electron microscopy (cryo-TEM).  Further structure-activity relationship 
studies can be performed to understand how the nature of the cation impacts delivery 
efficiency by varying it from guanidinium moieties to ammonium or phosphonium 
moieties. 
More broadly, given the highly cationic nature of the PTDMs developed for this 
thesis work, the siRNA PTDM library can be adapted for the delivery of plasmid DNA 
(pDNA).  Plasmid DNA delivery is advantageous because it is self-sustaining and allows 
for the prolonged expression of proteins within cells.  In addition, there is an extensive 
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library of commercially available plasmids, allowing for a range of potential therapeutic 
applications.  Given that siRNA and pDNA both consist of negatively charged 
nucleobases, they both would interact with cationic PTDMs through electrostatic 
interactions, allowing the siRNA PTDMs to be used as a starting point for pDNA 
delivery.27  Further optimization would likely be necessary to account for the much larger 
size of pDNA compared to siRNA, which would require more charges to be screened 
and for the cargo to be condensed considerably prior to delivery.28-32  Being able to 
deliver pDNA would not only show the versatility of our molecules but would also open 
up new areas of biology to explore.33-35  
Looking forward, as delivery capabilities continue to improve, the possibilities 
open up for more sophisticated treatment options.  One such option is the co-delivery of 
multiple cargoes.  Currently, many researchers have started exploring the co-delivery of 
siRNAs and chemotherapeutics, such as Paclitaxel or Doxorubicin.36-39  The siRNA in 
these treatments is used to knockdown genes that are providing cells with 
chemotherapeutic resistance.36-39  Transient knockdown of these pathways restores the 
chemotherapeutic agent’s potency and reduces the need for the development of new 
cancer drugs.36-39  Given that our ROMP-based protein mimics have demonstrated 
successful siRNA delivery, adaptation of this platform to the co-delivery of siRNA and 
small molecules is likely feasible.   
Another area where co-delivery could be advantageous is in relation to the 
CRISPR (clustered regularly interspaced short palindromic repeats)/Cas-9 system, 
which is an RNA-guided endonuclease technology currently being used for genome 
editing and repair. CRISPRs are sequences of prokaryotic DNA that consist of short 
base-pair sequences that are regularly repeated.  Cas9, in particular, is a CRISPR 
associated (Cas) endonuclease.40-42  For this system to function, a guide RNA (gRNA) 
needs to be co-expressed since it is this component that enables targeting of the specific 
	  
	   150 
DNA sequenced to be modified.40-42  Previous literature has demonstrated the co-
delivery of the gRNA and Cas9 proteins by lipid-mediated delivery and through covalent 
attachment of the components to CPPs.43,44  In both cases, they found it advantageous 
to deliver both the protein and guide RNA (gRNA) at the same time.43,44  They mention 
that using pDNA for this application has severe drawbacks, including that they may 
insert themselves into the genome permanently and disrupt endogenous genes or may 
leave the cell susceptible to long term exposure of the CRISPR/Cas9 components and 
potentially leading to unwanted side effects.43,44  They also note that using mRNA 
presents the problems of stability of the mRNA during delivery and potential 
immunogenicity effects from inserted foreign nucleic acids into the cell.43,44   
Given our groups history of designing PTDMs for siRNA and protein delivery, our 
platforms can likely be extended to the delivery of the components for the CRISPR/Cas-
9 system.  Proof-of-concept experiments charting the co-delivery of model RNAs and 
proteins, such as AlexaFluor-labeled siRNA and enhanced green fluorescent protein 
(EGFP) can be used to screen potential PTDMs for these applications.  This platform 
can then be evaluated using bioactive siRNA and proteins to demonstrate that the co-
delivery process did not alter molecular function.  Following this pre-screening, the 
platform can easily be extended to the CRISPR/Cas-9 system.  Given the versatility of 
the PTDM platform, it can be envisaged that either one PTDM or a mixture of PTDMs 
could be used for the delivery of both components.  In addition, the proven success of 
this system in hard-to-transfect cell types opens the possibilities of extending this 
platform to stem cells.  Since stem cells can be differentiated into many cell types, 
correcting the genome at this stage would permanently correct the mutation and produce 
a wide range of cells expressing the correct sequences.  
Overall, CPPMs and PTDMs appear to have an important role to play in the area 
of bioactive cargo delivery, having already demonstrated their ability to perform in the 
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arena of new immunological research and fundamental cell biology.  Therapeutic 
delivery for the treatment of human disease, though a more difficult and complex issue, 
remains the ultimate goal.  While the challenge is daunting, CPPMs and PTDMs are a 
promising technology undergoing continual refinement and offering many potential 
advantages.  This thesis work provides considerably more insight into how PTDM 
structure and composition impact their overall delivery capabilities and will no doubt help 
guide the future development of efficient PTDM for intracellular delivery.  
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6 CHAPTER 6 
EXPERIMENTAL 
6.1 Materials and Instrumentation 
Materials  
Maleic anhydride, maleimide, furan, 4-dimethylaminopyridine (DMAP), 1-(3-
Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), 1,3-di-boc-2-(2-
hydroxyethyl)guanidine, benzyl alcohol, 3,5-dinitrobenzyl alcohol, 3-nitrobenzyl alcohol, 
3,5-bis(trifluoromethyl)benzyl alcohol, 3-trifluoromethylbenzyl alcohol, 3,5-difluorobenzyl 
alcohol, 3,5-dimethylbenzyl alcohol, 3,5-dimethoxybenzyl alcohol, N-boc-ethanolamine, 
diisopropyl azodicarboxylate (DIAD), triphenylphosphine, ethyl vinyl ether, trifluoroacetic 
acid (TFA), methanol (MeOH), 1-propanol, 1-butanol, isobutanol, cyclohexylmethanol, 
ethyl acetate (EtOAc) dimethyl sulfoxide (DMSO), pentane, 2,2,2-trifluoroethanol (TFE), 
water, and tetrahydrofuran (THF) were obtained as reagent grade from Aldrich, Fisher 
Scientific, Fluka or Acros and used as received. 3rd generation Grubbs catalyst 
(Dichloro-di(3-bromopyridino)-N,N’- Dimesitylenoimidazolino-Ru=CHPh; G3) was 
synthesized as described previously by Grubbs and coworkers.1 Dichloromethane 
(CH2Cl2) (HPLC grade, Fisher Scientific) was distilled from CaH2 under nitrogen. 
Spectra/Por® 6 dialysis membranes with a MWCO of 2,000 g/mol and Biotech CD 
dialysis tubing with a MWCO of 100-500 g/mol were purchased from Spectrum Medical 
Industries. Egg yolk phosphatidylcholine (EYPC) brain phosphatidylserine (brain PS) 
lipids were purchased from Avanti Polar Lipids Inc. and 5(6)-carboxyfluorescein (CF) 
was purchased from Fluka.  Sterile, RNase-free phosphate buffered saline (Amresco) 
and heparin, from porcine intestinal mucosa, were purchased from VWR and bovine 
serum albumin (BSA) and DMEM/high with L-glutamine and sodium pyruvate were 
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purchased from Sigma Aldrich and used as received. FITC-siRNA (sc-36869), siRNA to 
hNOTCH1 (sc-36095), and RNase-free water were purchased from Santa Cruz 
Biotechnologies and R9, DeliverX Plus siRNA, Xfect, N-ter, RNAiMAX, and JetPEI were 
purchased from Peptide 2.0, Inc., Affymetrix, Clontech, Sigma Aldrich, Life 
Technologies, and Polyplus Transfection, respectively. Gibco RPMI 1640 glutaMAX and 
fetal bovine serum were purchased from Life Technologies and Penicillin/Streptomycin 
(10K/10K), MEM non-essential amino acids solution (10 mM, 100X), and sodium 
pyruvate solution (100 mM) were purchased from Lonza.  Anti-human CD3 epsilon MAb 
(Clone UCHT1) and human CD28 MAb (Clone 37407) were purchased from R&D 
Systems, anti-human NOTCH1 PE, Annexin V PE apoptosis detection kit, 7-AAD 
viability stain, and Foxp3/transcription faction staining buffer set were purchased from 
eBiosciences. hPBMCs were purchased from from Stemcell Technologies, Inc. in 
2.5x106 cells/aliquot (Product # 70047.2).  For experiments, cells from different donors 
were used.  The company obtained these cells using institutional review board approved 
consent forms and protocols. 
Instrumentation  
1H and 13C NMR spectra were recorded at 300 MHz and 75 MHz, respectively, using a 
Bruker DPX-300 NMR spectrometer. Chemical shifts (δ) are reported in ppm and 
coupling constants (J) in Hz. The abbreviations used for splitting patterns are: s, singlet; 
d, doublet; dd, doublet of doublets; t, triplet; tt, triplet of triplets; q, quartet; m, multiplet; 
comp, overlapping multiplets of magnetically non-equivalent protons; br, broad. Mass 
spectral data were obtained at the University of Massachusetts, Mass Spectrometry 
Facility from a JEOL JMS 700 instrument (JEOL, Peabody, MA). A CombiFlash® RF 
200 automated chromatography system with a variable UV-Vis detector (λ= 200-780 nm, 
Teledyne ISCO, Lincoln, NE) was used for purification of monomer 13. 120 g RediSep 
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Rf Flash Columns were used for the separations. All other compounds were purified 
using standard silica gel chromatography methods. 
 
A CombiFlash® RF 200 automated chromatography system with a variable UV-Vis 
detector (λ= 200-780 nm, Teledyne ISCO, Lincoln, NE) was used for purification of 
monomer 13. 120 g RediSep Rf Flash Columns were used for the separations.  All other 
compounds were purified using standard silica gel chromatography methods. 
 
Gel permeation chromatography (GPC) chromatograms for boc-protected polymers 
were obtained using an Agilent 1260 series system equipped with a refractive index (RI) 
and ultraviolet (UV) detectors, a PL Gel 5 µm guard column con two 5 µm analytical 
Mixed-C columns and a 5 µm analytical Mixed-D column (Agilent). All columns were 
connected in series and incubated at 40 °C. THF was used as the eluent with a flow rate 
of 1.0 mL/min. ~ 3 mg/mL samples were prepared using THF as the diluent and toluene 
as the flow marker. All samples were filtered through 0.45 µm PTFE syringe filters 
(Restek, Bellefonte, PA) Polymethyl methacrylate and polystyrene standards were used 
for the calibration. Dye release assays were performed using a Biotek SynergyMx 
fluorescence plate reader that was incubated to 25 °C. 
 
GPC chromatograms for deprotected polymers were obtained using an Agilent 1260 
series system equipped with a refractive index (RI) and ultraviolet (UV) detectors, an 
HFIPgel guard column (7 mm x 50 mm; Agilent) and three HFIPgel columns (7 mm x 
300 mm; Agilent).  All columns were connected in series and incubated at 40 °C.  TFE 
with 20 mM NaTFA salt was used as the eluent with a flow rate of 1.0 mL/min.  ~ 3 
mg/mL samples were prepared using TFE with 20 mM NaTFA salt as the diluent and 
methanol as the flow marker.  All samples were filtered through a 0.45 µm PTFE syringe 
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filters (Restek, Bellefonte, PA).  Poly(methyl methacrylate) standards were used for the 
calibration. 
 
Flow cytometry (FCM) experiments were performed using a Becton Dickinson LSRII (BD 
Biosciences) with eight color analysis capabilities and two excitation lasers: 488 nm and 
633 nm or a BD Dual LSRFortessa with eighteen color analysis capabilities and five 
excitation lasers: 355nm (UV), 405 nm, 488 nm 561 nm, and 640 nm.  Fluorescence 
signals were collected for 10,000 cells.  
 
HPLC was carried out a HP 5890 HPLC system equipped with a photodiode array 
detector using an Agilent Zorbax SB-C8, 80 Å, 4.6 x 150 mm ID (5 µm) column.  
Samples were eluted using a linear gradient of 100% water with 0.1% TFA to 100% 
acetonitrile with 0.1% TFA over 60 minutes at a flow rate of 1 mL/min, and were 
detected using a wavelength of 215 nm. 
6.2 Synthesis of π-rich and π-poor Half-esters 
 
Figure 6.1 Half-ester final products 2a-h.  
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Synthesis of 2a: The procedure reported by Lienkamp et al. was followed with minor 
modifications.2 One equivalent of 1, 1.25 equivalents of the corresponding substituted 
benzyl alcohol, and 10 mol% DMAP were dissolved in a minimal amount of freshly 
distilled CH2Cl2 and the reaction mixture was stirred under nitrogen at RT overnight.  The 
reaction mixture for 2a was concentrated via rotary evaporation and the half ester was 
recrystallized from a mixture of chloroform/hexanes (3:1, v/v) and isolated via vacuum 
filtration.  2a was then dried under vacuum at RT overnight.  
Yield: 52 %, white crystals 
1H NMR (300 MHz, DMSO-d6): δ 12.44 (br, 1H), 6.54 (s, 2H), 6.45 (comp, 3H), 5.12 (s, 
2H), 4.94 (q, 2H), 3.73 (s, 6H), 2.79 (m, 2H); 
13C NMR (75 MHz, DMSO-d6): δ 172.82, 171.60, 160.60, 138.42, 136.85, 136.67, 
105.69, 99.76, 80.27, 79.93, 65.90, 55.29, 46.92, 46.21;  
HR-MS (FAB) m/z [M+H]+: 334.1053 (calc.), 334.1047 (found) 
 
Synthesis of 2b-f: The procedure reported by Lienkamp et al. was followed with minor 
modifications.2  One equivalent of 1, 1.25 equivalents of the corresponding substituted 
benzyl alcohols, and 10 mol% DMAP were dissolved in a minimal amount of freshly 
distilled CH2Cl2 and the reaction mixture was stirred under nitrogen at RT overnight. 2b-f 
precipitated from solution and were isolated via vacuum filtration and washed with cold 
CH2Cl2. 2b-f were then dried under vacuum at RT overnight.  
 
2b. 43 %, white powder 
1H NMR (300 MHz, DMSO-d6): δ 12.41 (br, 1H), 6.95 (s, 3H), 6.45 (m, 2H), 5.10 (s, 2H), 
4.92 (q, 2H), 2.76 (s, 2H), 2.26, (s, 6H) 
13C NMR (75 MHz, DMSO-d6): δ 172.72, 171.56, 137.48, 136.76, 136.60, 135.83, 
129.39, 125.85, 80.17, 79.83, 66.03, 46.78, 46.03, 20.92;  
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HR-MS (FAB) m/z [M+H]+: 303.1262 (calc.), 303.1253 (found) 
 
2c. Yield: 60 %, white powder  
1H NMR (300 MHz, DMSO-d6): δ 12.46 (br, 1H), 7.36 (comp, 5H), 6.45 (m, 2H), 5.12 (m, 
2H), 5.01 (q, 2H), 2.77 (d, 2H);  
13C NMR (75 MHz, DMSO-d6): δ 172.74, 171.59, 136.79, 136.61, 136.07, 128.45, 
128.05, 128.02, 80.18, 79.84, 65.99, 46.82, 46.10; 
HR-MS (FAB) m/z [M+H]+: 275.0914 (calc.), 275.0903 (found) 
 
2d. Yield: 58 %, white powder 
1H NMR (300 MHz, DMSO-d6): δ 12.46 (br, 1H), 7.76 (br, 1H), 7.70 (comp, 2H), 7.62 (m, 
1H), 6.47 (m, 2H), 5.13 (comp, 4H), 2.82 (q, 2H);  
13C NMR (75 MHz, DMSO-d6): δ 172.87, 171.68, 137.66, 136.67, 136.63, 131.98, 
129.58, 129.18, 126.10, 124.71, 124.48, 122.49, 80.29, 79.94, 65.22, 47.01, 46.15;  
HR-MS (FAB) m/z [M+H]+: 343.0793 (calc.), 343.0804 (found) 
 
2e. Yield: 47 %, white powder  
1H NMR (300 MHz, DMSO-d6): δ 12.44 (br, 1H), 8.25 (m, 1H), 8.19 (m, 1H), 7.84 (m, 
1H), 7.68 (m, 1H), 6.47 (m, 2H), 5.17 (comp, 4H), 2.82 (q, 2H); 
13C NMR (75 MHz, DMSO-d6): δ 172.75, 171.60, 147.83, 138.41, 136.66, 136.58, 
134.43, 130.01, 122.86, 122.48, 80.22, 79.91, 64.75, 46.97, 46.07;  
HR-MS (FAB) m/z [M+H]+: 320.0770 (calc.), 320.1766 (found) 
 
2f. Yield: 41 %, white powder 
1H NMR (300 MHz, DMSO-d6): δ 12.47 (br, 1H), 7.15 (comp, 3H), 6.47 (m, 2H), 5.14, (d, 
2H), q (5.04, 2H), 2.82 (d, 2H); 
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13C NMR (75 MHz, DMSO-d6): δ 172.88, 171.57, 164.20, 164.03, 160.94, 160.77, 
140.75 (t, 9.6 Hz), 136.88, 136.66, 110.63 (m), 103.24 (t, 25.7 Hz), 80.30, 79.93, 64.59, 
47.03, 46.17;  
HR-MS (FAB) m/z [M+H]+: 320.0770 (calc.), 320.1766 (found) 
 
Synthesis of 2g-h: The procedure reported by Lienkamp et.al. was followed with minor 
modifications.2 One equivalent of 1, 1.25 equivalents of the corresponding substituted 
benzyl alcohols, and 10 mol% DMAP were dissolved in a minimal amount of freshly 
distilled CH2Cl2 and the reaction mixture was stirred under nitrogen at RT overnight. 
Product purification was attempted using column chromatography with EtOAc / CH2Cl2 
(1:4, v/v).  Although all starting material was removed, 2g-h were unstable in solution 
and byproducts from the retro Diels-Alder reaction were observed in the corresponding 
1H NMR spectra. The 1H NMR peaks for the corresponding unstable product are listed 
below and impurities are omitted. The impurity was isolated for 2h by column 
chromatography using CH2Cl2 / MeOH (9:1, v/v) and identified by 1H NMR, 13C NMR, 
and HR-MS (FAB).  
 
2g. 1H NMR (300 MHz, DMSO-d6): δ 12.55 (br, 1H), 8.08 (comp, 3H), 6.47 (m, 2H), 5.18 
(comp, 4H), 2.84 (q, 2H); 
 
2h. 1H NMR (300 MHz, DMSO-d6): δ 12.39 (br, 1H), 8.79 (m, 1H), 8.67 (m, 2H), 6.48 (m, 
2H), 5.31 (br, 2H), (d, 2H), 2.85 (q, 2H); 
Impurity peaks: δ 8.70, 8.58, 6.58, 5.45, 5.36, 5.34, 5.26, 4.75, 3.30;  
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Figure 6.2. Structure of the Retro-Diels-Alder impurity 4g.  
 
Half-ester Impurity 4g:  
1H NMR (300 MHz, DMSO-d6): δ 13.06 (br, 1H), 8.11 (comp, 3H), 6.47 (d, 2H), 5.37, (s, 
2H); 
13C NMR (75 MHz, DMSO-d6): δ 166.52, 165.16, 139.35, 132.04, 130.43 (q, 33.23 Hz), 
128.74, 128.47, 125.13, 121.79, 121.52, 64.56;  
HR-MS (FAB) m/z [M+H]+: 343.0237 (calc.), 343.0417 (found). 
6.3 Synthesis of π-rich and π-poor Diester Monomers: 
 
 
Figure 6.3.  Diester monomer final products 3a-f.  
 
6.3.1 Synthesis of 3a-f:  
The procedure reported by Lienkamp et.al. was followed with minor modifications.2  One 
equivalent of 2a-f, one equivalent of 1,3-Di-Boc-2-(2-hydroxyethyl)guanidine, and 10 
mol% DMAP were dissolved in CH2Cl2 and stirred at RT under nitrogen.  The solution 
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was then cooled down to 0°C in an ice bath and one equivalent of EDC was added. The 
solution was allowed to stir overnight under nitrogen and gradually return to RT.  The 
reaction mixture was then concentrated via rotary evaporation and purified by either 
column chromatography with EtOAc/CH2Cl2 (1/4, v/v) as the eluent or by using a 
CombiFlash purification system, with a 120 g silica cartridge and EtOAc/CH2Cl2 (1/4, v/v) 
as the eluent.  Pure fractions were combined and then concentrated via rotary 
evaporation. The sample was dried under vacuum overnight at RT to obtain a white 
solid. 
 
3a: Yield 77 %, white powder 
1H NMR (300 MHz, DMSO-d6): δ 11.48 (s, 1H), 8.41 (t, 1H), 6.50 (m, 2H), 6.45 (comp, 
3H), 5.16 (d, 2H), 4.97 (q, 2H), 4.10 (m, 1H), 3.95 (m, 1H), 3.73 (s, 6H), 2.87 (q, 2H), 
1.46 (s, 9H), 1.37 (s, 9H);  
13C NMR (75 MHz, CD3CN): δ 172.92, 172.67, 164.93, 162.32, 157.75, 154.12, 139.81, 
138.01, 137.96, 107.15, 100.85, 84.47, 81.81, 81.75, 79.94, 67.54, 64.03, 56.40, 48.18, 
47.91, 40.62, 28.81, 28.52; 
HR-MS (FAB) m/z [M+H]+: 620.2819 (calc.), 620.2819 (found) 
 
3b: Yield 74 %, white powder 
1H NMR (300 MHz, DMSO-d6): δ 11.49 (br, 1H), 8.41 (t, 1H), 6.94 (br, 3H), 6.46 (m, 2H), 
5.14 (d, 2H), 4.95 (q, 2H), 4.11 (m, 1H), 3.92 (m, 1H), 3.50 (m, 2H), 2.84 (q, 2H), 2.25 (s, 
6H), 1.46 (s, 9H), 1.37 (s, 9H);   
13C NMR (75 MHz, CD3CN): 172.90, 172.71, 164.95, 157.75 154.14, 139.47, 138.02, 
137.97, 137.33, 130.98, 127.54, 84.50, 81.81, 81.78, 79.95, 67.92, 63.99, 48.16, 47.84, 
40.67, 28.85, 28.55, 21.72; 
HR-MS (FAB) m/z [M+H]+: 588.2921 (calc.), 588.2908 (found) 
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3c: Yield 80 %, white powder 
1H NMR (300 MHz, DMSO-d6): δ 12.46 (br, 1H), 7.34 (m, 5H), 6.46 (m, 2H), 5.11 (d, 
2H), 5.01 (q, 2H), 2.77 (d, 2H);   
13C NMR (75 MHz, CD3CN): δ 172.48, 172.29, 164.51, 157.33, 153.70, 137.57, 137.50, 
137.06, 129.41, 129.21, 129.09, 84.04, 81.34, 81.32, 79.51, 67.37, 63.56, 47.68, 47.40, 
40.20, 28.35, 28.06; 
HR-MS (FAB) m/z [M+H]+: 560.2608 (calc.), 560.2616 (found) 
 
3d: Yield: 58 %, white powder 
1H NMR (300 MHz, DMSO-d6): δ 11.49 (s, 1H), 8.42, (t, 1H), 7.67 (comp, 4H), 6.47 (t, 
2H), 5.16 (comp, 4H), 4.10 (m, 1H), 3.94 (m, 1H), 3.49 (m, 2H), 2.88 (q, 2H), 1.45 (s, 
9H), 1.35 (s, 9H) 
13C NMR (75 MHz, CD3CN):  δ 172.87, 172.73, 164.95, 163.70, 157.78, 154.16, 138.88, 
138.02, 133.27, 130.78, 126.14 (m), 84.50, 81.84, 79.97, 66.91, 64.05, 48.09, 47.98, 
40.65, 28.86, 28.56,  
HR-MS (FAB) m/z [M+H]+: 628.2482 (calc.), 628.2459 (found) 
 
3e: Yield: 60 %, white powder  
1H NMR (300 MHz, DMSO-d6): δ 11.47 (s, 1H), 8.41 (t, 1H), 8.21 (m, 1H), 7.83 (m, 1H), 
7.69 (t, 1H), 6.47 (m, 2H), 5.18 (m, 4H), 4.11 (m, 1H), 3.96 (m, 1H), 3.49 (comp, 2H), 
2.90 (q, 2H), 1.45 (s, 9H), 1.36 (s, 9H);  
13C NMR (75 MHz, CD3CN): δ 172.87, 172.71, 164.91, 157.74, 154.12, 139.66, 137.99, 
135.62, 131.16, 124.24, 124.02, 84.49, 81.84, 81.79, 79.96, 66.45, 64.07, 48.01, 47.97, 
40.64, 28.78, 28.49  
HR-MS (FAB) m/z [M+H]+: 605.2441 (calc.), 605.2423 (found) 
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3f: Yield: 70 %, white powder 
1H NMR (300 MHz, DMSO-d6): δ 11.47 (s, 1H), 8.41 (t, 1H), 7.18 (m, 1H), 7.09 (comp, 
2H), 6.48 (m, 2H), 5.18 (s, 2H), 5.07 (q, 2H), 4.11 (m, 1H), 3.98 (m, 1H), 3.49 (m, 2H), 
2.90 (q, 2H), 1.45 (s, 9H), 1.37 (s, 9H); 
13C NMR (75 MHz, CD3CN): δ 171.54, 171.26, 164.61, 164.44, 163.57, 161.34, 161.17, 
156.41, 152.79, 140.63 (t, J = 9.55 Hz), 136.66, 110.49 (m), 103.10 (t, J = 25.5 Hz), 
83.14, 80.47, 78.61, 64.83, 62.75, 46.73, 46.68, 39.33, 27.49, 27.19; 
HR-MS (FAB) m/z [M+H]+: 596.2420 (calc.), 596.2409 (found) 
 
 
Figure 6.4.  Synthesis of diguanidine monomer. i)1,3-di-boc-2-(2-
hydroxyethyl)guanidine, DMAP, EDC, CH2Cl2,, 0°C to RT, overnight; 
 
The procedure reported by Lienkamp et.al. was followed with minor modifications.2 One 
equivalent of 1, two equivalents of 1,3-Di-Boc-2-(2-hydroxyethyl)guanidine, and 10 mol% 
DMAP were dissolved in CH2Cl2 and the reaction mixture was stirred overnight at RT 
under nitrogen.  After one day, the solution was cooled down to 0°C in ice bath and one 
equivalent of EDC was added. The solution was allowed to stir overnight under nitrogen 
and gradually return to RT.  The reaction mixture was then concentrated via rotary 
evaporation and purified using a CombiFlash purification system, with a 120 g silica 
cartridge and EtOAc/CH2Cl2 (1/4, v/v) as the eluent.  Pure fractions were combined and 
then concentrated via rotary evaporation. The sample was dried under vacuum overnight 
at RT to obtain a white solid. 
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Yield = 60 %, white solid 
1H NMR (300 MHz, DMSO-d6): δ 11.49 (s, 2H), 8.24 (s, 2H), 6.47 (s, 2H), 5.16 (s, 2H), 
4.14 (comp, 2H), 4.04 (comp, 2H), 3.53 (m, 4H), 2.82 (s, 2H), 1.47 (s, 18H), 1.39 (s, 
18H);  
13C NMR (75 MHz, CD3CN): δ 172.43, 164.51, 157.35, 153.72, 137.56, 84.05, 81.41, 
79.50, 63.72, 47.49, 40.21, 28.38, 28.09; 
HR-MS (FAB) m/z [M+H]+: 755.3827 (calc.), 755.3814 (found). 
6.4 Synthesis of π-rich and π-poor Imide Monomers 
 
Figure 6.5.  Imide monomer final products 7a-c. 
 
Synthesis of 7a-c: The procedure reported by Som et.al. was followed with minor 
modifications.5 1 equivalent of oxanorbornene imide (6), 1.25 equivalents of the 
corresponding alcohol, and one equivalent of triphenyl phosphine were dissolved in 40 
mL of freshly distilled THF under nitrogen and subsequently cooled to 0C using an ice 
bath.  Upon cooling, 1 equivalent of DIAD was added drop-wise to the solution.  The 
reaction was allowed to stir overnight and gradually return to RT.  The reaction was then 
concentrated using rotary evaporation and the product was recrystallized using diethyl 
ether and further purified by column chromatography using gradient elution with EtOAc 
and CH2Cl2 to yield pure 7a-c.  
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7a: Yield: 92 %, white powder 
1H NMR (300 MHz, CDCl3): δ 6.52 (t, 2H), 6.44 (d, 2H), 6.34 (t, 1H), 5.31 (s, 2H), 4.60 
(s, 2H), 3.75 (s, 6H) 2.88 (s, 2H);  
13C NMR (75 MHz, CDCl3): δ 175.99, 161.02, 137.60, 136.42, 105.33, 100.02, 55.04, 
47.67, 81.23, 42.46; 
HR-MS (FAB) m/z [M+H]+: 315.1107 (calc.), 315.1139 (found). 
 
7b: Yield: 90 %, white powder 
1H NMR (300 MHz, CDCl3): δ 7.30 (comp, 5H), 6.52 (s, 2H), 5.35 (s, 2H), 4.73 (s, 2H), 
2.91 (s, 2H); 
13C NMR (75 MHz, CDCl3): δ 176.03, 136.65, 135.54, 128.85, 127.90, 127.09, 80.83, 
42.57, 42.36; 
HR-MS (FAB) m/z [M+H]+: 451.2193 (calc.), 451.2183 (found). 
 
7c: Yield: 95 %, white powder (protect from light) 
1H NMR (300 MHz, CDCl3): δ 8.97 (br, 1H), 8.49 (br, 2H), 6.56 (s, 2H), 5.33 (s, 2H), 4.84 
(s, 2H), 2.97 (s, 2H);  
13C NMR (75 MHz, CDCl3): δ 175.69, 148.79, 139.64, 136.68, 128.31, 118.50, 81.27 
47.74, 41.22;  
HR-MS (FAB) m/z [M+H]+: 256.0974 (calc.), 256.0961 (found). 
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Figure 6.6.  Synthesis of guanidine-containing monomer. i) N-Boc-ethanolamine, PPh3, 
DIAD, THF, RT, 18 hr; ii) TFA/CH2Cl2 (1:1), RT, 3 hr; iii) Guanidinium triflate, NEt3, 
CH2Cl2, RT, 18 hr; 
 
Synthesis of 6: 1 equivalent of maleimide and 1.4 equivalents of furan were dissolved 
in 100 mL of EtOAc.  The reaction was stirred for 3 h at 90 °C.  After 3 h, the reaction 
was cooled to RT to allow the product to precipitate.   The exo Diels-Alder product, 6, 
was isolated by vacuum filration and was allowed to dry under vacuum at RT overnight.  
The spectroscopic data matched previous reports.6 
 
6: Yield = 55 %, white powder 
 1H NMR (300 MHz, DMSO-d6): δ 11.17 (br, 1H), 6.53 (s, 2H), 5.11 (s, 2H), 2.85 (s, 2H);  
 
Synthesis of 18:  The procedure reported by Schmidt et.al. was followed with minor 
modifications.7 1 equivalent of oxanorbornene imide, 1.15 equivalent of  N-boc-
ethanolamine, and 1 equivalent of triphenylphosphine were added to 100 mL of freshly 
distilled THF under nitrogen and cooled to 0 °C using an ice bath.  1 equivalent of DIAD 
was then added drop-wise to solution and the reaction was subsequently allowed to 
warm to room temperature and stir overnight.  After overnight stirring, the reaction was 
concentrated using rotary evaporation and precipitated twice into diethyl ether to yield 
16.  The product was isolated by vacuum filtration and allowed to dry.  The intermediate 
yield was 56 %.  16 was deprotected in 2 mL of trifluoroacetic acid (TFA) and 
precipitated into diethyl ether to yield 17.  17 was then directly dissolved in 100 mL of 
CH2Cl2 along with triethylamine and 1 equivalent of 1,3-di-boc-2-
(trifluoromethylsulfonyl)guanidine and allowed to stir at RT for 12 hr.  After 12 hr, the 
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solution was concentrated using rotary evaporation and washed with 10% potassium 
hydrogen sulfate (3x25mL), saturated sodium bicarbonate (3x25mL), and subsequently 
precipitated into diethyl ether to yield 18.  
 
18: Yield: 85 %, white powder 
1H NMR (300 MHz, CDCl3): δ 11.43 (br, 1H), 8.46 (s, 1H), 6.51 (s, 2H), 5.26 (s, 2H), 
3.69 (comp, 4H), 2.87 (s, 2H), 1.53 (s, 9H) 1.47 (s, 9H); 
13C NMR (75 MHz, DMSO-d6): δ 176.30, 156.65, 153.02, 136.54, 83.33, 80.97, 47.65, 
39.02,   
HR-MS (FAB) m/z [M+H]+: 451.2193 (calc.), 451.2183 (found). 
6.5 Synthesis of π-rich and π-poor Polymers: 
 
Figure 6.7.  Protected diester homopolymer CPPMs final products 8a-f. 
 
Synthesis of 8a-f: 20 equivalents of 3a-f and one equivalent of G3 catalyst were each 
dissolved in 1.5 mL of dry CH2Cl2 in separate Schlenk flasks.  The catalyst flask also 
contained a small stir bar. Three freeze-pump-thaw cycles were used to remove air.  
Following the third thaw step, the monomer flask was kept under nitrogen while the 
catalyst flask remained under vacuum. The corresponding monomer 3a-f was then 
cannulated into the vigorously stirring catalyst solution at RT.  After 1hr, the reaction was 
quenched with 3 mL of ethyl vinyl ether.  The quenched polymer solutions were allowed 
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to stir overnight at RT.  The solutions were then transferred to 20 mL scintillation vials 
and concentrated via rotary evaporation.  The crude polymers (8a-f) were then dissolved 
in a minimal amount of THF and added drop-wise to 100 mL of stirring pentanes to 
precipitate the polymer.  After 5-10 minutes of stirring, 8a-f were isolated via vacuum 
filtration using fine sinter funnels.  Polymers were dried under vacuum at RT overnight.  
 
8a: 1H NMR (300 MHz, Acetone-d6): δ 11.63 (br, 1H), 8.44 (br, 1H), 6.55 (comp, 2H), 
6.43 (br, 1H), 5.98 (br, 1H), 5.68 (br, 1H), 5.14 (comp, 3H), 4.74 (br, 1H), 4.16 (br, 2H), 
3.79 (br, 6H), 3.60 (br, 2H), 3.28 (br, 2H), 1.51 (s, 9H), 1.43 (s, 9H);  
 
8b: 1H NMR (300 MHz, Acetone-d6): δ 11.62 (br, 1H), 8.40 (br, 1H), 6.95 (comp, 3H), 
5.94 (br, 1H), 5.65 (br, 1H), 5.10 (comp, 3H), 4.70 (br, 1H), 4.10 (br, 2H), 3.57 (br, 2H), 
3.22 (br, 2H), 1.49 (s, 9H), 1.42 (s, 9H); 
 
8c: 1H NMR (300 MHz, DMSO-d6): δ 11.46 (br, 1H), 8.36 (br, 1H), 7.28 (br, 5H), 5.68 
(br, 1H), 5.78 (br, 1H), 5.56 (br, 1H), 5.01 (comp, 3H), 4.54 (br, 1H), 3.98 (br, 2H), 3.43 
(br, 2H), 3.20 (br, 2H), 1.39 (s, 9H), 1.33 (s, 9H); 
 
8d: 1H NMR (300 MHz, Acetone-d6): δ 11.63 (br, 1H), 8.44 (br, 1H), 7.69 (comp, 4H), 
5.98 (br, 1H), 5.70 (br, 1H), 5.25 (comp, 3H), 4.74 (br, 1H), 4.15 (br, 2H), 3.60 (br, 2H), 
3.31 (br, 2H), 1.49 (s, 9H), 1.41 (s, 9H); 
 
8e: 1H NMR (300 MHz, Acetone-d6): δ 11.60 (br, 1H), 8.42 (br, 1H), 8.23 (comp, 2H), 
7.86 (br, 1H), 7.70 (br, 1H), 5.98 (br, 1H), 5.70 (br, 1H), 5.23 (comp, 3H), 4.73 (br, 1H), 
4.17 (br, 2H), 3.60 (br, 2H), 3.33 (br, 2H), 1.49 (s, 9H), 1.42 (s, 9H);  
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8f: 1H NMR (300 MHz, Acetone-d6): δ 11.62 (br, 1H), 8.45 (br, 1H), 7.01 (comp, 3H), 
5.98 (br, 1H), 5.70 (br, 1H), 5.17 (comp, 3H), 4.74 (br, 1H), 4.18 (br, 2H), 3.62 (br, 2H), 
3.33 (br, 2H), 1.50 (s, 9H), 1.43 (s, 9H);  
 
Figure 6.8.  Deprotected diester homopolymer CPPM final products 9a-f 
 
Deprotection Procedure to Yield Polymers 9a-f: 8a-f were dissolved in 2 mL of 
CH2Cl2 and allowed to stir. 2 mL of TFA was then added drop-wise to the solution and 
allowed to stir overnight at RT.  Excess TFA was removed by azeotropic distillation with 
MeOH.  During this process, 5-7 mL of MeOH was added and then the sample was 
concentrated via rotary evaporation.  This process was repeated 7-9 times to ensure 
complete TFA removal. Following this, samples were dissolved in a water/MeOH 
mixture, transferred to Spectra/Por® 6 dialysis membranes (MWCO=2,000 g/mol), and 
dialyzed against RO water until the conductivity of the water remained < 0.2 µS (2-3 
days).  9a-f were then isolated from water by lyophilization.  
 
9a: 1H NMR (300 MHz, CD3CN): δ 7.79 (br, 1H), 7.08 (comp, 4H), 6.46 (comp, 3H), 5.86 
(br, 1H), 5.63 (br, 1H), 5.03 (comp, 3H), 4.66 (br, 1H), 4.10 (br, 1H), 3.99 (br, 1H), 3.75 
(br, 6H), 3.31 (comp, 4H);  
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9b: 1H NMR (300 MHz, CD3CN): δ 7.71 (comp, 2H), 7.33 (br, 1H), 6.95 (comp, 5 H), 
5.85 (br, 1H), 5.63 (br, 1H), 5.01 (comp, 3H), 4.65 (br, 1H), 4.08 (br, 1H), 3.94 (br, 1H), 
3.27 (comp, 4H), 2.27 (br, 6H); 
 
9c: 1H NMR (300 MHz, CD3CN): δ 7.36 (comp, 6H), 7.05 (comp, 3H), 5.85 (br, 1H), 5.64 
(br, 1H), 5.09 (comp, 3H), 4.66 (br, 1H), 4.08 (br, 2H), 3.92 (br, 1H), 3.28 (comp, 4H);  
 
9d: 1H NMR (300 MHz, CD3CN): δ 7.64 (comp, 5H), 7.09 (comp, 4H), 5.86 (br, 1H), 5.64 
(br, 1H), 5.12 (comp, 3H), 4.66 (br, 1H), 4.09 (br, 1H), 3.95 (br, 1H), 3.30 (comp, 4H);  
 
9e: 1H NMR (300 MHz, DMSO-d6): δ 8.18 (comp, 2H), 7.70 (comp, 3H), 7.30 (comp, 
4H), 5.82 (br, 1H), 5.61 (br, 1H), 5.37 (comp, 3H), 4.56 (br, 1H), 3.98 (comp, 2H), 3.28 
(comp, 4H); 
 
9f: 1H NMR (300 MHz, DMSO-d6): δ 7.81 (comp, 2H), 7.19 (comp, 6H), 5.84 (br, 1H), 
5.61 (br, 1H), 5.08 (br, 3H), 4.57 (br, 1H), 4.01 (br, 2H), 3.26 (comp, 4H); 
 
 
Figure 6.9. Protected imide random copolymer CPPM final products 11a-c. 
 
Synthesis of 11a-c: 20 equivalents of 7a-c and 20 equivalents of 19 were each 
dissolved in 1.5 mL of dry CH2Cl2 in the same Schlenk flasks. 1 equivalent of G3 catalyst 
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was dissolved in 1.5 mL of dry CH2Cl2 in a separate Schlenk flask with a stir bar.  Three 
freeze-pump-thaw cycles were used to remove air.  Following the third thaw step, the 
monomer flask was kept under nitrogen while the catalyst flask remained under vacuum. 
The corresponding monomers 7a-c and 18 were then cannulated into a vigorously 
stirring catalyst solution at RT.  After 1hr, the reaction was quenched with 3 mL of ethyl 
vinyl ether.  The quenched polymer solutions were allowed to stir overnight at RT.  The 
solutions were then concentrated via rotary evaporation and redissolved in a minimal 
amount of CH2Cl2 added drop-wise to 100 mL of stirring diethyl ether to precipitate the 
polymer.  After 5-10 minutes of stirring, 11a-c were isolated via vacuum filtration using 
fine sinter funnels.  Polymers were dried under vacuum at RT overnight. 
 
11a: 1H NMR (300 MHz, DMSO-d6): δ 11.46 (m, 1H), 8.45 (br, 1H), 6.36 (br, 3H), 5.92 
(br, 2H), 5.72 (br, 2H), 4.89 (br, 2H), 4.40 (br, 4H), 3.67 (br, 6H), 3.43 (br, 8H), 1.42 (s, 
9H), 1.36 (s, 9H); 
 
11b: 1H NMR (300 MHz, DMSO-d6): δ 11.47 (m, 1H), 8.46 (br, 1H), 7.25 (br, 5H), 5.92 
(br, 2H), 5.72, (br, 2H), 4.89 (br, 2H), 4.46 (m, 4H), 3.40 (m, 8H), 1.42 (s, 9H), 1.36 (s, 
9H) 
 
11c: 1H NMR (300 MHz, DMSO-d6): δ 11.44 (m, 1H), 8.72 (br, 1H) 8.51 (br, 3H), 5.92 
(br, 2H), 5.71 (br, 2H), 4.81 (br, 4H), 4.43 (br, 2H), 3.43 (comp, 8H), 1.46 (s, 9H), 1.40 
(s, 9H);  
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Figure 6.10. Deprotected imide random copolymer CPPM final products 12a-c. 
 
Deprotection Procedure to Yield Polymers 12a-c: 11a-c were dissolved in 2 mL of 
H2Cl2 and allowed to stir. 2 mL of TFA was then added drop-wise to the solution and 
allowed to stir overnight at RT.  Excess TFA was removed by azeotropic distillation with 
MeOH.  During this process, 5-7 mL of MeOH was added and then the sample was 
concentrated via rotary evaporation.  This process was repeated 7-9 times to ensure 
complete TFA removal. Following this, samples were dissolved in 5-10 mL of water and 
lyophilized to isolate 12a-c.  
 
12a: 1H NMR (300 MHz, DMSO-d6): δ 7.28 (comp, 5H), 6.37 (br, 3H), 5.96 (br, 2H), 5.74 
(br, 2H), 4.85 (br, 2H), 4.43 (br, 4H), 3.68 (br, 6H), 3.43 (comp, 8H);  
 
12b: 1H NMR (300 MHz, DMSO-d6): δ 7.52 (comp, 10H), 5.96 (br, 2H), 5.74 (br, 2H), 
4.87 (br, 2H), 4.49 (comp, 4H), 3.47 (comp, 8H); 
 
12c: 1H NMR (300 MHz, DMSO-d6): δ 8.82 (br, 1H), 8.59 (br, 2H), 7.34 (br, 5H), 6.04 
(br, 2H), 5.83 (br, 2H), 4.93 (br, 4H), 4.53 (br, 2H), 3.47 (comp, 8H); 
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Figure 6.11.  Protected diester random copolymer CPPM final products 14a, c, e. 
 
Synthesis of 14a, c, e: 12 equivalents of 13 and 8 equivalents of either 3a, 3c, or 3e 
were dissolved in 1.5 mL of dry CH2Cl2 in one Schlenk flask and 1 equivalent of G3 
catalyst was dissolved in 1.5 mL of dry CH2Cl2 in separate Schlenk flask containing a stir 
bar.  Three freeze-pump-thaw cycles were used to remove air.  Following the third thaw 
step, the monomer flask was kept under nitrogen while the catalyst flask remained under 
vacuum.  The corresponding monomer solution mixture of 13 and either 14a, c, e was 
then cannulated into the vigorously stirring catalyst solution at RT.  After 1hr, the 
reaction was quenched with 3 mL of ethyl vinyl ether.  The quenched polymer solutions 
were allowed to stir overnight at RT.  The solutions were then transferred to 20 mL 
scintillation vials and concentrated via rotary evaporation.  The crude polymers (14a, c, 
e) were then dissolved in a minimal amount of THF and added drop-wise to 100 mL of 
stirring pentanes to precipitate the polymer.  After 5-10 minutes of stirring, 14a, c, e were 
isolated via vacuum filtration using fine sinter funnels.  Polymers were dried under 
vacuum at RT overnight. 
 
14a: 1H NMR (300 MHz, CD3CN): δ 11.56 (br, 3H), 8.36 (br, 3H), 8.45 (comp, 3H), 5.88 
(br, 2H), 5.61 (br, 2H), 5.02 (comp, 4H), 4.67 (br, 2H), 4.12 (comp, 6H), 3.75 (s, 6H), 
3.52 (comp, 6H), 3.17 (br, 4H), 1.48 (s, 27H), 1.43 (s, 27H); n:m = 38:62 
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14c: 1H NMR (300 MHz, CD3CN): δ 11.56 (br, 3H), 8.36 (br, 3H), 7.34 (br, 5H), 5.88 (br, 
2H), 5.61 (br, 2H), 5.08 (comp, 4H), 4.66 (br, 2H), 4.12 (comp, 6H), 3.52 (comp, 6H), 
3.16 (br, 4H), 1.48 (s, 27H), 1.43 (s, 27H); n:m = 40:60 
 
14e: 1H NMR (300 MHz, CD3CN): δ 11.55 (br, 3H), 8.36 (br, 3H), 8.17 (br, 2H), 7.74 (br, 
1H), 7.60 (br, 1H), 5.88 (br, 2H), 5.63 (br, 2H), 5.11 (comp, 4H), 4.67 (br, 2H), 4.13 
(comp, 6H), 3.56 (comp, 6H), 3.17 (br, 4H), 1.48 (s, 27H), 1.43 (s, 27H); n:m = 39:61 
 
 
Figure 6.12.  Deprotected diester random copolymer CPPM final products 15a, c, e. 
 
Deprotection Procedure to Yield Polymers 15a, c, e: 14a, c, e were dissolved in 2 mL 
of CH2Cl2 and allowed to stir.  2 mL of TFA was then added drop-wise to the solution 
and allowed to stir overnight at RT.  Excess TFA was removed by azeotropic distillation 
with MeOH.  During this process, 5-7 mL of MeOH was added and then the sample was 
concentrated via rotary evaporation.  This process was repeated 7-9 times to ensure 
complete TFA removal. Following this, samples were dissolved in a water/MeOH 
mixture, transferred to Spectra/Por® 6 dialysis membranes (MWCO=2,000 g/mol), and 
dialyzed against RO water until the conductivity of the water remained < 0.2 µS.  15a, c, 
e were then isolated from water by lyophilization. 
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15a: 1H NMR (300 MHz, DMSO-d6): δ 7.86 (br, 3H), 7.41 (comp, 12H), 6.47 (br, 3H), 
5.83 (br, 2H), 5.60 (br, 2H), 4.99 (br, 4H), 4.58 (br, 2H), 4.04 (comp, 6H), 3.72 (br, 6H), 
3.27 (comp, 10H). 
 
15c: 1H NMR (300 MHz, DMSO-d6): δ 7.89 (comp, 5H), 7.33 (comp, 15H), 5.83 (br, 2H), 
5.60 (br, 2H), 5.06 (br, 4H), 4.58 (br, 2H), 4.05 (comp, 6H), 3.27 (comp, 10H) 
 
15e: 1H NMR (300 MHz, DMSO-d6): δ 8.19 (br, 3H), 7.56 (comp, 16H), 5.83 (br, 2H), 
5.60 (br, 2H), 5.20 (br, 2H), 4.98 (br, 2H), 4.58 (br, 2H), 4.04 (comp, 6H), 3.29 (comp, 
10H).    
 
6.6 Synthesis of Monomers for the Exploration of Cationic Charge Content and 
Polymer Architecture on siRNA Internalization and Delivery 
 
Figure 6.13.  Synthesis of hydrophobic monomer MePh. i) Benzyl alcohol, DMAP, 
CH2Cl2,, RT, overnight;  ii) MeOH, DMAP, EDC, CH2Cl2,, 0°C to RT, overnight; 
 
Synthesis of 1:  Maleic anhydride (100.0 g, 1.02 mol) was dissolved in 1 L toluene and 
150 mL of furan (140.7 g, 2.05 mol) was added.  The solution was stirred for 3 days at 
room temperature (RT) according to the literature. The product (1) was then filtered, 
washed with hexanes, and dried under vacuum overnight at RT to obtain a colorless 
powder.  Spectroscopic data and yield were consistent with the literature.2 
 
1H NMR (300 MHz, DMSO-d6): δ = 6.57 (s, 2H), 5.35 (s, 2H), 3.31 (s, 2H); 
 
	  
	   176 
Synthesis of 2c:  The procedure reported by Lienkamp et al. was followed with minor 
modifications.2  One equivalent of 1, 1.25 equivalents of the corresponding substituted 
benzyl alcohols, and 10 mol% DMAP were dissolved in a minimal amount of freshly 
distilled CH2Cl2 and the reaction mixture was stirred under nitrogen at RT overnight. 2 
precipitated from solution and was isolated using vacuum filtration and washed with cold 
CH2Cl2. 2 was then dried under vacuum at RT overnight.  
 
2. Yield: 60 %, white powder  
1H NMR (300 MHz, DMSO-d6): δ = 12.46 (br, 1H), 7.36 (comp, 5H), 6.45 (m, 2H), 5.12 
(m, 2H), 5.01 (q, 2H), 2.77 (d, 2H);  
13C NMR (75 MHz, DMSO-d6): δ = 172.74, 171.59, 136.79, 136.61, 136.07, 128.45, 
128.05, 128.02, 80.18, 79.84, 65.99, 46.82, 46.10; 
HR-MS (FAB) m/z [M+H]+: 275.0914 (calc.), 275.0903 (found). 
 
Synthesis of 19 (MePh):  The procedure reported by Lienkamp et al. was followed with 
minor modifications.2  One equivalent of 2, one equivalent of MeOH, and 10 mol% 
DMAP were dissolved in CH2Cl2 and stirred at RT under nitrogen.  The solution was then 
cooled down to 0°C in an ice bath and one equivalent of EDC was added. The solution 
was allowed to stir overnight under nitrogen and gradually return to RT.  The reaction 
mixture was then concentrated via rotary evaporation and purified by either column 
chromatography with EtOAc/CH2Cl2 (1/4, v/v) as the eluent or by using a CombiFlash 
purification system, with a 120 g silica cartridge and EtOAc/CH2Cl2 (1/4, v/v) as the 
eluent.  Pure fractions were combined and then concentrated using rotary evaporation. 
The sample was dried under vacuum overnight at RT to obtain a white solid. 
  
3: Yield 82 %, white powder. 
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1H NMR (300 MHz, CD3CN): δ = 7.38 (comp, 5H), 6.44 (comp, 2H), 5.14 (d, 2H), 5.06 
(comp, 2H), 3.50 (s, 3H), 2.84 (q, 2H).  
13C NMR (75 MHz, CD3CN): δ = 173.35, 172.84, 137.95, 137.91, 137.51, 129.84, 
129.60, 129.50, 81.64, 81.63, 67.72, 52.75, 47.96, 47.89. 
HR-MS (FAB) m/z [M+H]+: 289.1076 (calc.), 289.1078 (found). 
6.7 Synthesis of Polymers for the Exploration of Cationic Charge Content and 
Polymer Architecture on siRNA Internalization and Delivery 
 
Figure 6.14.  Synthesis of Boc-protected homopolymer PTDMs (20a-f). i) Dichloro-di(3-
bromopyridino)-N,N’-Dimesitylenoimidazolino-Ru=CHPh (G3) catalyst, CH2Cl2,, RT, 90 
min; ii) Ethyl vinyl ether, RT, overnight; Polymers were synthesized with m = 5, 10, 20, 
40, 60 and 80. 
 
Homopolymer Synthesis of 20a-f: 5, 10, 20, 40, 60, or 80 equivalents of 13 and one 
equivalent of G3 catalyst were each dissolved in 1.5 mL of dry CH2Cl2 in separate 
schlenk flasks.  The catalyst flask also contained a small stir bar. Three freeze-pump-
thaw cycles were used to remove air.  Following the third thaw step, the monomer flask 
was kept under nitrogen while the catalyst flask remained under vacuum.  Monomer 13 
was then cannulated into the vigorously stirring catalyst solution at RT.  After 1.5 hr, the 
reaction was quenched with 3 mL of ethyl vinyl ether.  The quenched polymer solutions 
were allowed to stir overnight at RT.  The solutions were then transferred to 20 mL 
scintillation vials and concentrated using rotary evaporation.  20a-e were then dissolved 
in a minimal amount of THF and added drop-wise to 100 mL of cold, stirring pentanes to 
precipitate the polymers.  After 5-10 minutes of stirring, 20a-e were isolated using 
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vacuum filtration with fine sinter funnels.  Polymers were dried under vacuum at RT 
overnight.  
 
20a (m=5): 1H NMR (500 MHz, CD3CN): δ = 11.53 (br, 2H), 8.35 (br, 2H), 5.88 (trans) 
and 5.62 (cis) (br, 2H total), 5.04 (cis) and 4.66 (trans) (br, 2H total), 4.17 (br, 4H), 3.56 
(br, 4H), 3.17 (br, 2H), 1.47 (s, 18H), 1.42 (s, 18H). 
 
20b (m=10): 1H NMR (300 MHz, CD3CN): δ = 11.52 (br, 2H), 8.35 (br, 2H), 5.86 (trans) 
and 5.59 (cis) (br, 2H total), 5.05 (cis) and 4.65 (trans) (br, 2H total), 4.17 (br, 4H), 3.55 
(br, 4H), 3.15 (br, 2H), 1.46 (s, 18H), 1.41 (s, 18H).  
 
20c (m=20): 1H NMR (300 MHz, CD3CN): δ = 11.54 (br, 2H), 8.35 (br, 2H), 5.86 (trans) 
and 5.59 (cis) (br, 2H total), 5.05 (cis) and 4.66 (trans) (br, 2H total), 4.17 (br, 4H), 3.55 
(br, 4H), 3.14 (br, 2H), 1.46 (s, 18H), 1.41 (s, 18H). 
 
20d (m=40): 1H NMR (500 MHz, CD3CN): δ = 11.54 (br, 2H), 8.35 (br, 2H), 5.86 (trans) 
and 5.61 (cis) (br, 2H total), 5.05 (cis) and 4.66 (trans) (br, 2H total), 4.16 (br, 4H), 3.55 
(br, 4H), 3.14 (br, 2H), 1.46 (s, 18H), 1.41 (s, 18H). 
 
20e (m=60): 1H NMR (500 MHz, CD3CN): δ = 11.54 (br, 2H), 8.35 (br, 2H), 5.86 (trans) 
and 5.61 (cis) (br, 2H total), 5.05 (cis) and 4.66 (trans) (br, 2H total), 4.17 (br, 4H), 3.56 
(br, 4H), 3.17 (br, 2H), 1.46 (s, 18H), 1.41 (s, 18H). 
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20f (m=80): 1H NMR (500 MHz, CD3CN): δ = 11.54 (br, 2H), 8.35 (br, 2H), 5.86 (trans) 
and 5.61 (cis) (br, 2H total), 5.05 (cis) and 4.66 (trans) (br, 2H total), 4.16 (br, 4H), 3.55 
(br, 4H), 3.15 (br, 2H), 1.46 (s, 18H), 1.41 (s, 18H). 
 
Figure 6.15.  Deprotection of boc-protected homopolymers (20a-f) to yield the dGn 
series of PTDMs.  i) TFA/CH2Cl2 (1:1), RT, overnight. dGn series further purified by 
dialysis with molecular weight cut-off : 100-500 g/mol. 
 
Deprotection Procedure to Yield dG Polymer Series: 20a-e were dissolved in 2 mL of 
CH2Cl2 and allowed to stir.  2 mL of TFA was then added drop-wise to the solution and 
allowed to stir overnight at RT.  Excess TFA was removed by azeotropic distillation with 
MeOH.  During this process, 5-7 mL of MeOH was added and then the sample was 
concentrated using rotary evaporation.  This process was repeated 7-9 times to ensure 
complete TFA removal. Following this, samples were dissolved in a water/MeOH 
mixture, transferred to Biotech CE dialysis tubing membranes with a MWCO 100-500 
g/mol and dialyzed against RO water until the conductivity of the water remained < 0.2 
µS (2-3 days on dialysis).  The dG series was then aqueous filtered and isolated from 
water by lyophilization.  
 
dG5: 1H NMR (500 MHz, DMSO-d6): δ = 7.93 (br, 2H), 7.42 (br, 8H), 5.84 (trans) and 
5.60 (cis) (br, 2H total), 4.96 (cis) and 4.63 (trans) (br, 2H total), 4.10 (br, 4H), 3.38 (br, 
4H), 3.33 (br, 2H). 
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dG10: 1H NMR (300 MHz, DMSO-d6): δ = 7.99 (br, 2H), 7.43 (br, 8H), 5.83 (trans) and 
5.60 (cis) (br, 2H total), 4.96 (cis) and 4.62 (trans) (br, 2H total), 4.05 (br, 4H), 3.40 (br, 
4H), 3.27 (br, 2H). 
 
dG20: 1H NMR (300 MHz, DMSO-d6): δ = 7.98 (br, 2H), 7.43 (br, 8H), 5.82 (trans) and 
5.57 (cis) (br, 2H total), 4.96 (cis) and 4.57 (trans) (br, 2H total), 4.05 (br, 4H), 3.37 (br, 
4H), 3.28 (br, 2H).  
 
dG40: 1H NMR (500 MHz, DMSO-d6): δ = 7.98 (br, 2H), 7.44 (br, 8H), 5.82 (trans) and 
5.58 (cis) (br, 2H total), 4.97 (cis) and 4.61 (trans) (br, 2H total), 4.03 (br, 4H), 3.40 (br, 
4H), 3.27 (br, 2H). 
 
dG60: 1H NMR (500 MHz, DMSO-d6): δ = 7.98 (br, 2H), 7.44 (br, 8H), 5.82 (trans) and 
5.58 (cis) (br, 2H total), 4.97 (cis) and 4.57 (trans) (br, 2H total), 4.03 (br, 4H), 3.38 (br, 
4H), 3.28 (br, 2H). 
 
dG80: 1H NMR (500 MHz, DMSO-d6): δ = 7.98 (br, 2H), 7.43 (br, 8H), 5.82 (trans) and 
5.58 (cis) (br, 2H total), 4.96 (cis) and 4.57 (trans) (br, 2H total), 4.03 (br, 4H), 3.37 (br, 
4H), 3.32 (br, 2H). 
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Figure 6.16.  Synthesis of Boc-protected block copolymer PTDMs (21a-f). i) Dichloro-
di(3-bromopyridino)-N,N’-Dimesitylenoimidazolino-Ru=CHPh (G3) catalyst, CH2Cl2,, RT, 
10 min; ii) dG, CH2Cl2, RT, 90 min; iii) Ethyl vinyl ether, RT, overnight; Polymers were 
synthesized with n = 5, 10, 20, 40, 60 and 80. 
 
Block Copolymer Synthesis of 21a-f: 5 equivalents of 19, 5, 10, 20, 40, 60, or 80 
equivalents of 13, and one equivalent of G3 catalyst were each dissolved in 1.5 mL of 
dry CH2Cl2 in separate schlenk flasks.  The catalyst flask also contained a small stir bar. 
Three freeze-pump-thaw cycles were used to remove air.  Following the third thaw step, 
the flasks containing 13 and 19 were kept under nitrogen while the catalyst flask 
remained under vacuum.  Monomer 19 was then cannulated into the vigorously stirring 
catalyst solution at RT.  After 10 min, a small aliquot (0.05 mL) was removed from the 
solution for analysis and then monomer 13 was cannulated into the vigorously stirring 
polymerization solution at RT reaction.  After 1.5 hr, the polymerizations were quenched 
with 3 mL of ethyl vinyl ether and allowed to stir overnight at RT.  The solutions were 
then transferred to 20 mL scintillation vials and concentrated using rotary evaporation.  
21a-f were then dissolved in a minimal amount of THF and added drop-wise to 100 mL 
of cold, stirring pentanes to precipitate the polymers.  After 5-10 minutes of stirring, 21a-f 
were isolated using vacuum filtration with fine sinter funnels.  Polymers were dried under 
vacuum at RT overnight.  
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Figure 6.17.  Representative 1H NMR spectrum of 21b to demonstrate the determination 
of block copolymer composition from unique peaks from each distinct repeat unit (dG 
and MePh).  Data reflects true integrations for the polymer peaks and are not modified to 
display the number of hydrogen atoms expected to be found for each monomer, when 
analyzed independently.  
 
Note: All 1H NMR data reported below for 21a-f reflects the numbers of hydrogen atoms 
expected to be found for each type of monomer repeat unit and do not necessarily 
reflect their relative abundance in the polymer samples.  
 
21a (n=5; m=5): 1H NMR (300 MHz, CD3CN): δ = 11.53 (br, 2H), 8.35 (br, 2H), 7.34 (br, 
6H), 5.86 (trans) and 5.60 (cis) (comp, 4H total), 5.07 (comp, 2H), 5.07 (cis) and 4.65 
(trans) (comp, 4H), 4.17 (br, 4H), 3.51 (comp, 7H), 3.15 (br, 4H), 1.47 (s, 18H), 1.42 (s, 
18H).  
n:m = 5 : 5 
 
21b (n=5; m=10): 1H NMR (500 MHz, CD3CN): δ = 11.54 (br, 2H), 8.36 (br, 2H), 7.33 
(br, 6H), 5.86 (trans) and 5.59 (cis) (comp, 4H total), 5.05 (comp, 2H), 5.05 (cis) and 
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4.64 (trans) (comp, 4H total), 4.17 (br, 4H), 3.55 (comp, 7H), 3.14 (br, 4H), 1.46 (s, 18H), 
1.41 (s, 18H).  
n:m = 5 : 10 
 
21c (n=5; m=20): 1H NMR (500 MHz, CD3CN): δ = 11.54 (br, 2H), 8.35 (br, 2H), 7.34 
(br, 6H), 5.86 (trans) and 5.60 (cis) (comp, 4H) total, 5.05 (comp, 2H) 5.05 (cis) and 4.65 
(trans) (comp, 4H total), 4.16 (br, 4H), 3.55 (comp, 7H), 3.15 (br, 4H), 1.46 (s, 18H), 1.41 
(s, 18H). 
n:m = 5 : 20 
 
21d (n=5; m=40): 1H NMR (500 MHz, CD3CN): δ = 11.54 (br, 2H), 8.35 (br, 2H), 7.34 
(br, 6H), 5.86 (trans) and 5.61 (cis) (comp, 4H) total, 5.05 (comp, 2H) 5.05 (cis) and 4.66 
(trans) (comp, 4H total), 4.17 (br, 4H), 3.55 (comp, 7H), 3.14 (br, 4H), 1.46 (s, 18H), 1.41 
(s, 18H). 
n:m = 5 : 40 
 
21e (n=5; m=60): 1H NMR (500 MHz, CD3CN): δ = 11.54 (br, 2H), 8.35 (br, 2H), 7.34 
(br, 6H), 5.86 (trans) and 5.60 (cis) (comp, 4H) total, 5.05 (comp, 2H) 5.05 (cis) and 4.66 
(trans) (comp, 4H total), 4.16 (br, 4H), 3.55 (comp, 7H), 3.14 (br, 4H), 1.46 (s, 18H), 1.41 
(s, 18H). 
n:m = 5 : 60 
 
21f (n=5; m=80): 1H NMR (500 MHz, CD3CN): δ = 11.54 (br, 2H), 8.35 (br, 2H), 7.34 (br, 
6H), 5.86 (trans) and 5.61 (cis) (comp, 4H) total, 5.05 (comp, 2H) 5.05 (cis) and 4.66 
(trans) (comp, 4H total), 4.17 (br, 4H), 3.55 (comp, 7H), 3.14 (br, 4H), 1.46 (s, 18H), 1.41 
(s, 18H). 
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n:m = 5 : 80 
 
 
Figure S6.18.  Deprotection of boc-protected block copolymers (21a-f) to yield the 
MePh5-b-dGn series of PTDMs.  i) TFA/CH2Cl2 (1:1), RT, overnight. MePh5-b-dGn series 
further purified by dialysis with molecular weight cut-off : 100-500 g/mol. 
 
Deprotection Procedure to Yield MePh5-b-dGn Polymer Series: 21a-f were dissolved 
in 2 mL of CH2Cl2 and allowed to stir.  2 mL of TFA was then added drop-wise to the 
solution and allowed to stir overnight at RT.  Excess TFA was removed by azeotropic 
distillation with MeOH.  During this process, 5-7 mL of MeOH was added and then the 
sample was concentrated using rotary evaporation.  This process was repeated 7-9 
times to ensure complete TFA removal. Following this, samples were dissolved in a 
water/MeOH mixture, transferred to Biotech CE dialysis tubing membranes with a 
MWCO 100-500 g/mol and dialyzed against RO water until the conductivity of the water 
remained < 0.2 µS (2-3 days on dialysis).  The MePh5-b-dGn series was then aqueous 
filtered and isolated from water by lyophilization.  
 
MePh5-b-dG5: 1H NMR (300 MHz, CD3CN-d6): δ = 7.88 (br, 2H), 7.35 (comp, 6H), 7.07 
(comp, 8H), 5.87 (trans) and 5.62 (cis) (br, 4H total), 5.07 (comp, 2H), 5.07 (cis) and 
4.68 (trans) (comp, 4H total), 4.15 (br, 4H), 3.42 (comp, 7H), 3.20 (br, 4H). 
 
MePh5-b-dG10: 1H NMR (500 MHz, DMSO-d6): δ 7.96 (br, 2H), 7.39 (comp, 14H), 5.83 
(trans) and 5.59 (cis) (comp, 4H total), 5.01 (comp, 2H), 5.01 (cis) and 4.58 (trans) 
(comp, 4H total), 4.07 (4H, br), 3.38 (7H, br), 3.27 (4H, br); 
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MePh5-b-dG20: 1H NMR (500 MHz, DMSO-d6): δ 7.98 (br, 2H), 7.40 (comp, 14H), 5.83 
(trans) and 5.59 (cis) (comp, 4H total), 5.03 (comp, 2H), 5.03 (cis) and 4.61 (trans) 
(comp, 4H total), 4.04 (4H, br), 3.40 (7H, br), 3.28 (4H, br); 
 
MePh5-b-dG40: 1H NMR (500 MHz, DMSO-d6): δ 7.98 (br, 2H), 7.44 (comp, 14H), 5.82 
(trans) and 5.59 (cis) (comp, 4H total), 4.97 (comp, 2H), 4.97 (cis) and 4.58 (trans) 
(comp, 4H total), 4.10 (4H, br), 3.40 (7H, br), 3.28 (4H, br); 
 
MePh5-b-dG60: 1H NMR (500 MHz, DMSO-d6): δ 7.99 (br, 2H), 7.44 (comp, 14H), 5.82 
(trans) and 5.58 (cis) (comp, 4H total), 4.97 (comp, 2H), 4.97 (cis) and 4.61 (trans) 
(comp, 4H total), 4.04 (4H, br), 3.40 (7H, br), 3.28 (4H, br); 
 
MePh5-b-dG80: 1H NMR (500 MHz, DMSO-d6): δ = 7.99 (br, 2H), 7.33 (comp, 14H), 5.84 
(trans) and 5.57 (cis) (comp, 4H total), 4.97 (comp, 2H), 4.97 (cis) and 4.60 (trans) 
(comp, 4H total), 4.04 (4H, br), 3.40 (7H, br), 3.31 (4H, br); 
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6.8 Synthesis of Monomers for the Exploration of Hydrophobic Content Effects 
on siRNA Internalization 
 
Figure 6.19.  Synthesis of hydrophobic monomers. i) Methanol, DMAP, CH2Cl2,, RT, 
overnight;  ii) R1OH or R2OH, DMAP, EDC, CH2Cl2,, 0°C to RT, overnight; 
 
Synthesis of 1:  Maleic anhydride (100.0 g, 1.02 mol) was dissolved in 1 L toluene and 
150 mL of furan (140.7 g, 2.05 mol) was added.  The solution was stirred for 3 days at 
room temperature (RT) according to the literature. The product (1) was then filtered, 
washed with hexanes, and dried under vacuum overnight at RT to obtain a colorless 
powder.  Spectroscopic data and yield were consistent with the literature.2 
 
1H NMR (300 MHz, DMSO-d6): δ = 6.57 (s, 2H), 5.35 (s, 2H), 3.31 (s, 2H); 
 
Synthesis of 22:  The procedure reported by Lienkamp et al. was followed with minor 
modifications.2  One equivalent of 1, 1.25 equivalents of methanol, and 10 mol% DMAP 
were dissolved in a minimal amount of freshly distilled CH2Cl2 and the reaction mixture 
was stirred under nitrogen at RT overnight. The reaction was rotary evaporated to 
remove CH2Cl2 and 2 was subsequently recrystallized from a mixture of 
chloroform/hexanes (3/1, v/v).  2 was later isolated by vacuum filtration and allowed to 
dry under vacuum at RT overnight.  
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2. Yield: 62 %, white powder  
1H NMR (500 MHz, DMSO-d6): δ = 12.35 (br, 1H), 6.45 (q, 2H), 5.08 (s, 2H), 3.54 (s, 
3H), 2.72 (s, 2H); 
13C NMR (125 MHz, DMSO-d6): δ =  172.66, 172.11, 136.73, 136.61, 80.05, 79.72, 
51.49, 46.69, 45.99; 
HR-MS (FAB) m/z [M+H]+: 199.0606 (calc.), 199.0611 (found). 
 
Synthesis of 23a-g:  The procedure reported by Lienkamp et al. was followed with 
minor modifications.2  Since both substituents to be added to theses monomers was 
identical, there was no need to isolate the half-ester intermediate as in the case for 
monomers 24b-g.  For this reaction, one equivalent of 1, two equivalents of R1OH, and 
10 mol% DMAP were dissolved in CH2Cl2 and stirred at RT under nitrogen.  The solution 
was then cooled down to 0°C in an ice bath and one equivalent of EDC was added. The 
solution was allowed to stir overnight under nitrogen and gradually return to RT.  The 
reaction mixture was then concentrated using rotary evaporation and purified using a 
CombiFlash purification system, with a 120 g silica cartridge and EtOAc/CH2Cl2 (1/4, v/v) 
as the eluent.  Pure fractions were combined and then concentrated using rotary 
evaporation. The sample was dried under vacuum overnight at RT to obtain a white 
solid. 
 
23a (dMe): Yield 76 %, white powder. 
1H NMR (500 MHz, DMSO-d6): δ = 6.46 (s, 2H), 5.11 (s, 2H), 3.55 (s, 6H), 2.82 (s, 2H); 
13C NMR (125 MHz, DMSO-d6): δ = 171.70, 136.61, 79.74, 51.63, 46.23; 
HR-MS (FAB) m/z [M+H]+: 213.0763 (calc.), 213.0749 (found). 
 
23b (dEt): Yield 74 %, white powder. 
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1H NMR (500 MHz, DMSO-d6): δ = 6.46 (s, 2H), 5.10 (s, 2H), 4.01 (m, 4H), 2.78 (s, 2H), 
1.16 (t, 6H); 
13C NMR (125 MHz, DMSO-d6): δ = 171.13, 136.59, 79.76, 60.17, 46.18, 13.93; 
HR-MS (FAB) m/z [M+H]+: 241.1076 (calc.), 241.1097 (found). 
 
23c (dPr): Yield 70 %, opaque oil. 
1H NMR (500 MHz, DMSO-d6): δ = 6.46 (s, 2H), 5.10 (s, 2H), 3.92 (m, 4H), 2.80 (s, 2H), 
1.55 (m, 4H), 0.87 (t, 6H); 
13C NMR (125 MHz, DMSO-d6): δ = 171.20, 136.60, 79.86, 65.74, 46.22, 21.39, 10.25; 
HR-MS (FAB) m/z [M+H]+: 269.1389 (calc.), 269.1374 (found). 
 
23d (dBu): Yield 82 %, white, waxy solid. 
1H NMR (500 MHz, DMSO-d6): δ = 6.46 (s, 2H), 5.09 (s, 2H), 3.96 (m, 4H), 2.78 (s, 2H), 
1.52 (m, 4H), 1.31 (m, 4H), 0.88 (t, 6H); 
13C NMR (125 MHz, DMSO-d6): δ =171.18, 136.58, 79.85, 63.95, 46.19, 30.05, 19.59, 
13.53; 
HR-MS (FAB) m/z [M+H]+: 297.1702 (calc.), 297.1711 (found). 
 
23e (diBu): Yield 47 %, white powder. 
1H NMR (500 MHz, DMSO-d6): δ = 6.47 (s, 2H), 5.09 (s, 2H), 3.74 (comp, 4H), 2.82 (s, 
2H), 1.83 (m, 2H), 0.87 (d, 12H); 
13C NMR (125 MHz, DMSO-d6): δ = 171.10, 136.58, 79.92, 70.18, 46.25, 27.11, 18.86; 
HR-MS (FAB) m/z [M+H]+: 297.1702 (calc.), 297.1643 (found). 
 
23f (dPh): Yield 80 %, white powder. 
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1H NMR (500 MHz, CD3CN): δ = 7.34 (comp, 10H), 6.44 (s, 2H), 5.16 (s, 2H), 4.97 
(comp, 4H), 2.87 (s, 2H); 
13C NMR (125 MHz, CD3CN): δ = 172.37, 137.52, 137.03, 129.41, 129.14, 129.06, 
81.30, 67.26, 47.58; 
HR-MS (FAB) m/z [M+H]+: 365.1389 (calc.), 365.1385 (found). 
 
23g (dCy): Yield 67 %, white powder. 
1H NMR (500 MHz, DMSO-d6): δ = 6.46 (s, 2H), 5.09 (s, 2H), 3.76 (comp, 4H), 2.79 (s, 
2H), 1.65 (comp, 10H), 1.54 (s, 2H), 1.17 (comp, 6H), 0.92 (comp, 4H); 
13C NMR (125 MHz, DMSO-d6): δ = 171.61, 137.07, 80.40, 69.69, 46.69, 36.93, 29.56, 
26.35, 25.88.  
HR-MS (FAB) m/z [M+H]+: 377.2328 (calc.), 377.2299 (found). 
 
Synthesis of 24b-g:  The procedure reported by Lienkamp et al. was followed with 
minor modifications.2  One equivalent of 22, one equivalent of R2OH, and 10 mol% 
DMAP were dissolved in CH2Cl2 and stirred at RT under nitrogen.  The solution was then 
cooled down to 0°C in an ice bath and one equivalent of EDC was added. The solution 
was allowed to stir overnight under nitrogen and gradually return to RT.  The reaction 
mixture was then concentrated via rotary evaporation and purified using a CombiFlash 
purification system, with a 120 g silica cartridge and EtOAc/CH2Cl2 (1/4, v/v) as the 
eluent.  Pure fractions were combined and then concentrated using rotary evaporation. 
The sample was dried under vacuum overnight at RT to obtain a white solid. 
 
24b (MeEt): Yield 75 %, opaque oil. 
1H NMR (500 MHz, DMSO-d6): δ = 6.46 (s, 2H), 5.10 (s, 2H), 4.01 (m, 2H), 3.56 (s, 3H), 
2.80 (s, 2H), 1.15 (m, 3H); 
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13C NMR (125 MHz, DMSO-d6): δ = 171.71, 171.17, 136.62, 79.76, 60.27, 51.52, 46.27, 
46.16, 13.97; 
HR-MS (FAB) m/z [M+H]+: 227.0919 (calc.), 227.0911 (found). 
 
24c (MePr): Yield 65 %, opaque oil. 
1H NMR (500 MHz, DMSO-d6): δ = 6.46 (s, 2H), 5.11 (s, 2H), 3.92 (m, 2H), 3.56 (s, 3H), 
2.81 (s, 2H), 1.55 (m, 2H), 0.87 (t, 3H); 
13C NMR (125 MHz, DMSO-d6): δ = 171.69, 171.24, 136.63, 136.59, 79.81, 79.76, 
65.01, 51.55, 46.29, 46.15, 21.40, 10.24; 
HR-MS (FAB) m/z [M+H]+:  
 
24d (MeBu): Yield 69 %, opaque oil. 
1H NMR (500 MHz, CD3CN): δ = 6.46 (s, 2H), 5.10 (s, 2H), 3.96 (m, 2H), 3.55 (s, 3H), 
2.80 (s, 2H), 1.52 (m, 2H), 1.31 (m, 2H), 0.88 (t, 3H); 
13C NMR (125 MHz, DMSO-d6): δ = 171.67, 171.23, 136.63, 136.59, 79.82, 79.77, 
84.02, 51.54, 46.28, 46.15, 30.07, 18.56, 13.55; 
HR-MS (FAB) m/z [M+H]+: 255.1232 (calc.), 255.1229 (found). 
 
24f (MePh): Yield 82 %, white powder. 
1H NMR (500 MHz, CD3CN): δ = 7.38 (comp, 5H), 6.44 (comp, 2H), 5.14 (d, 2H), 5.06 
(comp, 2H), 3.50 (s, 3H), 2.84 (q, 2H).  
13C NMR (125 MHz, CD3CN): δ = 173.35, 172.84, 137.95, 137.91, 137.51, 129.84, 
129.60, 129.50, 81.64, 81.63, 67.72, 52.75, 47.96, 47.89. 
HR-MS (FAB) m/z [M+H]+: 289.1076 (calc.), 289.1078 (found). 
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6.9 Synthesis of Polymers for the Exploration of Hydrophobic Content Effects 
on siRNA Internalization 
 
Figure 6.20.  Synthesis of Boc-protected block copolymer PTDMs (25a-f, 26a-c, 27a-c, 
28-30). i) Dichloro-di(3-bromopyridino)-N,N’-Dimesitylenoimidazolino-Ru=CHPh (G3) 
catalyst, CH2Cl2,, RT, 10 min; ii) dG, CH2Cl2, RT, 90 min; iii) Ethyl vinyl ether, RT, 
overnight;  
 
Block Copolymer Synthesis of 25a-g, 26a-c, 27a-c, 28-30: 5, 10, 20, or 40 
equivalents of hydrophobic monomers (23a,b,e-g or 24f), 5, 10, 20, or 40 equivalents of 
18, and one equivalent of G3 catalyst were each dissolved in 1.5 mL of dry CH2Cl2 in 
separate schlenk flasks.  The catalyst flask also contained a small stir bar. Three freeze-
pump-thaw cycles were used to remove air.  Following the third thaw step, the flasks 
containing 23a,b,e-g or 24f and 13 were kept under nitrogen while the catalyst flask 
remained under vacuum.  Monomer 23a,b,e-g or 24f was then cannulated into the 
vigorously stirring catalyst solution at RT.  After 10 min, a small aliquot (0.05 mL) was 
removed from the solution for analysis and then monomer 13 was cannulated into the 
vigorously stirring polymerization solution at RT reaction.  After 1.5 hr, the 
polymerizations were quenched with 3 mL of ethyl vinyl ether and allowed to stir 
overnight at RT.  The solutions were then transferred to 20 mL scintillation vials and 
concentrated using rotary evaporation.  25a-g, 26a-c, 27a-c, and 28-30 were then 
dissolved in a minimal amount of THF and added drop-wise to 100 mL of cold, stirring 
pentanes to precipitate the polymers.  After 5-10 minutes of stirring, 25a-g, 26a-c, 27a-c, 
and 28-30 were isolated using vacuum filtration with fine sinter funnels.  Polymers were 
dried under vacuum at RT overnight.  
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Note: All 1H NMR data reported below for 25a-g, 26a-c, 27a-c, and 28-30 reflects the 
numbers of hydrogen atoms expected to be found for each type of monomer repeat unit 
and do not necessarily reflect their relative abundance in the polymer samples.  An 
example of the NMR block copolymer composition calculation is shown in Figure	  6.17.  
 
25a (n=5; m=5): 1H NMR (300 MHz, CD3CN): δ = 11.53 (br, 2H), 8.35 (br, 2H), 7.34 (br, 
6H), 5.86 (trans) and 5.60 (cis) (comp, 4H total), 5.07 (comp, 2H), 5.07 (cis) and 4.65 
(trans) (comp, 4H), 4.17 (br, 4H), 3.51 (comp, 7H), 3.15 (br, 4H), 1.47 (s, 18H), 1.42 (s, 
18H);  
n:m = 5 : 5 
 
25b (n=5; m=10): 1H NMR (500 MHz, CD3CN): δ = 11.54 (br, 2H), 8.36 (br, 2H), 7.33 
(br, 6H), 5.86 (trans) and 5.59 (cis) (comp, 4H total), 5.05 (comp, 2H), 5.05 (cis) and 
4.64 (trans) (comp, 4H total), 4.17 (br, 4H), 3.55 (comp, 7H), 3.14 (br, 4H), 1.46 (s, 18H), 
1.41 (s, 18H);  
n:m = 5 : 10 
 
25c (n=5; m=20): 1H NMR (500 MHz, CD3CN): δ = 11.54 (br, 2H), 8.35 (br, 2H), 7.34 
(br, 6H), 5.86 (trans) and 5.60 (cis) (comp, 4H) total, 5.05 (comp, 2H) 5.05 (cis) and 4.65 
(trans) (comp, 4H total), 4.16 (br, 4H), 3.55 (comp, 7H), 3.15 (br, 4H), 1.46 (s, 18H), 1.41 
(s, 18H); 
n:m = 5 : 20 
 
25d (n=5; m=40): 1H NMR (500 MHz, CD3CN): δ = 11.54 (br, 2H), 8.35 (br, 2H), 7.34 
(br, 6H), 5.86 (trans) and 5.61 (cis) (comp, 4H) total, 5.05 (comp, 2H) 5.05 (cis) and 4.66 
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(trans) (comp, 4H total), 4.17 (br, 4H), 3.55 (comp, 7H), 3.14 (br, 4H), 1.46 (s, 18H), 1.41 
(s, 18H). 
n:m = 5 : 40 
 
25e (n=10; m=10): 1H NMR (500 MHz, CD3CN): δ = δ =11.54 (br, 2H), 8.35 (br, 2H), 
7.33 (br, 5H), 5.84 (trans) and 5.61 (cis) (comp, 4H) total, 5.07 (comp, 2H), 5.00 (cis) 
and 4.66 (trans) (comp, 4H total), 4.16 (br, 4H), 3.56 (comp, 7H), 3.14 (br, 4H), 1.46 (s, 
18H), 1.41 (s, 18H); 
n:m = 10 : 10 
 
25f (n=20; m=20): 1H NMR (500 MHz, CD3CN): δ = δ =11.54 (br, 2H), 8.35 (br, 2H), 
7.33 (br, 5H), 5.82 (trans) and 5.60 (cis) (comp, 4H) total, 5.07 (comp, 2H), 4.99 (cis) 
and 4.65 (trans) (comp, 4H total), 4.18 (br, 4H), 3.56 (comp, 7H), 3.14 (br, 4H), 1.47 (s, 
18H), 1.41 (s, 18H); 
n:m = 20 : 20 
 
25g (n=40; m=40): 1H NMR (500 MHz, CD3CN): δ =11.53 (br, 2H), 8.35 (br, 2H), 7.33 
(br, 5H), 5.83 (trans) and 5.59 (cis) (comp, 4H) total, 5.07 (comp, 2H), 5.00 (cis) and 
4.66 (trans) (comp, 4H total), 4.17 (br, 4H), 3.56 (comp, 7H), 3.14 (br, 4H), 1.47 (s, 18H), 
1.41 (s, 18H); 
n:m = 40 : 40 
 
26a (n=5; m=5): 1H NMR (500 MHz, CD3CN): δ =11.54 (br, 2H), 8.35 (br, 2H), 5.85 
(trans) and 5.59 (cis) (comp, 4H) total, 5.00 (cis) and 4.65 (trans) (comp, 4H total), 4.16 
(br, 4H), 3.63 (comp, 10H), 3.14 (br, 4H), 1.47 (s, 18H), 1.41 (s, 18H); 
n:m = 5 : 5 
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26b (n=5; m=10): 1H NMR (500 MHz, CD3CN): δ = 11.54 (br, 2H), 8.35 (br, 2H), 5.86 
(trans) and 5.60 (cis) (comp, 4H) total, 4.99 (cis) and 4.66 (trans) (comp, 4H total), 4.16 
(br, 4H), 3.60 (comp, 10H), 3.13 (br, 4H), 1.47 (s, 18H), 1.41 (s, 18H); 
n:m = 5 : 10 
 
26c (n=5; m=20): 1H NMR (500 MHz, CD3CN): δ = 11.54 (br, 2H), 8.35 (br, 2H), 5.86 
(trans) and 5.60 (cis) (comp, 4H) total, 4.99 (cis) and 4.66 (trans) (comp, 4H total), 4.16 
(br, 4H), 3.60 (comp, 10H), 3.14 (br, 4H), 1.46 (s, 18H), 1.41 (s, 18H); 
n:m = 5 : 20 
 
27a (n=5; m=5): 1H NMR (500 MHz, CD3CN): δ = 11.54 (br, 2H), 8.35 (br, 2H), 7.28 (br, 
6H), 5.86 (trans) and 5.60 (cis) (comp, 4H total), 4.97 (cis) and 4.66 (trans) (comp, 4H), 
4.16 (br, 4H), 3.55 (comp, 7H), 3.15 (br, 4H), 1.46 (s, 18H), 1.41 (s, 18H); 
n:m = 5 : 5 
 
27b (n=5; m=10): 1H NMR (500 MHz, CD3CN): δ = 11.54 (br, 2H), 8.35 (br, 2H), 7.28 
(br, 6H), 5.86 (trans) and 5.59 (cis) (comp, 4H total), 4.97 (cis) and 4.66 (trans) (comp, 
4H), 4.16 (br, 4H), 3.55 (comp, 7H), 3.15 (br, 4H), 1.46 (s, 18H), 1.41 (s, 18H);  
n:m = 5 : 10 
 
27c (n=5; m=20): 1H NMR (500 MHz, CD3CN): δ = 11.54 (br, 2H), 8.35 (br, 2H), 7.28 
(br, 6H), 5.86 (trans) and 5.61 (cis) (comp, 4H total), 4.97 (cis) and 4.65 (trans) (comp, 
4H), 4.16 (br, 4H), 3.55 (comp, 7H), 3.15 (br, 4H), 1.46 (s, 18H), 1.41 (s, 18H); 
n:m = 5 : 20 
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28 (n=5; m=20):  1H NMR (500 MHz, CD2Cl2): δ = 11.54 (br, 2H), 8.47 (br, 2H); 5.92 
(trans) and 5.64 (cis) (comp, 4H total), 5.13 (cis) and 4.73 (trans) (comp, 4H), 4.26 
(comp, 4H), 4.15 (br, 4H), 3.65 (comp, 4H), 3.19 (br, 4H), 1.53 (s, 18H), 1.47 (s, 18H), 
1.27 (br, 6H);  
n:m = 4 : 21 
 
29 (n=5; m=20): 1H NMR (500 MHz, CD2Cl2): δ = 11.54 (br, 2H), 8.48 (br, 2H); 5.92 
(trans) and 5.64 (cis) (comp, 4H total), 5.14 (cis) and 4.73 (trans) (comp, 4H), 4.26 
(comp, 4H), 3.86 (br, 4H), 3.65 (comp, 4H), 3.18 (br, 4H) 1.93 (br, 2H), 0.94 (br, 12H); 
n:m = 6 : 19 
 
30 (n=5; m=20): 1H NMR (500 MHz, CD2Cl2): δ = 11.54 (br, 2H), 8.48 (br, 2H); 5.92 
(trans) and 5.64 (cis) (comp, 4H total), 5.13 (cis) and 4.73 (trans) (comp, 4H), 4.26 
(comp, 7H), 4.15 (br, 2H), 3.64 (comp, 8H), 3.18 (br, 4H), 1.74 (br, 4H), 1.49 (comp, 
46H), 1.27 (comp, 4H), 0.98 (br, 2H); 
n:m = 6 : 19 
 
 
Figure 6.21. Deprotection of boc-protected block copolymers (6a-f) to yield the BCP of 
PTDMs.  I) TFA/CH2Cl2 (1:1), RT, overnight. BCP PTDMs further purified by dialysis 
using membranes with molecular weight cut-off : 100-500 g/mol. 
 
Deprotection Procedure to Yield MePhn-b-dGm, dMen-b-dGm, dPhn-b-dGm, dEtn-b-
dGm, diBun-b-dGm, and dCyn-b-dGm Polymers: 25a-g, 26a-c, 27a-c, and 28-30 were 
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dissolved in 2 mL of CH2Cl2 and allowed to stir.  2 mL of TFA was then added drop-wise 
to the solution and allowed to stir overnight at RT.  Excess TFA was removed by 
azeotropic distillation with MeOH.  During this process, 5-7 mL of MeOH was added and 
then the sample was concentrated using rotary evaporation.  This process was repeated 
7-9 times to ensure complete TFA removal. Following this, samples were dissolved in a 
water/MeOH mixture, transferred to Biotech CE dialysis tubing membranes with a 
MWCO 100-500 g/mol and dialyzed against RO water until the conductivity of the water 
remained < 0.2 µS (2-3 days on dialysis).  The MePh5-b-dGm series was then aqueous 
filtered and isolated from water by lyophilization.  
 
MePh5-b-dG5: 1H NMR (500 MHz, CD3CN-d6): δ = 7.88 (br, 2H), 7.35 (comp, 6H), 7.07 
(comp, 8H), 5.87 (trans) and 5.62 (cis) (br, 4H total), 5.07 (comp, 2H), 4.92 (cis) and 
4.68 (trans) (comp, 4H total), 4.15 (br, 4H), 3.42 (comp, 7H), 3.20 (br, 4H). 
 
MePh5-b-dG10: 1H NMR (500 MHz, DMSO-d6): δ 7.96 (br, 2H), 7.39 (comp, 14H), 5.83 
(trans) and 5.59 (cis) (comp, 4H total), 5.01 (comp, 2H), 4.93 (cis) and 4.58 (trans) 
(comp, 4H total), 4.07 (4H, br), 3.38 (7H, br), 3.27 (4H, br); 
 
MePh5-b-dG20: 1H NMR (500 MHz, DMSO-d6): δ 7.98 (br, 2H), 7.40 (comp, 14H), 5.83 
(trans) and 5.59 (cis) (comp, 4H total), 5.03 (comp, 2H), 4.92 (cis) and 4.61 (trans) 
(comp, 4H total), 4.04 (4H, br), 3.40 (7H, br), 3.28 (4H, br); 
 
MePh5-b-dG40: 1H NMR (500 MHz, DMSO-d6): δ 7.98 (br, 2H), 7.44 (comp, 14H), 5.82 
(trans) and 5.59 (cis) (comp, 4H total), 4.97 (comp, 2H), 4.97 (cis) and 4.58 (trans) 
(comp, 4H total), 4.10 (4H, br), 3.40 (7H, br), 3.28 (4H, br); 
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MePh10-b-dG10: 1H NMR (500 MHz, DMSO-d6): δ = 7.92 (br, 2H), 7.43 (comp, 6H), 7.32 
(comp, 8H), 5.80 (trans) and 5.59 (cis) (br, 4H total), 5.04 (comp, 2H), 4.94 (cis) and 
4.57 (trans) (comp, 4H total), 4.05 (br, 4H), 3.37 (comp, 7H), 3.21 (br, 4H); 
 
MePh20-b-dG20: 1H NMR (500 MHz, DMSO-d6): δ = 7.96 (br, 2H), 7.43 (comp, 6H), 7.32 
(comp, 8H), 5.80 (trans) and 5.59 (cis) (br, 4H total), 5.04 (comp, 2H), 4.94 (cis) and 
4.57 (trans) (comp, 4H total), 4.04 (br, 4H), 3.36 (comp, 7H), 3.22 (br, 4H); 
 
MePh40-b-dG40: 1H NMR (500 MHz, DMSO-d6): δ = 7.94 (br, 2H), 7.42 (comp, 6H), 7.32 
(comp, 8H), 5.82 (trans) and 5.59 (cis) (br, 4H total), 5.06 (comp, 2H), 4.92 (cis) and 
4.57 (trans) (comp, 4H total), 4.04 (br, 4H), 3.38 (comp, 7H), 3.24 (br, 4H); 
 
dMe5-b-dG5: 1H NMR (500 MHz, DMSO-d6): δ = 7.88 (br, 2H), 7.35 (comp, 8H), 5.83 
(trans) and 5.60 (cis) (br, 4H total), 4.90 (cis) and 4.59 (trans) (comp, 4H total), 4.04 
(comp, 4H), 3.59 (br, 6H), 3.36 (br, 4H), 3.23 (br, 4H); 
 
dMe5-b-dG10: 1H NMR (500 MHz, DMSO-d6): δ = 7.89 (br, 2H), 7.38 (comp, 8H), 5.86 
(trans) and 5.60 (cis) (br, 4H total), 4.91 (cis) and 4.60 (trans) (comp, 4H total), 4.05 
(comp, 4H), 3.60 (br, 6H), 3.38 (br, 4H), 3.24 (br, 4H); 
 
dMe5-b-dG20: 1H NMR (500 MHz, DMSO-d6): δ = 7.89 (br, 2H), 7.39 (comp, 8H), 5.86 
(trans) and 5.60 (cis) (br, 4H total), 4.92 (cis) and 4.59 (trans) (comp, 4H total), 4.05 
(comp, 4H), 3.59 (br, 6H), 3.39 (br, 4H), 3.25 (br, 4H); 
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dPh5-b-dG5: 1H NMR (500 MHz, DMSO-d6): 7.89 (br, 2H), 7.26 (comp, 18H), 5.84 
(trans) and 5.60 (cis) (br, 4H total), 4.97 (comp, 4H), 4.97 (cis) and 4.59 (trans) (comp, 
4H total), 4.03 (br, 4H), 3.36 (comp, 4H), 3.23 (br, 4H); 
 
dPh5-b-dG10: 1H NMR (500 MHz, DMSO-d6): δ = 7.91 (br, 2H), 7.36 (comp, 18H), 5.83 
(trans) and 5.60 (cis) (br, 4H total), 4.97 (comp, 4H), 4.97 (cis) and 4.60 (trans) (comp, 
4H total), 4.04 (br, 4H), 3.38 (comp, 4H), 3.23 (br, 4H); 
 
dPh5-b-dG20: 1H NMR (500 MHz, DMSO-d6): δ = 7.96 (br, 2H), 7.35 (comp, 18H), 5.83 
(trans) and 5.59 (cis) (br, 4H total), 4.97 (comp, 4H), 4.97 (cis) and 4.59 (trans) (comp, 
4H total), 4.04 (br, 4H), 3.37 (comp, 4H), 3.24 (br, 4H); 
 
dEt5-b-dG20: 1H NMR (500 MHz, DMSO-d6): δ = 7.97 (br, 2H), 7.43 (comp, 8H), 5.83 
(trans) and 5.58 (cis) (br, 4H total), 4.96 (cis) and 4.57 (trans) (comp, 4H total), 4.05 
(comp, 8H), 3.36 (comp, 4H), 3.24 (br, 4H), 1.15 (br, 6H); 
 
diBu5-b-dG20: 1H NMR (500 MHz, DMSO-d6): δ = 7.97 (br, 2H), 7.43 (comp, 8H), 5.83 
(trans) and 5.60 (cis) (br, 4H total), 4.96 (cis) and 4.57 (trans) (comp, 4H total), 4.04 
(comp, 4H), 3.76 (br, 4H), 3.36 (comp, 4H), 3.24 (br, 4H), 1.83 (2H), 1.15 (br, 12H); 
 
dCy5-b-dG20: 1H NMR (500 MHz, DMSO-d6): δ = 7.97 (br, 2H), 7.42 (comp, 8H), 5.82 
(trans) and 5.59 (cis) (br, 4H total), 4.97 (cis) and 4.58 (trans) (comp, 4H total), 4.04 
(comp, 6H), 3.77 (br, 2H), 3.36 (comp, 6H), 3.24 (br, 4H), 1.64 (comp, 10H), 1.17 (comp, 
6H), 0.91 (comp, 4H); 
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6.10 Molecular Modeling  
Aromatic groups studied were modeled using Spartan 2004 software (Wavefunction, 
Inc., Irvine, CA) to obtain electronic potential maps. These maps were then used to 
visualize difference in electron densities of various aromatic groups, including those 
incorporated into amino acids phenylalanine, tyrosine, and tryptophan as well as 
electron-rich and electron-poor systems incorporated into our CPPMs. Electrostatic 
potential values for the center of all aromatic rings modeled were also determined.  
6.11 Vesicle Preparation and Dye Release Assays 
Preparation of EYPC-LUVs⊃CF.7,8 A thin lipid film was prepared by concentrating a 
solution of 25 mg EYPC in chloroform via rotary evaporation at RT. The sample was 
further dried under vacuum overnight at RT protected from light.  Lipids were hydrated 
for 1 hr with 1.0 mL CF/Tris saline buffer (10 mM Tris, 10 mM NaCl, 50 mM CF, pH 7.5) 
and vortexed every 15 min for 1 hr.  The resulting suspension was then subjected to six 
freeze-thaw cycles (liquid N2 to freeze and 25 °C water bath to thaw), and then extruded 
nine times through a polycarbonate membrane (pore size = 100 nm).  Extra-vesicular 
dye was removed by size exclusion chromatography (Sephadex G-50 superfine, Sigma-
Aldrich) with Tris saline buffer (10 mM Tris, 107 mM NaCl, pH 7.5). The vesicle stock 
solution recovered from the column was collected in 2-3 fractions and stored at 4°C 
protected from light.  These vesicles were used for the following dye-release assay. 
 
Preparation of EYPC/Brain PS (80/20)-LUVs⊃CF.  The vesicle preparation was 
identical to that of the EYPC-LUVs⊃CF, with the exception that 20% Brain PS lipids, by 
weight, were used for the preparation.   
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Dye-release Assay.59 All fluorescence measurements were taken at 25 °C with an 
excitation wavelength of 492 nm and an emission wavelength of 517 nm using a Biotek 
SynergyMx fluorescence plate reader. 1960 µL of Tris saline buffer was added to each 
well of a 12-well plate along with 20 µL of a working solution of EYPC-LUVs⊃CF (diluted 
to a post-triton fluorescence of 70,000 counts).  After shaking in the plate reader for 3 
minutes at 25 °C, the baseline fluorescence, F0, was read. Then, 20 µL polymer 
solutions (in DMSO) of varying concentrations were added to the wells while stirring. 
After shaking in the plate reader for 10 minutes at 25 °C, the fluorescence intensity (F10) 
was measured again.  20 µL of Triton X-100 (5% in DMSO) was then added to each of 
the wells to lyse the vesicles and release all of the dye. The final fluorescence 
measurement (Ft) was taken after 3 minutes of shaking in the plate reader at 25 °C.  A 
cartoon depiction of this assay can be seen in Figure 2.4.1.  The results were normalized 
according to the baseline and Triton controls to yield fractional dye release (Y) according 
the equation S1. 
If = (F10 – F0) / (Ft – F0)        (S1) 
For Hill analysis, Y was plotted against polymer concentration, c, and fit to the Hill 
equation, S2, to give the effective concentration (EC50), which is the concentration of 
polymer that results in 50 % of the maximum fluorescence intensity. 
If = If,0 + (If,max – If,0) / [(1 + c / EC50)n]       (S2) 
Where, If,0  and If are the minimum and maximum value of I obtained, respectively. 
6.12 Polymer/siRNA Complexation Using Gel Retardation Assays 
PTDMs were complexed with siRNA at N:P ratios of 0.5:1, 1:1, 2:1, 4:1, 8:1, and 12:1 in 
microfuge tubes, with the siRNA amount held constant at 1 µg.  Complexes were 
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allowed to incubate at RT for 30 minutes prior to agarose gel electrophoresis with 
sodium boric acid conductive medium.  
6.13 FITC-siRNA Uptake in Jurkat T Cells 
General Procedure 
Polymers were dissolved in sterile DMSO to make 1 mM stock solutions.  Polymers were 
stored at -20 °C in 50 µL aliquots.  On the day of the experiment, Jurkat T cells were 
harvested, centrifuged, counted, and re-suspended in complete cell growth medium with 
10% FBS to a density of 4x105 cells/mL (1 mL final volume in a 12-well plate).  Polymers 
with charge contents less than 40 were diluted to 0.1 mM with PBS and polymers with 
charge contents of 40 or larger were diluted to 0.005 mM with PBS (pH 7.4).  Polymers 
were mixed with siRNA (10 µM stock solution, 50 nM in final well) at an N/P ratio, where 
N is the number of positively charged nitrogen groups in the polymer structures and P is 
the number of negatively charged phosphate groups in the FITC-siRNA duplexes, of 8/1 
in PBS (100 µL total for each complex solution).  This N/P ratio was previously 
optimized.3   Complexes were incubated at RT for 30 minutes prior to adding them drop-
wise to each well and gently pipetting the media in each well up and down to evenly mix 
in the complex solutions..  Cells were then incubated at 37 °C in a 5% CO2 atmosphere 
for 4 hr.  After 4 hr, cells were harvested and washed 3 times with 500 µL of a 20 U/mL 
heparin solution.  Cells were either re-suspended in 200 µL of FACS wash buffer after 
the final wash for analysis or prepared for viability staining.  See procedure below.  For 
flow cytometry analysis, the fluorescence signal was collected for 10,000 cells. The cell 
populations were gated in order to assess the percent of positive cells, which reflected 
the percentage of the cell population that received FITC-siRNA.  The calculated median 
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fluorescence intensity (MFI) represented the amount of cargo delivered to the cells.  
Results for percent positive cells and MFI can be found in the main text (Figure 2).  
Comparison to Commercially Available Reagents  
For experiments in which polymers were compared to commercially available reagents, 
the setup was identical to the general procedure with the exception that all commercially 
available reagents were handled in accordance with the recommended procedures.  
Summaries of these conditions are documented below.  The concentration of siRNA in 
the final experiment wells remained at 50 nM for consistency.  For flow cytometry 
analysis, the fluorescence signal was collected for 10,000 cells. The cell populations 
were gated in order to assess the percent of positive cells, which reflected the 
percentage of the cell population that received FITC-siRNA.  The calculated MFI values 
reflected the amount of cargo delivered to the cells.  Results for percent positive cells 
and MFI can be found in the main text (Figure 3). 
 
R9.  This reagent was purchased from Peptide 2.0 and dissolved in PBS to make a 1 
mM stock solution.  The N:P ratio used for this experiment was 8:1 to be consistent with 
the ratios used for the polymeric reagents.  
 
DeliverX.  This reagent was purchased from Affymetrix.  The recommended reagent 
quantities were used as documented in the user manual.  No further optimization was 
performed. For these experiments, DeliverX was first sonicated for five minutes to obtain 
a homogeneous solution.  Following this, 5 µL of siRNA was dissolved in 45 µL of siRNA 
Buffer 1 and 7 µL of DeliverX was dissolved in 43 µL of siRNA Buffer 2.  Both solutions 
were vortex mixed prior to mixing both solutions together.  This solution was gently 
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vortex mixed and then allowed to incubate at RT for 20 minutes prior to adding it to the 
cell suspension.   
 
Xfect.  This reagent was purchased from CloneTech.  Optimization was not required as 
per the directions on the company’s website and in the user manual.  The amounts of 
siRNA and polymer delivery reagent to be used for each transfection were pre-
determined by the company based on the well size and volume of media to be used.  
For these experiments 5 µL of siRNA was added to in 45 µL of Xfect reaction buffer.  In 
a separate tube, 8 uL of Xfect polymer solution was added to 42 µL of Xfect reaction 
buffer.  Both samples were vortex mixed prior to adding the polymer solution to the 
siRNA solution and vortex mixing.  The complex was allowed to incubate at RT for 20 
minutes prior to adding it to the cell suspension. 
 
N-ter.  This reagent was purchased from Sigma Aldrich.  The ratio of siRNA to 
transfection peptide to be used was documented in the user manual, where it was also 
noted that this ratio did not require further optimization.  For these experiments, 5 µL of 
siRNA was added to 45 µL of PBS and 7 µL of N-ter was added to 43 µL of RNase-free 
water.  The solutions were gently vortexed before combining them together.  The 
combined solution was then vortexed and allowed to incubate at RT for 20 minutes prior 
to adding to the cell suspension.   
 
RNAiMAX. This reagent was purchased from Life Technologies.  The ratio of siRNA to 
transfection reagent used was documented in the user manual.  For these experiments, 
5 µL of siRNA was added to 45 µL of serum free media and 15 µL of RNAiMAX was 
added to 35 µL of serum free media.  These solutions were gently vortexed before 
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combining the solutions and gently vortex mixing the combined solution.  The complex 
was allowed to incubate at RT for 20 minutes prior to adding to the cell suspension. 
 
JetPEI.  This reagent was purchased from Polyplus Transfection.  The ratio of siRNA to 
transfection reagent used was the same as documented for pDNA.  For these 
experiments, 5 µL of siRNA was added to 45 µL of a 150 mM NaCl solution and 1.5 µL 
of JetPEI was added to 48.5 µL of a 150 mM NaCl solution.  These solutions were gently 
vortexed before combining the solutions and gently vortex mixing the combined solution.  
The complex was allowed to incubate at RT for 30 minutes prior to adding to the cell 
suspension. 
6.14 Viability in Jurkat T Cells 
General Annexin V / 7-AAD Viability Assay Procedure   
This assay was used to assess apoptosis (Annexin V staining) as well as overall viability 
(7-AAD staining), in order to have a more complete understanding of how 
polymer/siRNA treatment affected the cell populations. Following wash steps 
documented above, cells were washed with 200 µL of 1X Annexin V binding buffer and 
subsequently spun down.  Cells were re-suspended in 100 µL of an PE-Annexin V / 
binding buffer stock solution (1.2 mL of binding buffer + 60 µL PE-Annexin; Solution was 
scaled up or down as needed.)  Cells were then incubated at RT for 15 minutes 
protected from light.  After the incubation, cells were brought up to 200 µL with Annexin 
V binding buffer and spun down.  Cells were re-suspended in 200 µL of a 7-AAD stock 
solution (2.4 mL of binding buffer + 60 µL of 7-AAD stain; Solution was scaled up or 
down as needed) and transferred to FCM tubes for analysis.  For flow cytometry 
analysis, the fluorescence signal was collected for 10,000 cells. The cell populations 
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were gated in order to assess the percent of positive cells, which reflected the 
percentage of dead cell in the population. 
Viability at 4 and 24 hr   
To assess cell viability at 4 and 24 hr, 4x105 cells/mL were treated as documented in the 
general FITC-siRNA uptake in Jurkat T cells procedure, with the exception that some 
cells were treated with just the polymer itself.  After the 4 hr treatment, cells were split in 
half (2x105 cells/mL in each half) and washed three times with 500 µL of a 20 U/mL 
heparin solution.  After the third wash, one half of the cells were viability stained as 
documented in the General Annexin V / 7-AAD viability assay procedure and analyzed 
by FCM and the other half were re-suspended in warm media and re-plated (2x105 
cells/mL) for analysis at 24 hr.  After 24 hr, the re-plated cells were harvested, washed 
three times with 500 µL of a 20 U/mL heparin solution, and prepared for viability staining 
and subsequent analysis.  For flow cytometry analysis, the fluorescence signal was 
collected for 10,000 cells. The cell populations were gated in order to assess the percent 
of positive cells, which reflected the percentage of dead cell in the population.  Note that 
the longer polymers with charge contents larger than 40 were not tested.  
 
Cell Counts 
In addition to viability staining at 4 and 24 hr, cells were counted at 24 hr to 
assess proliferation.  1/20 dilution of each experimental well in trypan blue was used for 
cell counts.  Since Jurkat T cells have a doubling time of 24 hr, it was anticipated that 
healthy cell populations would double by the 24 hr time point.  Cells were not counted at 
the 4 hr time point since they were initially counted at the start of the experiment.  
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6.15 FITC-siRNA Uptake in HeLa Cells 
General Procedure  
Polymers were dissolved in sterile DMSO to make 1 mM stock solutions.  Polymers were 
stored at -20 °C in 50 µL aliquots.  48 hr prior to the experiment, HeLa T cells were 
trypsinized, harvested, centrifuged, counted, and re-suspended in complete cell growth 
medium with 10% FBS to a density of 5x104 cells/mL (1 mL final volume in a 12-well 
plate).  Cells were then incubated for approximately 48 hr at 37 °C in a 5% CO2 
atmosphere to allow cells to become 70-90% confluent.  On the day of the experiment, 
fresh media is added to the cells.  Polymers with charge contents less than 40 were 
diluted to 0.1 mM with PBS and polymers with charge contents of 40 or larger were 
diluted to 0.005 mM with PBS (pH 7.4).  Polymers were mixed with FITC-siRNA (10 µM 
stock solution, 50 nM in final well) at an N/P ratio of 4/1 in PBS (100 µL total for each 
complex solution).  Complexes were incubated at RT for 30 minutes prior to adding them 
drop-wise to each well.  The 12-well plate was gently rocked back and forth to help 
evenly distribute the complex solutions.  Cells were then incubated at 37 °C in a 5% CO2 
atmosphere for 4 hr.  After 4 hr, cells were trypsinized, harvested, and washed 3 times 
with 500 µL a 20 U/mL heparin solution.  Cells were either re-suspended in 200 µL of 
FACS wash buffer after the final wash for analysis or prepared for viability staining.  See 
procedure below.  For flow cytometry analysis, the fluorescence signal was collected for 
10,000 cells. The cell populations were gated in order to assess the percentage of 
positive cells, which reflected the percentage of the cell population that received FITC-
siRNA.  The calculated MFI represented the amount of cargo delivered to the cells.   
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6.16 Viability in HeLa Cells 
General 7-AAD Viability Assay Procedure 
Following the wash steps documented above, cells were re-suspended in 200 µL of a 7-
AAD stock solution (2.4 mL of FACS wash buffer + 60 µL of 7-AAD stain; Solution was 
scaled up or down as needed) and transferred to FCM tubes for analysis.  For flow 
cytometry analysis, the fluorescence signal was collected for 10,000 cells. The cell 
populations were gated in order to assess the percent of positive cells, which reflected 
the percentage of dead cell in the population.  
 
6.17 hNOTCH1 Knockdown in Human Peripheral Blood Mononuclear Cells 
(hPBMCs)  
Cell enrichment 
The night before the experiment, human peripheral blood mononuclear cells (hPBMCs) 
were thawed and enriched for the viable cell population, a majority of which were T cells, 
overnight.  In this process, hPBMCs were thawed, added to 9 mL of warmed media 
(RPMI 1640 with 10% FBS), centrifuged, re-suspended in 2 mL of warmed media, and 
added to two wells of a 6-well plate.  Each well was brought up to 3 mL with warmed 
media and cells were incubated at 37 °C in a 5% CO2 atmosphere overnight.  
6.17.1 Well-plate coating 
The night before the experiment, a 24-well plate was antibody-coated with a solution 
contain anti-CD3 and anti-CD28.  For a stock solution that can coat 12 wells, 3.940 mL 
of PBS was added to a 15 mL centrifuge tube along with 40 µL of a 0.5 mg/mL solution 
of anti-CD3 in PBS and 20 µL of a 0.5 mg/mL solution of anti-CD28.  The solution was 
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lightly vortexed and 300 µL of it was transferred to each of 12 wells.  This stock solution 
preparation can be scaled up or down as needed.  
hPBMC Treatment and Incubation 
Polymers were dissolved in sterile DMSO to make 1 mM stock solutions.  Polymers were 
stored at -20 °C in 50 µL aliquots.  On the day of the experiment, hPBMCs were 
harvested, centrifuged, counted, and re-suspended in complete cell growth medium with 
10% FBS to a density of 1x106 cells/mL (1 mL final volume in a 12-well plate).  Polymers 
with charge contents less than 40 were diluted to 0.1 mM with PBS and polymers with 
charge contents of 40 or larger were diluted to 0.005 mM with PBS (pH 7.4).  Polymers 
were mixed with siRNA (10 µM stock solution, 100 nM in final well) at an N/P ratio of 8/1 
in PBS (100 µL total for each complex solution).  This N/P ratio was previously 
optimized.3  Complexes were incubated at RT for 30 minutes prior to adding them drop-
wise to each well and gently pipetting the media in each well up and down to evenly mix 
in the complex solutions.  Cells were then incubated at 37 °C in a 5% CO2 atmosphere 
for 4 hr.  After 4 hr, the cells were harvested, centrifuged, re-suspended in complete cell 
growth medium with 10% FBS and transferred to the coated well plate for stimulation.  At 
least one untreated sample was transferred to an uncoated well to serve as a stimulation 
control.  Cells were incubated at 37 °C in a 5% CO2 atmosphere for 48 hr.   
Flow Cytometry Analysis   
Harvesting   
After 48 hrs, cells were harvested, centrifuged, and washed with PBS.  Cells were re-
suspended in 200 µL of PBS and transferred to a 96-well plate.  Cells were washed two 
additional times with FACS wash buffer.  After the last wash, the cells were split in half, 
one part for intracellular staining for hNOTCH1 protein and one part for viability staining. 
	  
	   209 
Surface Staining   
Following the wash steps documented above, cells were resuspended in 100 µL of 
FACS wash buffer and stained with 5 µL of FITC-labeled anti-CD8 and 5 µL of APC-
labeled anti-CD4.  Cells were incubated for 30 minutes on ice protected from light.  After 
30 minutes, the cells were brought up to 200 µL with FACS wash buffer and spun down.  
Cell were washed two additional times with 200 µL FACS wash buffer and then prepared 
for intracellular staining or viability staining.  These stains were used to verify the CD4+ 
and CD8+ T cell populations present in the cell samples at 48 hours. The cell 
populations were roughly 30% CD8+ T cells and 50% CD4+ T cells.   
Intracellular Staining 
Following cell surface staining documented above, cells were re-suspended in 100 µL of 
the Foxp3 Fix/Perm Cocktail and incubated for 30 min on ice protected from light.  After 
the 30 min incubation, the cells were brought up to 200 µL with the permeabilization 
wash buffer, which was prepared by diluting a 5 mL of a 10X stock solution in 45 mL of 
deionized water.  Cells were washed three times with the permeablization wash buffer.  
After the third wash step, cells were re-suspended in 50 µL of the permeablization wash 
buffer, stained with 2 µL of anti-human NOTCH1 PE, and incubated for 30 min on ice 
protected light.  After the 30 min incubation, cells were washed three times with the 
permeablization wash buffer and then re-suspended in 200 µL of FACS wash buffer and 
transferred to FCM tubes for analysis.  For flow cytometry analysis, the fluorescence 
signal was collected for 10,000 cells. The cell populations were gated in order to assess 
the percent of positive cells, which reflected the percentage of the cell population 
expressing hNOTCH1 protein.  The calculated MFI represented the amount of 
hNOTCH1 protein present in the cells.  The percent relative protein expression 
represents the percent positive cells multiplied by the MFI, normalized to the blank, and 
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multiplied by 100%.  Results for the percent relative protein expression can be found in 
the main text (Figure 4). 
7-AAD Cell Viability Assay 
Following the wash steps documented above, cells were re-suspended in 200 µL of a 7-
AAD stock solution (2.4 mL of binding buffer + 60 µL of 7-AAD stain; Solution was 
scaled up or down as needed) and transferred to FCM tubes for analysis.  For flow 
cytometry analysis, the fluorescence signal was collected for 10,000 cells. The cell 
populations were gated in order to assess the percent of positive cells, which reflected 
the percentage of dead cell in the population.  Viability results can be found in the main 
text (Figure 4).  
 
Western Blot 
 
PBMCs, in the presence or absence of stimulation, were harvested at 48 hours post-
treatment and whole cell lysates were prepared using RIPA buffer. Lysates were 
resolved on an 8% SDS-PAGE gel and transferred to nitrocellulose membranes. 
Membranes were blocked with 5% milk in PBST and probed with Anti-cleaved Notch1 
Val1744 (D3B8, Cell Signaling Technology) or Anti-Glyceraldehyde-3-Phosphate 
Dehydrogenase Antibody (6C5, Merck Millipore). Membranes were then washed and 
incubated with their corresponding horseradish peroxidase-conjugated secondary 
antibodies (GE Healthcare). Oxidation of the chemiluminescent substrate (#34087, 
Thermo Fisher Scientific) was detected using a G:Box (Syngene). 
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6.18 Theoretical Calculations of LogP 
The octanol/water partition coefficient (LogP) values for all hydrophobic monomers were 
calculated using MarvinSketch software (ChemAxon Ltd.).  The weighted method was 
used, which provided a logP value that was the average of the Viswanadhan et al., 
Klopman et al., and PHYSPROP database methods.4-6  Each method was given equal 
weight in the calculation to provide a more accurate estimate of the logP values.   
6.19 HPLC  
Relative hydrophobicities of monomers were also determined by HPLC using a method 
adapted from Thaker et al.7 A linear gradient from 100% water with 0.1% TFA to 100% 
acetonitrile with 0.1% TFA over 60 minutes was used at a flow rate of 1 mL/minute.  5 
mg/mL monomer solutions in DMSO were prepared for analysis.  Samples that were 
more hydrophobic required higher percentages of acetonitrile to be present in the mobile 
phase to elute and, thus, correspond to higher retention times.  
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